2014 Annual Report
VISION TO TRANSFORM THE FUTURE
Corporate Profile
Impax Laboratories, Inc. (“Impax”) is a specialty pharmaceutical company focused on developing,
manufacturing and marketing generic and branded products. We are headquartered in Hayward,
California, and have additional facilities in New Jersey, Pennsylvania and Taiwan.
The New Impax
In March 2015, Impax completed its acquisition of Tower Holdings, Inc. (including operating subsidiaries
CorePharma LLC and Amedra Pharmaceuticals LLC), and Lineage Therapeutics Inc. In connection with
the closing of the acquisition, Impax reshaped the operating and reporting structure of its two divisions
into Impax Generics and Impax Specialty Pharma.
• Impax Generics now includes the Company’s legacy Global Pharmaceuticals business as well as
the acquired CorePharma and Lineage Therapeutics businesses.
• Impax Specialty Pharma now includes the legacy Impax Pharmaceuticals business as well as the
acquired Amedra Pharmaceuticals business.
Our Impax Generics division focuses on a broad range of therapeutic areas, including products having
technically challenging drug-delivery mechanisms or unique product formulations. In addition to
developing solid oral dosage products, our portfolio includes alternative dosage form products, primarily
through alliance and collaboration agreements with third parties.
Our Impax Specialty Pharma division is focused on the development and promotion, through our
specialty sales force, of proprietary branded pharmaceutical products for the treatment of Central
Nervous System disorders and other select specialty segments.
2014 Business Highlights
FOCUS ON QUALITY
Continued to fully implement a Quality Improvement Program
Introduced a Quality Begins With Me campaign that builds on the
foundation of our Quality Improvement Program
MAXIMIZE GENERIC AND
BRANDED PLATFORM
Total net generic revenues increased 38%
Launched authorized generic RENVELA®
Zomig® Nasal Spray revenues increased 39% and prescriptions increased 23%
OPTIMIZE R&D
Reorganized brand and generic R&D to yield process improvements and
efficiencies resulting in approximately $8 million of annual cost savings
Refocused internal brand and generic pipeline
Resubmitted New Drug Application for RYTARYTM (IPX066) with the U.S. Food
and Drug Administration and submitted a Marketing Authorization Application
to the European Medicines Agency
BUSINESS DEVELOPMENT
ACCELERATION
Announced proposed acquisition of Tower Holdings, Inc. and Lineage
Therapeutics Inc. for $700 million
Acquired Lamotrigine orally disintegrating tablet (ODT) and Ursodiol
tablet from Actavis
1
To Our Fellow Stockholders:
I joined Impax about a year ago as president and CEO because I saw a
company with an experienced team of professionals with a track record
of developing and commercializing products and a strong balance sheet.
With a solid foundation in place, we continued to leverage these strengths
in 2014, while focusing on strategic and operational objectives designed
to enhance our long term growth potential. I am proud of what we have
accomplished together in less than a year and excited about our future.
Strong 2014 Financial Performance
Our commercial teams delivered strong performance in fiscal 2014,
achieving revenue of $596 million, a 17% increase over 2013. The growth
was driven by successfully monetizing the exclusivity period for sales of
our authorized generic RENVELA® product, as well as organic growth
within our generic portfolio of solid oral and alternative dosage form
products. We continue to benefit from the growth of Zomig® Nasal Spray,
which is now the number one prescribed branded nasal spray for the
treatment of migraines in the United States. I am pleased to report that
our sales force increased sales of Zomig Nasal Spray by 39% and prescrip-
tions by 23% in 2014 compared to the prior year.
We successfully increased sales of our higher margin products resulting in a 62% increase in adjusted earnings before
interest, taxes, depreciation and amortization (EBITDA) in 2014 compared to 2013. On an adjusted basis (non-GAAP),
earnings per diluted share increased 61% to $1.32. On a GAAP basis, earnings per diluted share decreased to $0.81,
primarily due to the receipt of $150 million from pre-tax settlements in 2013.
Focusing on Four Core Areas
Our strategic and operational objectives focus on four core areas to drive operational improvements and growth across
the company. While we are pleased with our achievements to date, we still have work to do across these four areas in
order to realize higher levels of success in the future.
Our Focus on Quality is a company-wide initiative. We are committed to a quality and compliance program that will
enable us to continually meet and/or exceed expectations. Throughout 2014, we continued the implementation of our
KEY AREAS OF FOCUS
QUALITY
MAXIMIZE GENERIC AND
BRANDED PLATFORM
OPTIMIZE R&D
BUSINESS
DEVELOPMENT
ACCELERATION
global Quality Improvement Program, which serves as the foundation for how
we operate now and in the future. As part of this effort, we launched an internal
responsibility and awareness program called “Quality Begins With Me.” This
initiative reinforces the importance of quality and compliance across all areas
of our business. Our commitment to advancing a culture focused on quality
will continue to be a top priority.
We are Maximizing our Generic and Branded Platform to consistently make
and deliver quality products to our customers. Our customers are the lifeblood
of our business and as such, we are committed to creating a customer experi-
ence that creates value, builds long-term relationships and ensures repeat busi-
ness. With a history of successfully commercializing our product portfolio, we
once again were able to deliver on this objective as noted by our strong 2014 fi-
nancial performance. We will continue to allocate capital toward new products
and innovative solutions, while leveraging best practices so that we maximize
return on investment and continue to contribute to our financial strength.
2
In late 2014, we took steps to Optimize R&D across our brand and generic divisions. We restructured our teams to better
leverage our resources and improve R&D efficiency and effectiveness. Our brand R&D team is now focused on exist-
ing late-stage opportunities, while the generic R&D team continues to focus on a concentrated portfolio of high value
generic products. This organizational realignment is designed to ensure we are investing in internal projects and external
opportunities that enhance our pipelines, support our growth, and offer the great-
est return on investment.
With strong cash flow and a healthy balance sheet, we are well positioned to
execute on our Business Development Acceleration strategy. In October 2014, we
announced the $700 million acquisition of Tower Holdings, Inc. (including operat-
ing subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC), and Lineage
Therapeutics Inc. (together, the “Companies”). We closed the acquisition in March
of this year. The privately-held Companies specialize in the development, manu-
facture and commercialization of complex generic and branded pharmaceutical
products. This strategic acquisition brings multiple benefits. First, it accelerates our
growth by expanding our commercialized brand and generic product portfolio.
Second, it bolsters our operating foundation with a complementary product
pipeline. Third, it expands and diversifies our manufacturing footprint. We funded
this acquisition through a combination of our cash and a $435 million term loan.
We still have sufficient resources to pursue additional acquisitions and other
business development opportunities to expand and further diversify our business.
Our Mission and Vision
To achieve our vision of building a leading specialty pharmaceutical company that
creates value for patients, customers and stockholders, we will continue to focus
our efforts on:
• Instilling a quality culture and compliance process in all areas of the
business
• Providing superior customer service
• Growing and diversifying our portfolio through innovation and business
development
• Recruiting top talent and developing and investing in our employees
In closing, I would like to thank our employees for their dedication and contribu-
tion to advancing the company’s objectives across our four key areas of focus and
our Board of Directors for their support of our strategic vision. I would also like to
thank our investors for your continued support of the company. We are confident
in our future, and I believe we are well on our way to shaping an organization that
can continue to deliver product innovation, improved patient health, sustained
performance and returns to stockholders.
Sincerely,
Fred Wilkinson
President and Chief Executive Officer
Net Revenue
$596
$512
2013
2014
Adjusted EBITDA*
$187
$115
2013
2014
Adjusted EPS*
$1.32
$0.82
2013
2014
($ in millions except per share date)
*See reconcilliation of adjusted/
non-GAAP tables at the end of report
3
A Conversation with the CEO
How will the acquisition of Tower Holdings, Inc. (including
operating subsidiaries CorePharma LLC and Amedra
Pharmaceuticals LLC), and Lineage Therapeutics Inc.
contribute to the growth of the company?
By joining together our collective capabilities, we hope to accelerate Impax’s growth while also bolstering our
operating foundation with a robust product pipeline and an expanded, more diversified manufacturing foot-
print. We have added a growing, profitable, commercial portfolio of generics as well as a lead product in a new
brand franchise, which will enhance our Impax Specialty Pharma division.
We expect the acquisition to be an important contributor to our growth in 2015 and beyond. The combination
expands our commercialized generic portfolio to 47 products from 36 products, including an attractive growth
opportunity with the addition of an epinephrine auto-injector product (and its authorized generic Adrena-
click®).*
Our branded commercialized portfolio expands to six products from two products.* One of the new product
additions is Albenza® for invasive tapeworm infections. We believe this niche product has a well-developed
lifecycle management strategy to support continued returns. The addition of this new therapeutic area will allow
us to more efficiently utilize our brand commercial infrastructure.
The acquisition also enhances our generic pipeline with the addition of 10 products pending approval at the
FDA and a number of products at various stages of development.*
Adds 11 Commercialized Generic Products*
Adds 4 Commercialized Branded Products*
Adds 10 Generic Products Pending Approval at the FDA*
*Data as of March 10, 2015
4
What makes RYTARY™ an important new development for
the treatment of Parkinson’s disease and what are your
long-term expectations?
There are approximately one million Americans living with Parkinson’s disease and we are pleased to offer this
new therapy as a treatment option for those patients. RYTARY is designed to address one of the most significant
unmet needs for patients living with Parkinson’s disease, which is to reduce the amount of time during the day
when their symptoms are not adequately controlled.
We conducted two Phase III studies, which showed significant improvements in both the activities of daily
living and motor function. Patients with early Parkinson’s disease who took RYTARY experienced a significant
improvement in their ability to move and perform activities of daily living. Patients with advanced Parkinson’s
disease who took RYTARY experienced a reduction in “off ” time by 1.2 hours, with an increase in “on” time
without troublesome dyskensia (uncontrollable movements) by 1.0 hour.
More than 85 percent of Parkinson’s disease patients are taking carbidopa-levodopa products*. Our sales force
will focus on neurologists who write a large percentage of the prescriptions; approximately 8,100 of them in the
U.S. We expect a gradual launch that should build momentum over the next five years and we currently project
that during 2019 we should reach sales of approximately $275 million to $350 million.
In November 2014, we filed the Market Authorization Application to the European Medicines Agency and we
are in discussions with companies for commercialization rights outside of the U.S.
*Source: Decision Resources 2012- Parkinson’s Disease; IMS NPA; NDTI
5
Where is the company focusing its investments in generic
and branded research and development?
With the acquisition of CorePharma, we now have two internal generic R&D facilities located in Hayward,
California, and Middlesex, New Jersey. Also residing in Hayward is our branded division R&D organization.
As part of our 2014 R&D reorganization, we are now focusing on late stage branded products with near term
value. Our brand R&D portfolio includes an investigational transdermal bupivacaine patch for the treatment
of pain associated with post-herpetic neuralgia (PHN), which we in-licensed from Durect Corporation. We
31 ANDA’s
pending
at FDA*
are currently reviewing the next steps in the product’s development, including a
discussion with the FDA concerning a Phase II or Phase III program. Behind that,
we have a follow-on to RYTARY that we currently intend move forward in the
development process in the coming years.
The generic pipeline consists of 31 products pending at the FDA, 12 of which are
either confirmed or potential first-to-file or first-to-market opportunities.* We
also have a number of products in various stages of development. Our pipeline
is well diversified with a mix of solid-oral and alternative dosage form products
across a broad range of therapeutic areas.
*Data as of March 10, 2015
6
What is the company’s outlook for 2015?
We expect 2015 to shape up to be a growth year for Impax. In addition to the expansion of our branded and
generic commercialized portfolios as a result of the acquisition of Tower Holdings, Inc. and Lineage
Therapeutics Inc., we have a number of new product opportunities to
drive further growth.
Our CNS franchise expanded with the approval and launch of RYTARY.
The Specialty Pharma sales force of 77 representatives initiated promo-
tion of RYTARY in early April alongside Zomig® Nasal Spray. We have
confidence in our sales force as they have done a nice job of growing the
nasal spray prescriptions in a segment with several competing generic
products.
The Impax Generics division is expected to have a fairly active year with
the potential to launch a number of already approved products, as well
as several applications pending FDA approval. This portfolio of poten-
tial products is highly diversified, with potential approvals and launches
spread across our internal facilities as well as from external partnerships.
77 Reps
promoting
RYTARY and
Zomig® Nasal
Spray
How do you see Impax in the next three to five years?
We are in a solid financial position to fund R&D projects, invest in our quality systems and manufacturing
operations and pursue external growth opportunities. With a net leverage ratio of approximately 1.5 times (net
debt to EBITDA), we believe our balance sheet has capacity to continue to expand our generic and branded
divisions through M&A and business development.
Both divisions seek opportunities that match our business development strategy of driving success by leveraging
our technologies and formulation expertise and expanding our product offerings and distribution network. We
believe that we have the research and development expertise, commercial infrastructure and significant experi-
ence in successfully litigating Paragraph IV patent certifications to deliver quality generic medications that pro-
vide affordable alternatives to caregivers and patients. Central to our mission is focusing on difficult to formulate
and manufacture ANDAs and first-to-file and first-to-market opportunities.
For our Specialty Pharma division, Impax’s branded pharmaceutical business, a core component of our strategy
includes identifying proprietary and innovative branded pharmaceutical products that offer significant improve-
ments over existing therapies to treat CNS and pediatric disorders.
Our goal over the next three to five years, based on total gross sales, is to be a top 10 U.S. generic company with
a top 10 U.S. neurology franchise.
7
Twelve months-ended December 31 (in millions, except per-share data)
GAAP to Non-GAAP Net Income Reconciliation
Net income (loss)
Adjusted to add (deduct):
Amortization
Business development expenses
Hayward facility remediation costs
Employee severance
Payments received from litigation settlement
Intangible asset impairment charges
Provision for inventory reserve
R&D partner milestone payment
Loss on asset disposal
Payment for licensing agreement
Income tax effect
Adjusted net income (loss)
Adjusted net income (loss) per diluted share
Net income (loss) per diluted share
Adjusted EBITDA
Net income (loss)
Adjusted to add (deduct):
Interest income
Interest expense
Depreciation and other
Income tax (benefit) expense
EBITDA
Adjusted to add (deduct):
Amortization
Business development expenses
Hayward facility remediation costs
Employee severance
Payments received from litigation settlement
Intangible asset impairment charges
Provision for inventory reserve
R&D partner milestone payment
Loss on asset disposal
Payment for licensing agreement
Share-based compensation
Adjusted EBITDA
8
2014
2013
$57.4
$101.3
11.0
9.1
23.7
5.0
-
2.9
-
-
-
2.0
(17.9)
$93.2
$1.32
$0.81
2014
$57.3
(1.5)
0.0
22.9
33.2
112.1
11.1
9.1
23.7
5.0
-
2.9
-
-
-
2.0
20.9
$186.7
16.4
-
25.9
8.0
(153.0)
13.9
18.1
2.0
0.9
-
22.8
$56.1
$0.82
$1.47
2013
$101.3
(1.3)
0.4
19.6
45.7
165.7
16.4
-
25.9
8.0
(153.0)
13.9
18.1
2.0
0.9
-
17.6
$115.4
$101.3
(153.0)
16.4
-
25.9
8.0
13.9
18.1
2.0
0.9
-
22.8
2013
$101.3
(1.3)
0.4
19.6
45.7
(153.0)
16.4
-
25.9
8.0
13.9
18.1
2.0
0.9
-
17.6
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2014
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-34263
Impax Laboratories, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
65-0403311
(I.R.S. Employer Identification No.)
30831 Huntwood Avenue, Hayward, CA
(Address of principal executive offices)
94544
(Zip Code)
Registrant’s telephone number, including area code:
(510) 476-2000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, par value $0.01 per share
Name of each exchange on which registered:
The NASDAQ Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and
post such files).
Yes ☒ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation of S-K is not contained herein, and will not be contained, to the best of
registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☒
Accelerated filer ☐
Non-accelerated filer ☐
Smaller reporting company ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes ☐ No ☒
The aggregate market value of the registrant’s outstanding shares of common stock, other than shares held by persons who may be deemed affiliates of the registrant,
computed by reference to the price at which the registrant’s common stock was last sold on The NASDAQ Stock Market LLC as of the last business day of the
registrant’s most recently completed second fiscal quarter (June 30, 2014), was approximately $1,794,555,000.
(Do not check if a smaller reporting company)
As of February 13, 2015, there were 71,330,034 shares of the registrant’s common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Certain portions of the definitive proxy statement for the registrant’s Annual Meeting of Stockholders to be held on May 13, 2015 have been incorporated by reference
into Part III of this Annual Report on Form 10-K.
Forward-Looking Statements
PART I
TABLE OF CONTENTS
PART II
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures about Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
PART IV
Item 15.
Exhibits and Financial Statement Schedules
SIGNATURES
EXHIBIT INDEX
1
2
2
21
47
47
47
47
48
52
53
77
78
78
79
81
82
82
82
82
82
83
Forward-Looking Statements
Statements included in this Annual Report on Form 10-K that do not relate to present or historical conditions are “forward-looking statements.” Such forward-
looking statements involve risks and uncertainties that could cause results or outcomes to differ materially from those expressed in the forward-looking statements.
Forward-looking statements may include statements relating to our plans, strategies, objectives, expectations and intentions. Words such as “believes,” “forecasts,”
“intends,” “possible,” “estimates,” “anticipates,” and “plans” and similar expressions are intended to identify forward-looking statements. Our ability to predict results
or the effect of events on our operating results is inherently uncertain. Forward-looking statements involve a number of risks, uncertainties and other factors that
could cause actual results to differ materially from those discussed in this Annual Report on Form 10-K. Such risks and uncertainties include fluctuations in our
revenues and operating income, our ability to promptly correct the issues raised in the warning letter and Form 483 observations we received from the FDA, our ability
to successfully develop and commercialize pharmaceutical products in a timely manner, reductions or loss of business with any significant customer, the substantial
portion of our total revenues derived from sales of a limited number of products, the impact of consolidation of our customer base, the impact of competition, our
ability to sustain profitability and positive cash flows, any delays or unanticipated expenses in connection with the operation of our manufacturing facilities, the effect
of foreign economic, political, legal and other risks on our operations abroad, the uncertainty of patent litigation and other legal proceedings, the increased
government scrutiny on our agreements with brand pharmaceutical companies, product development risks and the difficulty of predicting FDA filings and approvals,
consumer acceptance and demand for new pharmaceutical products, the impact of market perceptions of us and the safety and quality of our products, our
determinations to discontinue the manufacture and distribution of certain products, our ability to achieve returns on our investments in research and development
activities, our ability to receive a return on our capital on our development of generic drugs, our ability to achieve expected results in our research and development
efforts in our branded pharmaceutical products, changes to FDA approval requirements, our ability to successfully conduct clinical trials, our reliance on third parties
to conduct clinical trials and testing, our lack of a license partner for commercialization of IPX066 outside of the United States, impact of illegal distribution and sale by
third parties of counterfeits or stolen products, the availability of raw materials and impact of interruptions in our supply chain, our policies regarding returns, rebates,
allowances and chargebacks, the use of controlled substances in our products, the effect of current economic conditions on our industry, business, results of
operations and financial condition, disruptions or failures in our information technology systems and network infrastructure caused by third party breaches or other
events, our reliance on alliance and collaboration agreements, our reliance on licenses to proprietary technologies, our dependence on certain employees, our ability to
comply with legal and regulatory requirements governing the healthcare industry, the regulatory environment, the effect of certain provisions in our government
contracts, our ability to protect our intellectual property, exposure to product liability claims, risks relating to goodwill and intangibles, changes in tax regulations, our
ability to manage our growth, including through potential acquisitions and investments, our ability to meet expectations regarding the timing and completion of the
proposed transaction with Tower Holdings Inc. and Lineage Therapeutics Inc., our ability to consummate such proposed transaction, the conditions to the completion
of such proposed transaction (including the receipt of the regulatory approvals required for the transaction not being obtained on the terms expected or on the
anticipated schedule), the integration of the acquired business being more difficult, time-consuming or costly than expected, operating costs, customer loss and
business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) being greater than expected
following the proposed transaction, the retention of certain key employees of the acquired business being difficult, the acquired business's expected or targeted future
financial and operating performance and results, the combined company's capacity to bring new products to market, and the possibility that we may be unable to
achieve expected synergies and operating efficiencies in connection with the proposed transaction within the expected time-frames or at all and to successfully
integrate the acquired business, uncertainties involved in the preparation of our financial statements, our ability to maintain an effective system of internal control over
financial reporting, the effect of terrorist attacks on our business, the location of our manufacturing and research and development facilities near earthquake fault lines,
expansion of social media platforms and other risks described below in “Item 1A Risk Factors.” You should not place undue reliance on forward-looking statements.
Such statements speak only as to the date on which they are made, and we undertake no obligation to update or revise any forward-looking statement, regardless of
future developments or availability of new information.
RYTARY™ is a trademark of Impax Laboratories, Inc. Other names are for informational purposes only and are used to identify companies and products and
may be trademarks of their respective owners.
1
Item 1.
Overview
Business
PART I
We are a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as our drug delivery technology, to
the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as “generics,” in addition to the development and
marketing of branded products. We operate in two segments, referred to as the “Global Pharmaceuticals Division” (“Global Division”) and the “Impax Pharmaceuticals
Division” (“Impax Division”). The Global Division concentrates its efforts on the development, manufacture, sale and distribution of our generic products, which are
the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than
by a brand name. The Impax Division is engaged in the development of proprietary brand pharmaceutical products that we believe represent improvements to already-
approved pharmaceutical products addressing the treatment of central nervous system (“CNS”) disorders. The Impax Division is also engaged in the sale and
distribution of branded Zomig® (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development
and Supply Agreement (“AZ Agreement”) with AstraZeneca UK Limited (“AstraZeneca”). Each of the Global Division and the Impax Division also generates revenue
from research and development services provided to unrelated third-party pharmaceutical entities. See “Item 15. Exhibits and Financial Statement Schedules — Note
17. Segment Information,” for financial information about our segments for the years ended December 31, 2014, 2013 and 2012.
The following information summarizes our generic pharmaceutical product development activities since inception through February 6, 2015:
●
●
●
65 Abbreviated New Drug Applications (“ANDAs”) approved by the U.S. Food and Drug Administration (“FDA”), which include generic versions
of brand name pharmaceuticals such as Brethine®, Florinef®, Minocin®, Claritin-D® 12-hour, Claritin-D® 24-hour, Wellbutrin SR®, Wellbutrin XL®,
Ditropan XL®, Depakote ER® and Prilosec®.
21 applications pending at the FDA that represent approximately $11.1 billion in 2014 U.S. product sales.
21 products in various stages of development for which applications have not yet been filed.
In addition, we have one internally developed branded pharmaceutical product, RYTARY™ (IPX066), an extended release oral capsule formulation of
carbidopa-levodopa for the treatment of Parkinson’s disease (“PD”), post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication
and/or manganese intoxication which was approved by the FDA on January 7, 2015. We also have other programs in varying stages of development.
Our Strategy
We plan to continue to expand our Global Division through targeted ANDAs and a first-to-file and first-to-market strategy. Our products and product
candidates are generally difficult to formulate and manufacture, providing certain competitive advantages. In addition to our product pipeline of 21 pending
applications at the FDA as of February 6, 2015, we are continuing to evaluate and pursue external growth initiatives including acquisitions and partnerships.
A core component of our strategy includes our ongoing focus in our Impax Division on proprietary brand-name pharmaceutical products to treat CNS
disorders. We believe that we have the research, development and formulation expertise to develop branded products that will deliver significant improvements over
existing therapies. We plan to continue investing in our development pipeline.
Acquisition of Tower Holdings, Inc. and Lineage Therapeutics Inc.
On October 8, 2014, we entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) pursuant to which we will acquire all the outstanding
shares of common stock of Tower Holdings, Inc. (“Tower”), including its operating subsidiaries CorePharma, LLC and Amedra Pharmaceuticals LLC, and of Lineage
Therapeutics Inc. (“Lineage”) (the “Transaction”) for a purchase price of $700.0 million in cash, subject to customary adjustments for working capital, net debt and
transaction expenses. The closing of the Transaction is subject to the satisfaction or waiver of certain customary closing conditions, including approvals under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, the accuracy of the representations and warranties, and performance of covenants. The privately-held
companies to be acquired in the Transaction specialize in the development, manufacture and commercialization of complex generic and branded pharmaceutical
products. Following the closing of the Transaction, which is expected to occur in the first quarter of 2015, Tower and Lineage will become our wholly owned
subsidiaries. We expect to finance the Transaction from cash on hand and borrowings under a new credit facility, as discussed in “Item 15. Exhibits and Financial
Statement Schedules - Note 11. Revolving Line of Credit.”
2
Global Division
In the generic pharmaceutical market, we focus our efforts on developing, manufacturing, selling and distributing controlled-release generic versions of
selected brand-name pharmaceuticals covering a broad range of therapeutic areas and having technically challenging drug-delivery mechanisms or unique product
development formulations. We employ our technologies and formulation expertise to develop generic products that reproduce brand-name products’ physiological
characteristics but do not infringe any valid patents relating to such brand-name products. Generic products contain the same active ingredient and are of the same
route of administration, dosage form, strength and indication(s) as brand-name products already approved for use in the United States by the FDA. We generally
focus our generic product development on brand-name products as to which the patents covering the active pharmaceutical ingredient have expired or are near
expiration, and we employ our experience to develop bioequivalent versions of controlled-release brand-name products. We also develop, manufacture, sell and
distribute specialty generic pharmaceuticals that we believe present certain competitive advantages, such as difficulty in raw materials sourcing, complex formulation
or development characteristics or special handling requirements. Our Global Division also generates revenues from research and development services provided under
a joint development agreement with an unrelated third-party pharmaceutical entity. In addition to our focus on solid oral dosage products, we have expanded our
generic pharmaceutical products portfolio to include alternative dosage form products, primarily through alliance and collaboration agreements with third parties, such
as our development, supply and distribution agreement with TOLMAR, Inc. (“Tolmar”) pursuant to which we received an exclusive license to commercialize up to 11
generic topical prescription drug products, including ten currently approved products and one product pending at the FDA, in the United States and its territories.
We sell and distribute generic pharmaceutical products primarily through four sales channels:
●
●
●
●
the “Global Product” sales channel: generic pharmaceutical prescription products we sell directly to wholesalers, large retail drug chains, and
others;
the “Rx Partner” sales channel: generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance and
collaboration agreements;
the “Private Label” sales channel: generic pharmaceutical over-the-counter (“OTC”) and prescription products we sell to unrelated third parties
who in-turn sell the product under their own label; and
the “OTC Partner” sales channel: sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical companies
pursuant to alliance, collaboration and supply agreements.
As of February 6, 2015, we marketed 96 generic pharmaceutical products representing dosage variations of 29 different pharmaceutical compounds through
our Global Division, and five other generic pharmaceutical products, representing dosage variations of two different pharmaceutical compounds, through our alliance
and collaboration agreement partners. As of February 6, 2015, our marketed generic products include, but are not limited to, authorized generic Adderall XR®,
fenofibrate (generic to Lofibra®), authorized generic Renvela® and oxymorphone hydrochloride extended release tablets (AB rated to original OPANA® ER).
3
As of February 6, 2015, we had 21 applications pending at the FDA. The following table lists our publicly identified product applications pending at the FDA
as of February 6, 2015:
Product
Generic of
Colesevelam Tablets 625 mg
Dutasteride/Tamsulosin Capsules 0.5 mg/0.4 mg
Ezetimibe Simvastatin Tablets 10/10 mg, 10/20 mg, 10/40 mg, 10/80 mg
Fenofibric Acid DR Capsules 45 and 135 mg
Fentanyl Buccal Tablet 100, 200, 400, 600, 800 mcg
Guanfacine ER Tablets 1, 2, 3, 4 mg
Methylphenidate HCI 18, 27, 36 and 54 mg ER Tablets
Mixed Amphetamine Salts ER Capsules 5, 10, 15, 20, 25, 30 mg
Oxycodone ER Tablets (new formulation) 10, 15, 20, 30, 40, 60, 80 mg
Oxymorphone ER Tablets version 5, 7.5, 10, 15, 20, 30 and 40 mg (new formulation)
Risedronate Sodium DR Tablets 35 mg
Sevelamer Carbonate Tablets 800 mg
4
Welchol®
Jalyn®
Vytorin®
Trilipix®
Fentora®
Intuniv®
Concerta®
Adderall XR®
Oxycontin®
Opana® ER
Atelvia®
Renvela®
Impax Division
The Impax Division is focused on the development and promotion through our specialty sales force of proprietary branded pharmaceutical products for the
treatment of CNS disorders, which include migraine, multiple sclerosis, Parkinson’s disease and postherpetic neuralgia. We estimate there are approximately 11,000
neurologists in the United States. Historically, a concentrated number of these neurologists are responsible for writing the majority of CNS prescriptions. CNS is the
largest therapeutic category in the United States with 2014 sales of about $69.7 billion, or 18% of the $389 billion U.S. prescription drug market. CNS product sales grew
6.2% in 2014, compared to 12.5% growth for the overall pharmaceutical market, while total CNS prescriptions increased 2.4%, consistent with the overall pharmaceutical
industry growth rate. (Source: IMS Health).
Our branded pharmaceutical product portfolio consists of commercial CNS products and development stage projects. In February 2012, we licensed from
AstraZeneca the exclusive U.S. commercial rights to Zomig® (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations pursuant to the terms of the
AZ Agreement, and began sales of the branded Zomig® products under our label during the year ended December 31, 2012 through our specialty sales force. As part
of the AZ Agreement, we also have non-exclusive rights to develop new products containing zolmitriptan and to exclusively commercialize these products in the
United States in connection with the Zomig® brand. With the addition of Zomig® to the promotional product portfolio, we increased our specialty sales team during
2012. In May 2013, our exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and we launched authorized generic versions of those
products in the United States.
In the development of our pipeline products, we apply formulation and development expertise to develop differentiated, modified, or controlled-release
versions of drug substances that are currently marketed either in the U.S. or outside the U.S. We currently have one internally developed branded pharmaceutical
product, RYTARY™ (IPX066) for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication
and/or manganese intoxication, which was approved by the FDA on January 7, 2015. We filed the required documents for a Market Authorization Application to the
European Medicines Agency (EMA) for IPX066 (RYTARY™) on November 5, 2014 and the filing was accepted by the EMA on November 26, 2014. We are also seeking
to identify a licensing partner for the development and commercialization of IPX066 in countries outside of the U.S.
The RYTARY™ NDA was submitted as a 505(b)(2) application and includes data from three controlled Phase III studies and two open label extensions of
RYTARY™ in early and advanced Parkinson’s disease. In these trials, RYTARY™ has been studied in approximately 1,000 Parkinson’s disease subjects. Our Phase III
clinical program for RYTARY™ included the APEX-PD clinical trial in subjects with early Parkinson’s disease, completed in September 2010, the ADVANCE-PD clinical
trial in subjects with advanced Parkinson’s disease, completed in March 2011, and the ASCEND-PD comparative study of RYTARY™ and carbidopa-levodopa (“CD-
LD”) plus entacapone in subjects with advanced Parkinson’s disease, completed in August 2011. RYTARY™ is an extended release oral capsule formulation of CD-LD
which is intended to maintain consistent plasma concentration of levodopa for a longer duration versus immediate release levodopa, which may have an impact on
fluctuations in clinical response.
We have a number of product candidates that are in varying stages of development and currently intend to expand our portfolio of branded pharmaceutical
products through internal development and through licensing and acquisitions.
5
Alliance and Collaboration Agreements
We have entered into several alliance and collaboration agreements with respect to certain of our products and services and may enter into similar agreements
in the future. These agreements typically obligate us to deliver multiple goods and/or services over extended periods. Such deliverables include manufactured
pharmaceutical products, exclusive and semi-exclusive marketing rights, distribution licenses, and research and development services. Our alliance and collaboration
agreements often include milestones and provide for payments upon achievement of these milestones. For more information about the types of milestone events in our
agreements and how we categorize them, see “Item 15. Exhibits and Financial Statement Schedules — Note 12. Alliance and Collaboration Agreements.”
Global Division – Alliance and Collaboration Agreements
License and Distribution Agreement with Shire
In January 2006, we entered into a License and Distribution Agreement with an affiliate of Shire Laboratories, Inc., which was subsequently amended (“Prior
Shire Agreement”), under which we received a non-exclusive license to market and sell an authorized generic of Shire’s Adderall XR® product (“AG Product”) subject
to certain conditions, but in any event by no later than January 1, 2010. We commenced sales of the AG Product in October 2009. On February 7, 2013, we entered into
an Amended and Restated License and Distribution Agreement with Shire (the “Amended and Restated Shire Agreement”), which amended and restated the Prior
Shire Agreement. The Amended and Restated Shire Agreement was entered into by the parties in connection with the settlement of our litigation with Shire relating to
Shire’s supply of the AG Product to us under the Prior Shire Agreement. During 2013, we received a payment of $48,000,000 from Shire in connection with such
litigation settlement, which was recorded in the first quarter of 2013 under the line item “Other Income” on our consolidated statement of operations.
Under the Amended and Restated Shire Agreement, Shire was required to supply the AG Product and we are responsible for marketing and selling the AG
Product subject to the terms and conditions thereof until the earlier of (i) the first commercial sale of our generic equivalent product to Adderall XR® and (ii) September
30, 2014 (the “Supply Term”), subject to certain continuing obligations of the parties upon expiration or early termination of the Supply Term, including Shire’s
obligation to deliver AG Products still owed to us as of the end of the Supply Term. We are required to pay a profit share to Shire on sales of the AG Product, of which
we owed a profit share payable to Shire of $21,089,000, $20,406,000 and $70,948,000 on sales of the AG Product during the years ended December 31, 2014, 2013 and
2012, respectively, with a corresponding charge included in the cost of revenues line in our consolidated statement of operations. Although the Supply Term expired
on September 30, 2014, we are permitted under the terms of the agreement to sell AG Products that we hold in our inventory or owed to us by Shire under the
agreement until all such products are sold. We will continue to pay a profit share to Shire on sales of such products.
Development, Supply and Distribution Agreement with Tolmar, Inc.
In June 2012, we entered into a Development, Supply and Distribution Agreement with Tolmar (“Tolmar Agreement”). Under the terms of the Tolmar
Agreement, Tolmar granted us an exclusive license to commercialize up to 11 generic topical prescription drug products, including ten currently approved products and
one product pending approval at the FDA, in the United States and its territories. Under the terms of the Tolmar Agreement, Tolmar is responsible for developing and
manufacturing the products, and we are responsible for marketing and sale of the products. We are required to pay a profit share to Tolmar on sales of each product
commercialized pursuant to the terms of the Tolmar Agreement. We paid Tolmar a $21,000,000 upfront payment upon signing of the agreement and a $1,000,000
milestone payment during the year ended December 31, 2012. During the fourth quarter ended December 31, 2013, we made a $12,000,000 payment to Tolmar upon
Tolmar’s achievement of a regulatory milestone event in accordance with the terms of the agreement. During the fourth quarter of 2014, we paid a $2,000,000 milestone
payment to Tolmar related to the Diclofenac Sodium Gel 3% (Solaraze) product pursuant to the Tolmar Agreement in accordance with the terms thereof. Under the
Tolmar Agreement, we may be required to pay up to an aggregate of $10,000,000 in additional contingent milestone payments if certain commercialization events occur.
We are required to pay a profit share to Tolmar on sales of the topical products, of which we owed a profit share payable to Tolmar of $15,995,000, $3,905,000
and $551,000 on sales of the topical products during the years ended December 31, 2014, 2013 and 2012, respectively, with a corresponding charge included in the Cost
of Revenues line item on our consolidated statement of operations.
6
Rx Partner and OTC Partner Alliance Agreements
We have entered into alliance agreements with unrelated third-party pharmaceutical companies pursuant to which our partner distributes a specified product
or products which we developed and, in some cases manufacture. Pursuant to these alliance agreements we typically receive payment on delivery of the product, and
share in the resulting profits, or receive a royalty or receive other payments from our partners. Our alliance agreements are separated into two sales channels, the “Rx
Partner” sales channel, for generic prescription products sold through our partners under their own label, and the “OTC Partner” sales channel, for sales of generic
pharmaceutical OTC products sold through our partner under their own label. The revenue recognized and the percentage of gross revenue for each of the periods
noted, for the Rx Partner and the OTC Partner alliance agreements, was as follows:
$’s in 000’s
Gross Revenue and % Gross Revenue
Rx Partner
OTC Partner
2014
Year Ended December 31,
2013
2012
$
$
14,114
1,319
1% $
1% $
11,639
1,173
1% $
1% $
12,945
11,602
1%
1%
Rx Partner Alliance Agreement with Teva
We entered into a Strategic Alliance Agreement with Teva Pharmaceuticals Curacao N.V., a subsidiary of Teva Pharmaceutical Industries Limited, in June 2001,
which was subsequently amended (“Teva Agreement”). Under the Teva Agreement, we agreed to develop, manufacture and supply generic versions of 11 controlled-
release generic pharmaceutical branded and OTC products and a 12th product we have not yet publicly identified, as follows:
● Wellbutrin SR® 100 and 150 mg extended release tablets
●
Zyban® 150 mg extended release tablets
● Claritin-D® 12-hour 120 mg 12-hour extended release tablets
● Claritin-D® 24-hour 240 mg 24-hour extended release tablets
● Claritin Reditabs® 10 mg orally disintegrating tablets
● Ditropan XL® 5, 10 and 15 mg extended release tablets
● Glucophage XR® 500 mg extended release tablets
● Concerta® 18, 27, 36 and 54 mg extended release tablets
● Allegra-D® 60/120 mg extended release tablets
● Wellbutrin XL® 150 and 300 mg extended release tablets
●
Prilosec® 10 mg, 20 mg, 40mg extended release tablets
The 12 covered products under the Teva Agreement represent 22 different product/strength combinations, of which, as of February 6, 2015, three are
currently being marketed and four are awaiting FDA approval. Of the 22 product/strength combinations, 20 are publicly disclosed. In July 2010, we amended the Teva
Agreement to terminate its provisions with respect to the Prilosec® products. Additionally, in exchange for the return of product rights, the Company agreed to pay to
Teva a profit share on future sales of the Allegra-D® product, if any, with such profit share payments not to exceed an aggregate amount of $3.0 million. As of
February 6, 2015, we are supplying Teva with Ditropan XL® 5, 10 and 15 mg extended release tablets as the other products have either been returned to us, are
manufactured by Teva at its election, were voluntarily withdrawn from the market, have not yet approved by the FDA or our obligations to supply such product
expired or were terminated in accordance with the agreement.
7
Under the Teva Agreement, Teva is required to pay us a fixed percentage of defined profits on its sales of products, except for the Claritin® products, and
reimburses us for our manufacturing costs, for a term of 10 years from the initial commercialization of each product. Additionally, under the Teva Agreement, we share
with Teva the profits (up to a maximum of 50%) from the sale of the generic pharmaceutical OTC versions of the Claritin® products, sold through our OTC Partners’
alliance agreement.
Our remaining obligations under the Teva Agreement are to continue our efforts to obtain FDA approval of those products not yet approved, and
manufacture and supply the approved products to Teva. Our obligation to manufacture and supply each product extends for 10 years following the commercialization
of the product. For more information about the Teva Agreement, see “Item 15. Exhibits and Financial Statement Schedules – Note 12. Alliance and Collaboration
Agreements.”
OTC Partner Alliance Agreements
We have a Development, License and Supply Agreement with Pfizer, Inc., formerly Wyeth LLC (“Pfizer”) relating to our generic Claritin-D® 12-hour extended
release product (the “Pfizer Agreement”). Under the Pfizer Agreement, which was entered into in 2002, we received an upfront payment of $0.35 million and product
development milestone payments aggregating $2.0 million. We also receive quarterly royalty payments which are calculated as a percentage (less than 10%) of Pfizer’s
sales of products covered by the agreement. Pfizer launched the 12-hour product in May 2003 as its OTC Alavert D-12 Hour®. We do not expect to receive any
additional milestone payments under the agreement. This agreement with Pfizer terminates in April 2018. In December 2011, we and Pfizer entered into an agreement
with L. Perrigo Company (“Perrigo”) whereby the parties agreed that we would supply our generic Claritin-D® 5 mg/120 mg 12-hour extended release product tablets to
Perrigo in the United States and its territories. The agreements with Pfizer and Perrigo are no longer a core area of our business and the over-the-counter
pharmaceutical products we sell to Pfizer and Perrigo under the agreements are older products which are only sold to Pfizer and Perrigo. We recognize profit share
revenue in the period earned.
Research Partner Alliance Agreement
In November 2008, we entered into a Joint Development Agreement with Valeant Pharmaceuticals International, Inc., formerly Medicis Pharmaceutical
Corporation (“Valeant”), providing for collaboration in the development of five dermatological products, including four of our generic products and one branded
advanced form of Valeant’s SOLODYN® product. Valeant paid us an upfront fee of $40.0 million in December 2008. We have also received an aggregate of $15.0 million
in milestone payments consisting of two $5.0 million milestone payments, paid by Valeant in March 2009 and September 2009, a $2.0 million milestone payment received
in December 2009, and a $3.0 million milestone payment received in March 2011. We have the potential to receive up to an additional $8.0 million of contingent
regulatory milestone payments as well as the potential to receive royalty payments from sales, if any, by Valeant of its advanced form SOLODYN® product under this
agreement. We believe that all of the milestones under this agreement are substantive and expect to recognize the proceeds from these regulatory milestones as
revenue when achieved. We do not expect to receive any of these additional milestone payments during the fiscal year ending December 31, 2015. To the extent we
commercialize any of the four generic dermatology products covered by the agreement, we will pay to Valeant a gross profit share on sales of such products. We began
selling one of the four dermatology products during the year ended December 31, 2011. During the three month period ended March 31, 2013, we extended the revenue
recognition period for the Joint Development Agreement from the previous recognition period ending in November 2013 to December 2014 due to changes in the
estimated timing of completion of certain research and development activities. All deferred revenue under the Joint Development Agreement was recognized as of
December 31, 2014.
Impax Division – Alliance and Collaboration Agreements
Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited
In January 2012, we entered into the AZ Agreement with AstraZeneca. Under the terms of the AZ Agreement, AstraZeneca granted to us an exclusive license
to commercialize the tablet, orally disintegrating tablet and nasal spray formulations of Zomig® (zolmitriptan) products for the treatment of migraine headaches in the
United States and in certain U.S. territories, except during an initial transition period when AstraZeneca fulfilled all orders of Zomig® products on our behalf and paid
us the gross profit on such Zomig® product sales. We are obligated to fulfill certain minimum requirements with respect to the promotion of currently approved
Zomig® products as well as other dosage strengths of such products approved by the FDA in the future. We may, but have no obligation to, develop and
commercialize additional products containing zolmitriptan and additional indications for Zomig®, subject to certain restrictions as set forth in the AZ Agreement. We
will be responsible for conducting clinical studies and preparing regulatory filings related to the development of any such additional products and would bear all
related costs. During the term of the AZ Agreement, AstraZeneca will continue to be the holder of the NDA for existing Zomig® products, as well as any future
dosage strengths thereof approved by the FDA, and will be responsible for certain regulatory and quality-related activities for such Zomig® products. AstraZeneca
will manufacture and supply Zomig® products to us and we will purchase our requirements of Zomig® products from AstraZeneca until a date determined in the AZ
Agreement. Thereafter, AstraZeneca may terminate its supply obligations upon certain advance notice, in which case we would have the right to manufacture or have
manufactured our own requirements for the applicable Zomig® product.
8
Under the terms of the AZ Agreement, AstraZeneca was required to make payments to us representing 100% of the gross profit on sales of AstraZeneca-
labeled Zomig® products during the specified transition period. Under the terms of the AZ Agreement, we made quarterly payments totaling $130.0 million to
AstraZeneca during the year ended December 31, 2012. Beginning in January 2013, we were obligated to pay AstraZeneca tiered royalty payments based on net sales
of Zomig® products, depending on brand exclusivity and subject to customary reductions and other terms and conditions set forth in the AZ Agreement. We are also
obligated to pay to AstraZeneca royalties after a certain specified date based on gross profit from sales of authorized generic versions of the Zomig® products subject
to certain terms and conditions set forth in the AZ Agreement. In May 2013, our exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired
and we launched authorized generic versions of those products in the United States.
After December 31, 2015, we may terminate the AZ Agreement for convenience upon specified notice. We may also terminate the AZ Agreement if certain of
AstraZeneca’s annual manufacturing costs reflected in the supply price increase by more than a certain threshold. The AZ Agreement may also be terminated under
certain other circumstances, including for material breach, as set forth in the AZ Agreement.
License, Development and Commercialization Agreement with Glaxo Group Limited
In December 2010, we entered into a License, Development and Commercialization Agreement with Glaxo Group Limited (“GSK”). Under the terms of the
agreement with GSK, GSK received an exclusive license to develop and commercialize IPX066 (brand name RYTARY™ in the United States) throughout the world,
except in the U.S. and Taiwan, and certain follow on products at the option of GSK. Under the terms of the agreement, GSK paid an $11.5 million upfront payment to us
in December 2010, and we had the potential to receive up to an additional $169.0 million of contingent milestone payments. In April 2013, we announced that our
collaboration with GSK for the development and commercialization of IPX066 outside the United States and Taiwan was being terminated as a result of delays in the
anticipated regulatory approval and launch dates in countries in which GSK had rights to commercialize the product and the License, Development and
Commercialization Agreement was terminated. At the end of July 2013, GSK’s rights to develop and commercialize IPX066 outside the United States and Taiwan were
transferred back to us.
9
Development and Co-Promotion Agreement with Endo Pharmaceuticals Inc.
In June 2010, we entered into a Development and Co-Promotion Agreement (“Endo Agreement”) with Endo Pharmaceuticals Inc. ("Endo") under which we
have agreed to collaborate in the development and commercialization of a next-generation advanced form of RYTARY™ (IPX066) ("Endo Agreement Product"). Under
the provisions of the Endo Agreement, in June 2010, Endo paid to us a $10.0 million upfront payment. We have the potential to receive up to an additional $30.0 million
of contingent milestone payments which includes $15.0 million contingent upon the achievement of clinical events, $5.0 million contingent upon the achievement of
regulatory events, and $10.0 million contingent upon the achievement of commercialization events. We believe that all of the milestones under this agreement are
substantive and expect to recognize the proceeds from these milestones as revenue when achieved. Upon commercialization of the Endo Agreement Product in the
United States, Endo will have the right to co-promote such product to non-neurologists, which will require us to pay Endo a co-promotion service fee of up to 100% of
the gross profits attributable to prescriptions for the Endo Agreement Product which are written by the non-neurologists. Upon FDA approval of an NDA for the Endo
Agreement Product, we will have the right (but not the obligation) to begin manufacture and sale of such product.
We also entered into a Settlement and License Agreement with Endo in June 2010 (the “Endo Settlement Agreement”) pursuant to which Endo agreed to make
a payment to us should prescription sales of Opana® ER, as defined in the Endo Settlement Agreement, fall below a predetermined contractual threshold in the quarter
immediately prior to our Global Division launching a generic version of Opana® ER. As a result of the launch of our generic version of Opana® ER in January 2013 and
the level of sales of Endo’s Prescription Opana® ER during the fourth quarter of 2012, we recorded a $102,049,000 settlement gain during the three month period ended
March 31, 2013, which is included in “Other Income” in the consolidated statement of operations.
Co-Promotion Agreement with Pfizer Inc.
In March 2010, we entered into a First Amendment to our Co-Promotion Agreement ("Pfizer Co-Promotion Agreement") with Pfizer. Our obligation to provide
physician detailing sales calls under the Pfizer Co-Promotion Agreement ended on June 30, 2012. Prior to such time, we received a fixed fee for providing such
physician detailing sales calls within a contractually defined range of an aggregate number of physician detailing sales calls rendered, determined on a quarterly basis.
Pfizer owned the product and was responsible for all pricing and marketing literature as well as product manufacture and fulfillment. We recognized revenue of $7.1
million in the year ended December 31, 2012 under the Pfizer Co-Promotion Agreement, which is presented in the line item “Other Revenues” in “Item 15. Exhibits and
Financial Statement Schedules – Note 20 - Supplementary Financial Information.”
Agreement with DURECT Corporation
During the three month period ended March 31, 2014, the Company entered into an agreement with DURECT Corporation (“Durect”) granting the Company
the exclusive worldwide rights to develop and commercialize DURECT’s investigational transdermal bupivacaine patch for the treatment of pain associated with post-
herpetic neuralgia (PHN), referred to by the Company as IPX239. The Company paid Durect a $2,000,000 up-front payment upon signing of the agreement. The
Company has the potential to pay up to $61,000,000 in additional contingent milestone payments upon the achievement of predefined development and
commercialization milestones. If IPX239 is commercialized, Durect would also receive a tiered royalty on product sales.
10
Our Controlled-Release Technology
We have developed a number of different controlled-release delivery technologies which may be utilized with a variety of oral dosage forms and drugs.
Controlled-release drug delivery technologies are designed to release drug dosages at specific times and in specific locations in the body and generally provide more
consistent and appropriate drug levels in the bloodstream than immediate-release dosage forms. Controlled-release pharmaceuticals may improve drug efficacy, ensure
greater patient compliance with the treatment regimen, reduce side effects or increase drug stability and be more patient friendly by reducing the number of times a
drug must be taken.
We believe our controlled-release drug delivery technologies are flexible and can be applied to develop a variety of pharmaceutical products, both generic and
branded. Our technologies utilize a variety of polymers and other materials to encapsulate or entrap the active pharmaceutical ingredients and to release them at
varying rates or at predetermined locations in the gastrointestinal tract.
Competition
The pharmaceutical industry is highly competitive and is affected by new technologies, new developments, government regulations, health care legislation,
availability of financing, and other factors. Many of our competitors have longer operating histories and substantially greater financial, research and development,
marketing, and other resources than we have. We compete with numerous other companies that currently operate, or intend to operate, in the pharmaceutical industry,
including companies that are engaged in the development of controlled-release drug delivery technologies and products, and other manufacturers that may decide to
undertake development of such products. Our principal competitors in the generic pharmaceutical products market are Teva Pharmaceutical Industries Ltd., Actavis
plc., Mylan Inc., Ranbaxy Laboratories Ltd., Lannett Company, Inc., Lupin Pharmaceuticals, Inc., Par Pharmaceutical Companies, Inc. and Sandoz.
Due to our focus on relatively hard to replicate controlled-release products, competition in the generic pharmaceutical market is sometimes limited to those
competitors who possess the appropriate drug delivery technology. The principal competitive factors in the generic pharmaceutical market are:
●
●
●
●
●
the ability to introduce generic versions of products promptly after a patent expires;
price;
product quality;
customer service (including maintenance of inventories for timely delivery); and
the ability to identify and market niche products.
In the brand-name pharmaceutical market, we market Impax-labeled branded Zomig® products pursuant to the AZ Agreement. We received approval from the
FDA on January 7, 2015 to market and sell RYTARY™, our first internally developed branded pharmaceutical product for the treatment of Parkinson’s disease, and we
currently plan to fully launch our sales and marketing efforts for the product in early April 2015. We currently expect our principal competitors in the branded
pharmaceutical products market to include pharmaceutical companies that are focused on Parkinson’s disease and other CNS disorders.
A description of the competition we face from brand-name and generic pharmaceutical companies is included in “Item 1A. Risk Factors”.
Sales and Marketing
We market and sell our generic pharmaceutical prescription drug products within the continental United States and the Commonwealth of Puerto Rico. We
have not made sales in any other jurisdictions over the last three fiscal years. We derive a substantial portion of our revenue from sales to a limited number of
customers. The customer base for our products consists primarily of drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order
pharmacies. We market our products both directly, through our Global Division, and indirectly through our Rx Partner and OTC Partner alliance and collaboration
agreements. Together, our five major customers, McKesson Corporation, Cardinal Health, Amerisource-Bergen, CVS Caremark Corporation and Wal-Mart Stores,
accounted for 80% of our gross revenue for the year ended December 31, 2014. These five customers individually accounted for 36%, 20%, 19%, 3% and 2%,
respectively, of our gross revenue for the year ended December 31, 2014. We do not have long-term contracts in effect with our five major customers. A reduction in or
loss of business with any one of these customers, or any failure of a customer to pay us on a timely basis, would adversely affect our business.
11
With respect to our branded pharmaceutical products, we began marketing Impax-labeled Zomig® products during the year ended December 31, 2012
pursuant to the terms of the AZ Agreement through our specialty sales force. We also currently expect to fully launch our sales and marketing efforts for RYTARY™,
our first internally developed branded pharmaceutical product for the treatment of Parkinson’s disease, in early April 2015.
Manufacturing and Distribution
We source our finished dosage form products from our own facilities in Hayward, California and Taiwan. We also use several contract manufacturers for this
purpose. We package our products at our Philadelphia, Pennsylvania facility and at several contract packagers. We operate our own distribution center in New Britain,
Pennsylvania.
We completed construction of a new manufacturing facility in Taiwan, installed equipment and received FDA approval of the facility during 2009. We initiated
construction of an expansion to the Taiwan facility during 2009 and have expanded the facility in stages. As of May 2014, the second phase of the expansion was
completed and the manufacturing equipment in the facility was qualified for their intended use. A major portion of this second phase expansion was dedicated to the
production of RYTARY™. We completed transfer of a substantial portion of our Hayward, California production to the lower cost production site in Taiwan during
2013 to create capacity for future products being launched from the Hayward facility. We currently plan to continue increasing production at our Taiwan facility of
tablets and capsules in support of transferred products and in preparation for the growth of RYTARY™ during 2015. See also “Item 15. Exhibits and Financial
Statement Schedules — Note 17. Segment Information” and “Note 18. Commitments and Contingencies” for a discussion of our Taiwan facility.
We maintain an inventory of our products in connection with our obligations under our alliance and collaboration agreements. In addition, for products
pending approval, we may produce batches for inventory in anticipation of the launch of the products. In the event that FDA approval is denied or delayed, we could
be exposed to the risk of this inventory becoming obsolete.
Raw Materials
The active chemical raw materials essential to our business are generally readily available from multiple sources in the United States and throughout the
world. Certain raw materials used in the manufacture of our products are, however, available from limited sources and, in some cases, a single source. Although we
have not experienced any material delays in receipt of raw materials to date, any curtailment in the availability of such raw materials could result in production or other
delays or, in the case of products for which only one raw material supplier exists or has been approved by the FDA, a material loss of sales with consequent adverse
effects on our business and results of operations. Also, because raw material sources for pharmaceutical products must generally be identified and approved by
regulatory authorities, changes in raw material suppliers may result in production delays, higher raw material costs, and loss of sales and customers. We obtain a
portion of our raw materials from foreign suppliers, and our arrangements with such suppliers are subject to, among other risks, FDA approval, governmental
clearances, export duties, political instability, and restrictions on the transfers of funds.
Those of our raw materials that are available from a limited number of suppliers include Bendroflumethiazide, Chloroquine, Colestipol, Digoxin, Fenofibrate,
Methyltestosterone, Nadolol, Pyridostigmine and Klucel®, all of which are active pharmaceutical ingredients except Klucel®, which is an excipient used in several
product formulations. The manufacturers of several of these products are sole-source suppliers. While none of the active ingredients is individually significant to our
business, the excipient, which is not covered by a supply agreement, is utilized in a number of significant products. Only a couple of the active ingredients are covered
by long-term supply agreements and, although to date we have only experienced occasional interruptions in supplies, no assurance can be given that we will continue
to receive uninterrupted or adequate supplies of such raw materials.
Any inability to obtain raw materials on a timely basis, or any significant price increases not passed on to customers, could have a material adverse effect on
us.
12
Quality Control
In late May 2011, we received a warning letter from the FDA related to an on-site FDA inspection of our Hayward, California manufacturing facility citing
deviations from current Good Manufacturing Practices (cGMP), which are extensive regulations governing manufacturing practices for finished pharmaceutical
products and which establish requirements for manufacturing processes, stability testing, record keeping and quality standards and controls. The FDA observations
set forth in the warning letter related to sampling and testing of in-process materials and drug products, production record review, and our process for investigating
the failure of certain manufacturing batches (or portions of batches) to meet specifications.
During the quarters ended March 31, 2012 and March 31, 2013, the FDA conducted inspections of our Hayward manufacturing facility and at the conclusion
of each inspection, we received a Form 483. The Form 483 issued during the quarter ended March 31, 2012 contained observations primarily relating to our Quality
Control Laboratory and the Form 483 issued during the quarter ended March 31, 2013 contained several observations pertaining to the operations of the Hayward
facility, three of which were designated by the FDA as repeat observations from inspections that occurred prior to the warning letter. We provided the FDA with what
we believe to be our complete written responses relating to the observations in the warning letter and the Form 483 issued in 2012. In connection with the Form 483
issued in 2013, we provided our written response to the FDA during the first quarter ended March 31, 2013 and provided the FDA with updates regarding the
completion status of our corrective actions. In late October 2013, at the FDA’s request, we participated in a regulatory meeting with representatives of the FDA to
provide additional information and clarifications on our response and updates related to the Form 483 issued in 2013. The FDA performed a re-inspection of our
Hayward manufacturing facility during June and July 2014. At the conclusion of the re-inspection, the FDA issued a Form 483 with seven inspectional observations,
two of which were designated by the FDA as repeat observations from the inspection that occurred in 2013. We provided the FDA with what we believe to be our
complete written response and updates regarding the completion status of our corrective actions through December 2014. To date, we have not been informed by the
FDA as to whether a satisfactory re-inspection of our Hayward manufacturing facility will be required to close out the warning letter and resolve the 2014 Form 483
observations on our Hayward manufacturing facility.
In July 2014, the FDA conducted an inspection of our Taiwan manufacturing facility and at the conclusion of the inspection, we received a Form 483 with ten
observations. At the time of the inspections, the FDA did not provide any status or classification to either the Form 483 observations on our Hayward or Taiwan
manufacturing facilities and, pursuant to its established regulatory process, would wait until they have received and reviewed our responses to classify those
inspections. We received and responded to a request for additional information from the FDA regarding our Taiwan facility in December 2014. On January 7, 2015, we
received approval from the FDA for RYTARY™, our first internally developed branded product for the treatment of Parkinson’s disease, which is manufactured in our
Taiwan facility.
To date, the FDA has not notified us of any additional enforcement actions at either the Hayward or Taiwan manufacturing facilities, however, no assurance
can be given as to whether the FDA will take any further actions. We are currently cooperating with the FDA to close out the warning letter and resolve the Form 483
observations. The warning letter and Form 483 observations do not currently place restrictions on our ability to manufacture and ship our existing products.
We have taken a number of steps to review our quality control and manufacturing systems and standards and are working with third-party experts to assist us
with our review and in enhancing such systems and standards. This work is ongoing and we are committed to improving our quality control and manufacturing
practices. We cannot be assured, however, that the FDA will be satisfied with our corrective actions and as such, we cannot be assured of when the warning letter will
be closed out. Unless and until the warning letter is closed out and the Form 483 observations resolved, it is possible we may be subject to additional regulatory action
by the FDA as a result of current or future FDA observations, including, among others, monetary sanctions or penalties, product recalls or seizure, injunctions, total or
partial suspension of production and/or distribution, and suspension or withdrawal of regulatory approvals. Additionally, the FDA has withheld and may continue to
withhold approval of pending drug applications listing our Hayward, California facility as a manufacturing location of finished dosage forms until the warning letter is
closed out and the Form 483 observations on our Hayward facility are resolved. Further, other federal agencies, our customers and partners in our alliance,
development, collaboration and other partnership agreements with respect to our products and services may take the warning letter and Form 483 observations into
account when considering the award of contracts or the continuation or extension of such partnership agreements. If we are unable promptly to correct the issues
raised in the warning letter and Form 483 observations, our business, consolidated results of operations and consolidated financial condition could be materially and
adversely affected.
13
Research and Development
We conduct most of our research and development activities at our facilities in Hayward, California, with a staff of 130 employees as of December 31, 2014. In
addition, we have outsourced a number of research and development projects to offshore laboratories.
We spent approximately $79.1 million, $68.9 million and $81.3 million on research and development activities during the years ended December 31, 2014, 2013
and 2012, respectively, as more fully set out in the tables below. The research and development expenses in the year ended December 31, 2014 included $1.5 million
related to our reduction in workforce, included in the line item “Personnel expenses” below.
Year Ended December 31, 2014
Clinical study expenses
Personnel expenses
Experimental materials
Outside services
Facility expenses
Legal expenses
Other
Total
Year Ended December 31, 2013
Clinical study expenses
Personnel expenses
Experimental materials
Outside services
Facility expenses
Legal expenses
Other
Total
Year Ended December 31, 2012
Clinical study expenses
Personnel expenses
Experimental materials
Outside services
Facility expenses
Legal expenses
Other
Total
Global
Division
Impax
Division
($ in millions)
Total
Impax
$
$
10.2
17.1
5.0
2.7
2.7
0.3
2.9
40.9
$
$
7.6
17.7
0.7
4.9
1.1
1.0
5.2
38.2
$
$
Global
Division
Impax
Division
($ in millions)
Total
Impax
14.9 $
14.9
2.8
2.4
2.6
0.9
2.9
41.4 $
6.0 $
15.7
1.1
1.4
1.1
0.4
1.8
27.5 $
Global
Division
Impax
Division
($ in millions)
Total
Impax
13.7 $
17.2
3.7
2.6
2.8
1.4
7.1
48.5 $
10.6
14.6
0.9
2.6
1.0
0.8
2.3
32.8 $
$
$
$
$
14
17.8
34.8
5.7
7.6
3.8
1.3
8.1
79.1
20.9
30.6
3.9
3.8
3.7
1.3
4.7
68.9
24.3
31.8
4.6
5.2
3.8
2.2
9.4
81.3
We do not generally track research and development expense by individual product in either the Global Division or the Impax Division.
In the Global Division, we focus our research and development efforts based on drug-delivery technology and on products that we believe may have certain
competitive advantages, rather than on any particular therapeutic area. As of February 6, 2015, the Global Division had 21 product applications pending with the FDA
and another 21 products in development. Accordingly, we believe that our generic pipeline products will, in the aggregate, generate a significant amount of revenue for
us in the future. However, while a generic product is still in development, we are unable to predict the level of commercial success that the product may ultimately
achieve given the uncertainties relating to the successful and timely completion of bioequivalence studies, ANDA filing, receipt of marketing approval and resolution
of any related patent litigation, as well as the amount of competition in the market at the time of product launch and thereafter and other factors detailed in “Item 1A
Risk Factors.” Additionally, we do not believe that any individual generic pipeline product is currently significant in terms of accrued or anticipated research and
development expense given the large volume of products under development in the Global Division, as detailed above. Further, on a per product basis, development
costs for generic products tend to be significantly lower than for branded products, as the process for establishing bioequivalence is significantly less extensive than
the standard clinical trial process. The regulatory approval process is significantly less onerous as well.
In the Impax Division, we currently have one internally developed branded pharmaceutical product, RYTARY™ (IPX066) for the treatment of Parkinson’s
disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the
FDA on January 7, 2015. We currently plan to fully launch our sales and marketing efforts for the product in early April 2015. We also have a number of product
candidates that are in varying stages of development. While we believe the pipeline products in this division are potentially viable, profitable product candidates for
us, given the uncertainties relating to the successful completion of clinical trials, the FDA approval process for branded products, reimbursement levels, the amount of
competition at the time of product launch and thereafter and other factors detailed in “Item 1A Risk Factors,” such pipeline products are too early in the development
process to be considered significant at this point in time.
15
Regulation
The manufacturing and distribution of pharmaceutical products are subject to extensive regulation by the federal government, primarily through the FDA and
the Drug Enforcement Administration (“DEA”), and to a lesser extent by state and local governments. The Food, Drug, and Cosmetic Act, Controlled Substances Act
and other federal statutes and regulations govern or influence the manufacture, labeling, testing, storage, record keeping, approval, advertising and promotion of our
products. Facilities used in the manufacture, packaging, labeling and repackaging of pharmaceutical products must be registered with the FDA and are subject to FDA
inspection to ensure that drug products are manufactured in accordance with current Good Manufacturing Practices. Noncompliance with applicable requirements can
result in product recalls, seizure of products, injunctions, suspension of production, refusal of the government to enter into supply contracts or to approve drug
applications, civil penalties and criminal fines, and disgorgement of profits.
FDA approval is required before any “new drug” may be marketed, including new formulations, strengths, dosage forms and generic versions of previously
approved drugs. Generally, the following two types of applications are used to obtain FDA approval of a “new drug.”
New Drug Application (“NDA”). For a drug product containing an active ingredient not previously approved by the FDA, a prospective manufacturer must
submit a complete application containing the results of clinical studies supporting the drug product’s safety and efficacy. An NDA is also required for a drug with a
previously approved active ingredient if the drug will be used to treat an indication for which the drug was not previously approved or if the dosage form, strength or
method of delivery is changed. The process required by the FDA before a pharmaceutical product may be approved for marketing in the U.S. generally involves the
steps listed below, which could take from approximately three to more than ten years to complete.
Laboratory and clinical tests;
●
●
Submission of an Investigational New Drug (“IND”) application, which must become effective before clinical studies may begin;
● Adequate and well-controlled human clinical studies to establish the safety and efficacy of the proposed product for its intended use;
●
Submission of an NDA containing the results of the preclinical tests and clinical studies establishing the safety and efficacy of the proposed
product for its intended use, as well as extensive data addressing such matters such as manufacturing and quality assurance;
Scale-up to commercial manufacturing; and
FDA approval of an NDA.
●
●
As noted above, the submission of an NDA is no guarantee that the FDA will find it complete and accept it for filing. The FDA reviews all NDAs submitted
before it accepts them for filing. It may refuse to file the application and instead request additional information, in which case, the application must be resubmitted with
the supplemental information. After the application is deemed filed by the FDA, FDA staff will review an NDA to determine, among other things, whether a product is
safe and efficacious for its intended use.
If, after reviewing the NDA, the FDA determines that the application cannot be approved in its current form, the FDA sends the NDA applicant a Complete
Response Letter identifying all outstanding deficiencies that preclude final approval. The FDA then halts its review until the applicant resubmits the NDA with new
information designed to address the deficiencies. An applicant receiving a Complete Response Letter may resubmit the application with data and information
addressing the FDA’s concerns or requirements, withdraw the application without prejudice to a subsequent submission of a related application or request a hearing
on whether there are grounds for denying approval of the application. If a product receives regulatory approval, the approval may be significantly limited to specific
diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require an
applicant to conduct Phase 4 testing which involves clinical trials designed to further assess a drug’s safety and effectiveness after NDA approval, and may require
surveillance programs to monitor the safety of approved products which have been commercialized. Once issued, the FDA may withdraw product approval if ongoing
regulatory requirements are not met or if safety or efficacy questions are raised after the product reaches the market. The agency may also impose requirements that
the NDA holder conduct new studies, make labeling changes, implement Risk Evaluation and Mitigation Strategies, and take other corrective measures.
16
Abbreviated New Drug Application (“ANDA”). For a generic version of an approved drug — a drug product that contains the same active ingredient as a
drug previously approved by the FDA and is in the same dosage form and strength, utilizes the same method of delivery and will be used to treat the same indications
as the approved product — the FDA requires only an abbreviated new drug application that ordinarily need not include clinical studies demonstrating safety and
efficacy. An ANDA typically requires only data demonstrating that the generic formulation is bioequivalent to the previously approved “reference listed drug,”
indicating that the rate of absorption and levels of concentration of the generic drug in the body do not show a significant difference from those of the reference listed
drug. In July 2012, the Generic Drug Fee User Amendments of 2012 (“GDUFA”) was enacted into law. The GDUFA legislation implemented fees for new ANDA
applications, Drug Master Files, product and establishment fees and a one-time fee for back-logged ANDA applications pending approval as of October 1, 2012. In
return, the program is intended to provide faster and more predictable ANDA reviews by the FDA and increased inspections of drug facilities. Under GDUFA, generic
product companies face significant penalties for failure to pay the new user fees, including rendering an ANDA application not “substantially complete” until the fee is
paid. Prior to the implementation of GDUFA, the FDA took an average of approximately 30 months to approve an ANDA.
Under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the “Hatch-Waxman Act”, which established the procedures
for obtaining approval of generic drugs, an ANDA filer must make certain patent certifications that can result in significant delays in obtaining FDA approval. If the
applicant intends to challenge the validity or enforceability of an existing patent covering the reference listed drug or asserts that its drug does not infringe such
patent, the applicant files a so called “Paragraph IV” certification and notifies the patent holder that it has done so, explaining the basis for its belief that the patent is
not infringed or is invalid or unenforceable. If the patent holder initiates a patent infringement suit within 45 days after receipt of the Paragraph IV Certification, the
FDA is automatically prevented from approving an ANDA until the earlier of 30 months after the date the Paragraph IV Certification is given to the patent holder,
expiration of the patents involved in the certification, or when the infringement case is decided in the ANDA applicant’s favor. In addition, the first company to file an
ANDA for a given drug containing a Paragraph IV certification can be awarded 180 days of market exclusivity following approval of its ANDA, during which the FDA
may not approve any other ANDAs for that drug product.
During any period in which the FDA is required to withhold its approval of an ANDA due to a statutorily imposed non-approval period, the FDA may grant
tentative approval to an applicant’s ANDA. A tentative approval reflects the FDA’s preliminary determination that a generic product satisfies the substantive
requirements for approval, subject to the expiration of all statutorily imposed non-approval periods. A tentative approval does not allow the applicant to market the
generic drug product.
The Hatch-Waxman Act contains additional provisions that can delay the launch of generic products. A five year marketing exclusivity period is provided for
new chemical compounds, and a three year marketing exclusivity period is provided for approved applications containing new clinical investigations essential to an
approval, such as a new indication for use, or new delivery technologies, or new dosage forms. The three year marketing exclusivity period applies to, among other
things, the development of a novel drug delivery system, as well as a new use. In addition, companies can obtain six additional months of exclusivity if they perform
pediatric studies of a reference listed drug product. The marketing exclusivity provisions apply to both patented and non-patented drug products. The Act also
provides for patent term extensions to compensate for patent protection lost due to time taken in conducting FDA required clinical studies and during FDA review of
NDAs.
The Generic Drug Enforcement Act of 1992 establishes penalties for wrongdoing in connection with the development or submission of an ANDA. In general,
the FDA is authorized to temporarily bar companies, or temporarily or permanently bar individuals, from submitting or assisting in the submission of an ANDA, and to
temporarily deny approval and suspend applications to market generic drugs under certain circumstances. In addition to debarment, the FDA has numerous
discretionary disciplinary powers, including the authority to withdraw approval of an ANDA or to approve an ANDA under certain circumstances and to suspend the
distribution of all drugs approved or developed in connection with certain wrongful conduct. The FDA may also withdraw product approval or take other correct
measures if ongoing regulatory requirements are not met or if safety or efficacy questions are raised after the product reaches the market.
17
Other Regulatory Requirements
We are subject to the Maximum Allowable Cost Regulations, which limit reimbursements for certain generic prescription drugs under Medicare, Medicaid, and
other programs to the lowest price at which these drugs are generally available. In many instances, only generic prescription drugs fall within the regulations’ limits.
Generally, the pricing and promotion of, method of reimbursement and fixing of reimbursement levels for, and the reporting to federal and state agencies relating to drug
products is under active review by federal, state and local governmental entities, as well as by private third-party reimbursers and individuals under whistleblower
statutes. At present, the Justice Department and U.S. Attorneys Offices and State Attorneys General have initiated investigations, reviews, and litigation into
industry-wide pharmaceutical pricing and promotional practices, and whistleblowers have filed qui tam suits. We cannot predict the results of those reviews,
investigations, and litigation, or their impact on our business.
Virtually every state, as well as the District of Columbia, has enacted legislation permitting the substitution of equivalent generic prescription drugs for brand-
name drugs where authorized or not prohibited by the prescribing physician, and some states mandate generic substitution in Medicaid programs.
In addition, numerous state and federal requirements exist for a variety of controlled substances, such as narcotics, that may be part of our product
formulations. The DEA, which has authority similar to the FDA’s and may also pursue monetary penalties, and other federal and state regulatory agencies have far
reaching authority.
The State of California requires that any manufacturer, wholesaler, retailer or other entity in California that sells, transfers, or otherwise furnishes certain so
called precursor substances must have a permit issued by the California Department of Justice, Bureau of Narcotic Enforcement. The substances covered by this
requirement include ephedrine, pseudoephedrine, norpseudoephedrine, and phenylpropanolamine, among others. The Bureau has authority to issue, suspend and
revoke precursor permits, and a permit may be denied, revoked or suspended for various reasons, including (i) failure to maintain effective controls against diversion of
precursors to unauthorized persons or entities; (ii) failure to comply with the Health and Safety Code provisions relating to precursor substances, or any regulations
adopted thereunder; (iii) commission of any act which would demonstrate actual or potential unfitness to hold a permit in light of the public safety and welfare, which
act is substantially related to the qualifications, functions or duties of the permit holder; or (iv) if any individual owner, manager, agent, representative or employee of
the permit applicant/permit holder willfully violates any federal, state or local criminal statute, rule, or ordinance relating to the manufacture, maintenance, disposal,
sale, transfer or furnishing of any precursor substances.
18
Patents, Trademarks and Licenses
We own or license a number of patents in the U.S. and other countries covering certain products and product candidates and have also developed brand names
and trademarks for other products and product candidates. Generally, the brand pharmaceutical business relies upon patent protection to ensure market exclusivity for
the life of the patent. We consider the overall protection of our patents, trademarks and license rights to be of material value and act to protect these rights from
infringement. However, our business is not dependent upon any single patent, trademark or license.
In the branded pharmaceutical industry, the majority of an innovative product’s commercial value is usually realized during the period in which the product has
market exclusivity. In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there can often
be very substantial and rapid declines in the branded product’s sales. The rate of this decline varies by country and by therapeutic category; however, following
patent expiration, branded products often continue to have market viability based upon the goodwill of the product name, which typically benefits from trademark
protection.
An innovator product’s market exclusivity is generally determined by two forms of intellectual property: patent rights held by the innovator company and any
regulatory forms of exclusivity to which the innovator is entitled.
Patents are a key determinant of market exclusivity for most branded pharmaceuticals. Patents provide the innovator with the right to exclude others from
practicing an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product, pharmaceutical
formulations, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products. Protection for individual products extends for
varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country,
depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.
Market exclusivity is also sometimes influenced by regulatory exclusivity rights. Many developed countries provide certain non-patent incentives for the
development of medicines. For example, the U.S., the EU and Japan each provide for a minimum period of time after the approval of a new drug during which the
regulatory agency may not rely upon the innovator’s data to approve a competitor’s generic copy. Regulatory exclusivity rights are also available in certain markets as
incentives for research on new indications, on orphan drugs and on medicines useful in treating pediatric patients. Regulatory exclusivity rights are independent of
any patent rights and can be particularly important when a drug lacks broad patent protection. However, most regulatory forms of exclusivity do not prevent a
competitor from gaining regulatory approval prior to the expiration of regulatory data exclusivity on the basis of the competitor’s own safety and efficacy data on its
drug, even when that drug is identical to that marketed by the innovator.
We estimate the likely market exclusivity period for each of our branded products on a case-by-case basis. It is not possible to predict the length of market
exclusivity for any of our branded products with certainty because of the complex interaction between patent and regulatory forms of exclusivity, and inherent
uncertainties concerning patent litigation. There can be no assurance that a particular product will enjoy market exclusivity for the full period of time that we currently
estimate or that the exclusivity will be limited to the estimate.
In addition to patents and regulatory forms of exclusivity, we also market products with trademarks. Trademarks have no effect on market exclusivity for a
product, but are considered to have marketing value. Trademark protection continues in some countries as long as used; in other countries, as long as registered.
Registration is for fixed terms and may be renewed indefinitely.
19
Environmental Laws
We are subject to comprehensive federal, state and local environmental laws and regulations that govern, among other things, air polluting emissions, waste
water discharges, solid and hazardous waste disposal, and the remediation of contamination associated with current or past generation handling and disposal
activities. We are subject periodically to environmental compliance reviews by various environmental regulatory agencies. While it is impossible to predict accurately
the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require
significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our business, operations or financial condition.
Available Information
We maintain an Internet website at the following address: www.impaxlabs.com. We make available on or through our Internet website certain reports and
amendments to those reports, as applicable, that we file with or furnish to the Securities and Exchange Commission (the “SEC”) in accordance with the Securities
Exchange Act of 1934, as amended (the “Exchange Act”). These include our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Our website also includes our Code of Business Conduct and Ethics and the charters of our Audit Committee, Nominating Committee,
Compensation Committee and Compliance Committee of our board of directors. We make this information available on our website free of charge, as soon as
reasonably practicable after we electronically file the information with, or furnish it to, the SEC. The contents of our website are not incorporated by reference in this
Annual Report on Form 10-K and shall not be deemed “filed” under the Exchange Act.
Corporate and Other Information
We were incorporated in the State of Delaware in 1995. Our corporate headquarters are located at 30831 Huntwood Avenue, Hayward, California, 94544. We
were formerly known as Global Pharmaceutical Corporation until December 14, 1999, when Impax Pharmaceuticals, Inc., a privately held drug delivery company, merged
into Global Pharmaceutical Corporation and the name of the resulting entity was changed to Impax Laboratories, Inc.
Unless otherwise indicated, all product sales data and U.S. market size data in this Annual Report on Form 10-K are based on information obtained from IMS
Health, unrelated third-party providers of prescription market data. We did not independently engage IMS Health to provide this information.
Employees
As of December 31, 2014, we had 1,061 full-time employees, of which 505 were in operations, 132 in research and development, 259 in the quality area, 120 in
legal and administration, and 45 in sales and marketing. None of our employees are subject to collective bargaining agreements with labor unions, and we believe our
employee relations are good.
20
Item 1A. Risk Factors
An investment in our common stock involves a high degree of risk. In deciding whether to invest in our common stock, you should consider carefully the
following risk factors, as well as the other information included in this Annual Report on Form 10-K. The materialization of any of these risks could have a material
adverse effect on our business, results of operations and financial condition. This Annual Report on Form 10-K contains forward looking statements that involve risks
and uncertainties. Our actual results could differ materially from the results discussed in the forward looking statements. Factors that could cause or contribute to
these differences include those discussed in this “Risk Factors” section. See “Forward-Looking Statements” on page 1 of this Annual Report on Form 10-K.
Risks Related to Our Business
Our revenues and operating income could fluctuate significantly.
Our revenues and operating results may vary significantly from year-to-year and quarter to quarter as well as in comparison to the corresponding quarter of
the preceding year. Variations may result from, among other factors:
●
●
the timing of FDA approvals we receive;
our ability to resolve the Form 483 observations and warning letter issued by the FDA and the effect of any product recalls or seizure, injunctions, total or partial
suspension of production and/or distribution, and suspension or withdrawal of regulatory approvals resulting therefrom;
the timing of process validation for particular drug products;
the timing of product launches, and market acceptance of such products launched;
changes in the amount we spend to research, develop, acquire, license or promote new products;
the outcome of our clinical trial programs;
serious or unexpected health or safety concerns with our products, the brand products we have genericized, or our product candidates;
the introduction of new products by others that render our products obsolete or noncompetitive;
the ability to maintain selling prices and gross margins on our products;
changes in our policies regarding returns, rebates, allowances and chargebacks for our products;
the outcome of our patent infringement litigation and other litigation matters and expenditures as a result of such litigation;
the ability to comply with complex governmental regulations which deal with many aspects of our business;
changes in coverage and reimbursement policies of health plans and other health insurers, including changes to Medicare, Medicaid and similar state programs;
increases in the cost of raw materials used to manufacture our products;
●
●
●
●
●
●
●
●
●
●
●
●
● manufacturing and supply interruptions, including product rejections or recalls due to failure to comply with manufacturing specifications;
●
●
●
●
the ability of our license partner(s) to secure regulatory approval, gain market share, sales volume, and sales milestone levels;
timing of revenue recognition related to our alliance and collaboration agreements;
the ability to protect our intellectual property and avoid infringing the intellectual property of others; and
the addition or loss of customers.
®
As an illustration, we earned significant revenues and gross profit from sales of our authorized generic Adderall XR and fenofibrate products during fiscal
years 2012, 2013 and 2014. With respect to our authorized generic Adderall XR® products, in June 2012, an unrelated pharmaceutical company received FDA approval
for a competitor product to our authorized generic Adderall XR products and began marketing this product. Further, we were dependent on another unrelated third-
party pharmaceutical company to supply us with such products we market and sell through our Global Division. Our supply agreement with such third party for the
supply of generic Adderall XR® products expired on September 30, 2014. Although we continue to market and sell generic Adderall XR products that we have in
inventory, we will not earn any future revenue from the sale of such products after we exhaust our inventory. With respect to our fenofibrate products, in October 2012,
a competitor product to our fenofibrate capsule was approved for sale by the FDA. As a result of these competing products, we have experienced significant
diminution of our sales revenue and gross profit from our generic Adderall XR® and fenofibrate products. In our branded products division, we earned significant
revenues and gross profit from sales of our Impax-labeled Zomig (zolmitriptan) tablet, orally disintegrating tablet and nasal spray formulation products that we began
selling during the year ended December 31, 2012 pursuant our Distribution, License, Development and Supply Agreement with AstraZeneca. In May 2013, our
exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and we experienced diminution of our sales revenue and gross profit from those
products as a result of increased competition. We launched authorized generic versions of those products in the United States. We continue to commercialize the
branded Zomig® nasal spray which has U.S. patents expiring as late as May 2021, which patents have been challenged by an ANDA filer seeking to market a generic
to Zomig® nasal spray.
®
®
®
21
Any further diminution of sales revenue and/or gross profit from such products or our other significant products due to existing or additional competition,
product supply or any other reasons in future periods may materially and adversely affect our results of operations in such periods.
Due to the fluctuations in revenue and operating results discussed in greater detail below, our quarterly operating results are difficult to predict and may
fluctuate significantly from period to period. We cannot predict with any certainty the timing or level of sales of our products in the future. As a result, period-to-period
comparisons of our operating results should not be relied upon as indications of our future performance and any full-year financial forecast should not be relied upon
as a guarantee of future performance for that year or for any given quarter within that year. If our quarterly sales or operating results fall below the expectations of
investors or securities analysts, the value of our securities could decline substantially.
We have received a warning letter and Form 483 observations from the FDA. If we are unable to promptly correct the issues raised in the warning letter and/or
Form 483 observations, our business, results of operations and financial condition could be materially and adversely affected.
In late May 2011, we received a warning letter from the FDA related to an on-site FDA inspection of our Hayward, California manufacturing facility citing
deviations from current Good Manufacturing Practices (cGMP), which are extensive regulations governing manufacturing practices for finished pharmaceutical
products and which establish requirements for manufacturing processes, stability testing, record keeping and quality standards and controls. The FDA observations
set forth in the warning letter related to sampling and testing of in-process materials and drug products, production record review, and our process for investigating
the failure of certain manufacturing batches (or portions of batches) to meet specifications. During the quarters ended March 31, 2012 and March 31, 2013, the FDA
conducted inspections of our Hayward manufacturing facility and at the conclusion of each inspection, we received a Form 483. The Form 483 issued during the
quarter ended March 31, 2012 contained observations primarily relating to our Quality Control Laboratory and the Form 483 issued during the quarter ended March 31,
2013 contained several observations pertaining to the operations of the Hayward facility, three of which were designated by the FDA as repeat observations from
inspections that occurred prior to the warning letter. We provided the FDA with what we believe to be our complete written responses relating to the observations in
the warning letter and the Form 483 issued in 2012. In connection with the Form 483 issued in 2013, we provided our written response and updates to the FDA
regarding the completion status of our corrective actions. In late October 2013, at the FDA’s request, we participated in a regulatory meeting with representatives of the
FDA to provide additional information and clarifications on our response and updates related to the Form 483 issued in 2013. The FDA performed a re-inspection of our
Hayward manufacturing facility during June and July 2014. At the conclusion of the re-inspection, the FDA issued a Form 483 with seven inspectional observations,
two of which were designated by the FDA as repeat observations from the inspection that occurred in 2013. We provided the FDA with what we believe to be our
complete written response and updates regarding the completion status of our corrective actions through December 2014. To date, we have not been informed by the
FDA as to whether a satisfactory re-inspection of our Hayward manufacturing facility will be required to close out the warning letter and resolve the 2014 Form 483
observations on our Hayward manufacturing facility.
In July 2014, the FDA conducted an inspection of our Taiwan manufacturing facility and at the conclusion of the inspection, we received a Form 483 with ten
observations. At the time of the inspections, the FDA did not provide any status or classification to either the Form 483 observations on our Hayward or Taiwan
manufacturing facilities and, pursuant to its established regulatory process, would wait until they have received and reviewed our responses to classify those
inspections. We received and responded to a request for additional information from the FDA regarding our Taiwan facility in December 2014. On January 7, 2015, we
received approval from the FDA for the sale and marketing of RYTARY™, our first internally developed branded product for the treatment of Parkinson’s disease,
which is manufactured in our Taiwan facility.
To date, the FDA has not notified us of any additional enforcement actions at either the Hayward or Taiwan manufacturing facilities; however, no assurance
can be given as to whether the FDA will take any further actions. We are currently cooperating with the FDA to close out the warning letter and resolve the Form 483
observations. The warning letter and Form 483 observations do not currently place restrictions on our ability to manufacture and ship our existing products.
22
We have taken a number of steps to review our quality control and manufacturing systems and standards and are working with third-party experts to assist us
with our review and in enhancing such systems and standards. This work is ongoing and we are committed to improving our quality control and manufacturing
practices. We cannot be assured, however, that the FDA will be satisfied with our corrective actions and as such, we cannot be assured of when the warning letter will
be closed out. Unless and until the warning letter is closed out and the Form 483 observations resolved, it is possible we may be subject to additional regulatory action
by the FDA as a result of current or future FDA observations, including, among others, monetary sanctions or penalties, product recalls or seizure, injunctions, total or
partial suspension of production and/or distribution, and suspension or withdrawal of regulatory approvals. Additionally, the FDA has withheld and may continue to
withhold approval of pending drug applications listing our Hayward, California facility as a manufacturing location of finished dosage forms until the warning letter is
closed out and the Form 483 observations on our Hayward facility are resolved. Further, other federal agencies, our customers and partners in our alliance,
development, collaboration and other partnership agreements with respect to our products and services may take the warning letter and Form 483 observations into
account when considering the award of contracts or the continuation or extension of such partnership agreements. If we are unable promptly to correct the issues
raised in the warning letter and Form 483 observations, our business, consolidated results of operations and consolidated financial condition could be materially and
adversely affected.
Our continued growth is dependent on our ability to continue to successfully develop and commercialize new products in a timely manner.
Our financial results depend upon our ability to introduce and commercialize additional generic and branded products in a timely manner. In the generic
pharmaceutical products market, revenue from newly launched generic products that we are the first to market is typically relatively high during the period immediately
following launch and can be expected generally to decline over time. Revenue from generic drugs in general can also be expected to decline over time. Revenue from
branded pharmaceutical products can be expected to decline as the result of entry of new competitors, particularly of companies producing generic versions of the
branded products. Our continued growth is therefore dependent upon our ability to continue to successfully introduce and commercialize new generic and
branded products. As of February 6, 2015, we had 21 product applications pending at the FDA for generic versions of brand-name pharmaceuticals. In our branded
products division, we have one internally developed branded pharmaceutical product, RYTARY™, an extended-release oral capsule formulation of carbidopa-
levodopa, for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese
intoxication that was approved by the FDA on January 7, 2015. We also have a number of other product candidates that are in varying stages of development. The
development and commercialization process for our products, particularly of our branded products, is time-consuming, costly and involves a high degree of business
risk. The FDA and the regulatory authorities may not approve our products submitted to them or our other products under development. Additionally, we may not
successfully complete our development efforts. Even if the FDA approves our products, we may not be able to market them successfully or profitably or, with respect
to our generics products, we may not be able to market them at all if we do not prevail in the patent infringement litigation in which we are involved. Our future results
of operations will depend significantly upon our ability to timely develop, receive FDA approval for, and market new pharmaceutical products or otherwise acquire new
products.
A substantial portion of our total revenues is derived from sales to a limited number of customers.
We derive a substantial portion of our revenue from sales to a limited number of customers. In 2014, our five major customers, McKesson Corporation,
Cardinal Health, Amerisource-Bergen, CVS Caremark Corporation and Wal-Mart Stores accounted for 36%, 20%, 19%, 3% and 2%, respectively, or an aggregate of
80%, of our gross revenue.
A reduction in, or loss of business with, any one of these customers, or any failure of a customer to pay us on a timely basis, would adversely affect our
business.
A substantial portion of our total revenues is derived from sales of a limited number of products.
We derive a substantial portion of our revenue from sales of a limited number of products. In 2014, our top five products in our Global Division accounted for
15%, 8%, 6%, 6% and 6%, or an aggregate of 41%, of Global product sales, net. In our Impax Division, revenue from sales of branded Zomig® products pursuant to our
Distribution, License, Development and Supply Agreement with AstraZeneca accounted for 100% of our Impax product sales, net. The sale of our products can be
significantly influenced by market conditions, as well as regulatory actions. We may experience decreases in the sale of our products in the future as a result of actions
taken by our competitors, such as price reductions, or as a result of regulatory actions related to our products or to competing products, which could have a material
impact on our results of operations. Actions which could be taken by our competitors, which may materially and adversely affect our business, results of operations
and financial condition, may include, without limitation, pricing changes and entering or exiting the market for specific products.
23
Sales of our products may be adversely affected by the continuing consolidation of our customer base.
A significant proportion of our sales is made to relatively few retail drug chains, wholesalers, and managed care purchasing organizations. These customers
are continuing to undergo significant consolidation. Such consolidation has provided and may continue to provide them with additional purchasing leverage, and
consequently may increase the pricing pressures that we face. Additionally, the emergence of large buying groups representing independent retail pharmacies, and the
prevalence and influence of managed care organizations and similar institutions, enable those groups to extract price discounts on our products.
Our net sales and quarterly growth comparisons may also be affected by fluctuations in the buying patterns of retail chains, major distributors and other trade
buyers, whether resulting from pricing, wholesaler buying decisions or other factors. In addition, since such a significant portion of our revenues is derived from
relatively few customers, any financial difficulties experienced by a single customer, or any delay in receiving payments from a single customer, could have a material
adverse effect on our business, results of operations and financial condition.
We face intense competition from both brand-name and generic pharmaceutical companies.
The pharmaceutical industry is highly competitive and many of our competitors have longer operating histories and substantially greater financial, research
and development, marketing, and other resources than we have. In addition, pharmaceutical manufacturers’ customer base consists of an increasingly limited number
of large pharmaceutical wholesalers, chain drug stores that warehouse products, mass merchandisers, mail order pharmacies. Our competitors may be able to develop
products competitive with or more effective or less expensive than our own for many reasons, including that they may have:
● proprietary processes or delivery systems;
● greater resources in the area of research and development and marketing;
● larger or more efficient production capabilities;
● more expertise in a particular therapeutic area;
● more expertise in preclinical testing and human clinical trials;
● more experience in obtaining required regulatory approvals, including FDA approval;
● more products; or
● more experience in developing new drugs and financial resources, particularly with regard to brand manufacturers.
With respect to generic pharmaceutical products, FDA approval of our ANDAs may be delayed if a branded pharmaceutical company files patent
infringement suits that automatically delay FDA approval of generic products, or obtains new patents and brings new patent infringement suits. Further, the FDA
approval process often results in the FDA granting final approval to a number of ANDAs for a given product at the time a patent for a corresponding brand product or
other market exclusivity expires. This often forces us to face immediate competition when we introduce a generic product into the market. As competition from other
generic pharmaceutical companies intensifies, selling prices and gross profit margins often decline, which has been our experience with our existing products.
Moreover, with respect to products for which we file a Paragraph IV certification, if we are not the first ANDA filer challenging a listed patent for a product, we are at a
significant disadvantage to the competitor that first filed an ANDA for that product containing such a challenge, which is awarded 180 days of market exclusivity for
the product. With respect to our 12 publicly disclosed product applications pending FDA approval for which we have filed Paragraph IV certifications as of February 6,
2015, we believe we are first to file for some strengths of one product and not on other strengths of such product and unrelated third parties are the first to file with
respect to the other 11 products. With respect to publicly disclosed products in which the applications are held by our third-party partners pursuant to alliance,
development or collaboration agreements and for which Paragraph IV certifications have been filed, third parties unrelated to us or our partners are first to file with
respect to one such product. Accordingly, the level of market share, revenue and gross profit attributable to a particular generic product that we develop is generally
related to the number of competitors in that product’s market and the timing of that product’s regulatory approval and launch, in relation to competing approvals and
launches. Although we cannot assure, we strive to develop and introduce new products in a timely and cost effective manner to be competitive in our industry (see
“Item 1 Business — Regulation”). Additionally, ANDA approvals often continue to be granted for a given product subsequent to the initial launch of the generic
product. These circumstances generally result in significantly lower prices and reduced margins for generic products compared to brand products. New generic market
entrants generally cause continued price and margin erosion over the generic product life cycle.
24
In addition to the competition we face from other generic pharmaceutical companies, we face competition from brand-name pharmaceutical companies related
to our generic products. Branded pharmaceutical companies often sell their branded products as “authorized generics” (an industry term that describes instances
when a brand-name manufacturer licenses a generic manufacturer to market the brand product under the licensee’s name and registration at typical generic discounts).
Our principal competitors in the generic pharmaceutical products market are Teva Pharmaceutical Industries Ltd., Actavis, plc., Mylan Inc., Ranbaxy
Laboratories Ltd., Lannett Company, Inc., Lupin Pharmaceuticals, Inc., Par Pharmaceutical Companies, Inc. and Sandoz.
In the brand-name pharmaceutical market, we market Impax-labeled branded Zomig® products pursuant to the AZ Agreement with AstraZeneca. In May 2013,
our exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and we experienced diminution of our sales revenue and gross profit from
those products as a result of increased competition. We launched authorized generic versions of both products in the United States in May 2013. We received
approval from the FDA on January 7, 2015 to market and sell RYTARY™, our first internally developed branded pharmaceutical product for the treatment of Parkinson’s
disease, and we currently plan to fully launch our sales and marketing efforts for the product in early April 2015. We currently expect our principal competitors in the
branded pharmaceutical market to include pharmaceutical companies that are focused on Parkinson’s disease and other CNS disorders. In addition, with respect to
products that we are developing internally and/or any additional products we may in-license from third parties, we expect that we will face increased competition from
large pharmaceutical companies, other drug delivery companies, and other specialty pharmaceutical companies that have focused on CNS disorders.
Any of the actions by our competitors as described above may significantly impact sales of our generic and branded products, which could have a material
adverse effect on our business, results of operations and financial condition.
We have experienced operating losses and negative cash flow from operations in the past, and our future profitability is uncertain.
Although 2007 was our first profitable year, and we continued to record net income on an annual basis through and including 2014, we do not know whether
our business will continue to be profitable or generate positive cash flow, and our ability to remain profitable or obtain positive cash flow is uncertain. To remain
operational and profitable, we must, among other things:
●
●
●
●
●
obtain FDA approval of our products;
successfully launch and market new products;
prevail in patent infringement litigation in which we are involved;
continue to generate or obtain sufficient capital on acceptable terms to fund our operations; and
comply with the many complex governmental regulations that deal with virtually every aspect of our business activities.
25
Any delays or unanticipated expenses in connection with the operation of our limited number of facilities could have a material adverse effect on our business.
A substantial portion of our manufacturing capacity as well as our current production is attributable to our two manufacturing facilities located in Hayward,
California and Taiwan and to certain third party suppliers. A significant disruption at any one of these facilities within our internal or third party supply chain, even on
a short-term basis, whether due to an adverse quality or compliance observation, including a total or partial suspension of production and/or distribution by regulatory
authorities, an act of God, civil or political unrest, or other events could impair our ability to produce and ship products to the market on a timely basis and could,
among other consequences, subject us to exposure to claims from customers. Any of these events could have a material adverse effect on our business, results of
operations and financial condition.
We completed construction of a new manufacturing facility in Taiwan, installed equipment, and received FDA approval during 2009. We initiated construction
of an expansion to the facility later that year and have expanded the Taiwan facility in stages. As of May 2014, the second phase of the expansion was completed and
the manufacturing equipment in the facility was qualified for their intended use. A major portion of the second phase of the expansion was dedicated to the production
of RYTARY™ for the treatment of Parkinson’s disease, which was approved by the FDA on January 7, 2015. We completed transfer of a substantial portion of our
Hayward, California production to the lower cost production site in Taiwan during 2013 to create capacity for future products being launched from the Hayward facility.
We currently plan to continue increasing production at our Taiwan facility of tablets and capsules in support of transferred products and in preparation for the growth
of RYTARY™.
While we have thus far not suffered any material delays, significant increases in estimated expenses or other material setbacks associated with the
construction, expansion and operation of the manufacturing facility in Taiwan, we cannot assure that costs of production will be within our projections or that the
expansion of the facility will ultimately result in profitable operations.
Our business is subject to the economic, political, legal and other risks of maintaining facilities and conducting clinical trials in foreign countries.
In 2010, we commenced shipment of commercial product from our new manufacturing facility in Taiwan, and we plan to increase our commercial manufacturing
operations in Taiwan in the future. In addition, certain clinical trials for our product candidates are conducted at multiple sites in Europe. These foreign operations are
subject to risks inherent in maintaining operations and doing business abroad, such as economic and political destabilization, international conflicts, restrictive actions
by foreign governments, expropriation or nationalization of property, changes in laws and regulations, changes in regulatory requirements, the difficulty of effectively
managing diverse global operations, adverse foreign tax or tariff laws, more limited intellectual property protection in certain foreign jurisdictions, and the threat posed
by potential international disease pandemics in countries that do not have the resources necessary to deal with such outbreaks. Further, as our global operations
require compliance with a complex set of foreign and U.S. laws and regulations, including data privacy requirements, labor relations laws, tax laws, anti-competition
regulations, import and trade restrictions, and export requirements, U.S. laws such as the Foreign Corrupt Practices Act of 1977, as amended, and local laws which also
prohibit corrupt payments to governmental officials or certain payments or remunerations to customers, there is a risk that some provisions may be inadvertently
breached. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, and prohibitions on the conduct
of our business. These foreign economic, political, legal and other risks could impact our operations and have an adverse effect on our business, results of operations
and financial condition.
We are routinely subject to patent litigation that can delay or prevent our commercialization of generic products or accelerate generic competition for our
branded products and we may also become involved in other legal proceedings, all of which force us to incur substantial expense to defend and expose us to
substantial liability.
Our generic products division is routinely subject to patent infringement litigation brought by branded pharmaceutical manufacturers seeking to delay FDA
approval to manufacture and market generic forms of their branded products. Likewise, our branded products division is currently involved in patent infringement
litigation against a generic drug manufacturer seeking FDA approval to market its generic drug prior to patent expiration. Patent infringement litigation involves many
complex technical and legal issues and its outcome is often difficult to predict, and the risk involved in doing so can be substantial. For generic product manufacturers,
the potential consequences to such generic companies in the event of an unfavorable outcome include delaying generic launch until patent expiration and potential
damages measured by the profits lost by the branded product manufacturer rather than the profits earned by the generic pharmaceutical company. For brand drug
manufacturers, an unfavorable outcome may significantly accelerate generic competition ahead of patent expiration. Such litigation usually involves significant
expense and can delay or prevent introduction or sale of our products.
26
As of February 6, 2015, our generic products division was involved in one patent infringement suit involving oxymorphone hydrochloride. For the year ended
December 31, 2014, we incurred costs of approximately $2.9 million in connection with our participation in this matter, as well as for other matters that were resolved in
2014. If this or any of our future patent litigation matters are resolved unfavorably, we or any alliance or collaboration partners may be enjoined from manufacturing,
developing or selling the product that is the subject of such litigation without a license from the other party. In addition, if we decide to market and sell generic
products prior to the resolution of patent infringement suits, we could be held liable for lost profits if we are found to have infringed a valid patent, or liable for treble
damages if we are found to have willfully infringed a valid patent. Although it is not currently possible to quantify the liability we could incur if any of these suits are
decided against us, any patent litigation could have a material adverse effect on our business, results of operations and financial condition. As of February 6, 2015, our
branded products division was involved in one patent infringement suit involving Zomig® nasal spray. If this patent litigation matter is resolved unfavorably, our
Zomig® nasal spray product may face generic competition significantly earlier than the date of patent expiration in May 2021.
In addition to patent infringement litigation claims, we are or may become a party to other litigation in the ordinary course of our business, including, among
others, matters alleging product liability, other intellectual property rights infringement, violations of securities laws, employment discrimination or breach of
commercial contract. A detailed description of our significant legal proceedings are described in “Item 15. Exhibits and Financial Statement Schedules – Note 19. Legal
and Regulatory Matters.” In general, litigation claims can be expensive and time consuming to bring or defend against and could result in settlements or damages that
could have a material adverse effect on our business, results of operations and financial condition.
Our agreements with brand pharmaceutical companies, which are important to our business, are facing increased government scrutiny in the U.S., which may
result in increased government actions and private litigation suits.
We are involved in numerous patent litigations in which we challenge the validity or enforceability of innovator companies’ listed patents and/or their
applicability to our generic pharmaceutical products, as well as patent infringement litigation in which generic companies challenge the validity or enforceability of our
patents and/or their applicability to their generic pharmaceutical products, and therefore settling patent litigations has been and is likely to continue to be an important
part of our business. Parties to such settlement agreements in the U.S., including us, are required by law to file them with the Federal Trade Commission (“FTC”) and
the Antitrust Division of the Department of Justice for review. The FTC has publicly stated that, in its view, some of the brand - generic settlement agreements violate
the antitrust laws and has brought actions against some brand and generic companies that have entered into such agreements. In June 2013, the U.S. Supreme Court in
its decision in FTC v. Actavis determined that “reverse payment” settlement agreements between brand and generic companies could violate antitrust laws. The
Supreme Court held that such settlement agreements are neither immune from antitrust attack nor presumptively illegal but rather should be analyzed under the “Rule
of Reason.” It is currently uncertain the effect the Supreme Court’s decision will have on our existing settlement agreements or its impact on our ability to enter into
such settlement agreements in the future or the terms thereof. The Supreme Court’s decision may result in heightened scrutiny from the FTC of such settlement
agreements and we may become subject to increased FTC investigations or enforcement actions arising from such settlement agreements. Further, private plaintiffs,
including direct and indirect purchasers of our products, may also become more active in bringing private litigation claims against us and other brand and generic
pharmaceutical companies alleging that such settlement agreements violate antitrust laws.
In May 2012, we received a Civil Investigative Demand (“CID”) from the FTC concerning its investigation into the drug SOLODYN and its generic
equivalents. According to the FTC, the investigation is to determine whether we, along with Medicis Pharmaceutical Corporation (now a wholly owned subsidiary of
Valeant Pharmaceuticals International, Inc.) and six other companies, have engaged or are engaged in unfair methods of competition in or affecting commerce by
entering into agreements regarding SOLODYN® or its generic equivalents and/or engaging in other conduct regarding the sale or marketing of SOLODYN® or its
generic equivalents. In February 2014, we received a CID from the FTC concerning its investigation into the drug Opana® ER and its generic equivalents. According to
the FTC, the investigation relates to whether we and Endo Pharmaceuticals, Inc. have engaged or are engaged in unfair methods of competition in or affecting
commerce by (i) entering into agreements regarding Opana® ER or its generic equivalents and/or (ii) engaging in other conduct regarding the regulatory filings, sale or
marketing of Opana® ER or its generic equivalents. To our knowledge, no proceedings by the FTC have been initiated against us at this time in either of the FTC’s
investigations into SOLODYN and Opana® ER; however no assurance can be given as to the timing or outcome of these investigations.
®
®
27
Private plaintiffs have also filed class action complaints against us and other manufacturers of SOLODYN®, Opana® ER and their respective generic
equivalents. A detailed description of the SOLODYN® and Opana® ER FTC investigations and class action suits are described in “Item 15. Exhibits and Financial
Statement Schedules – Note 19. Legal and Regulatory Matters.” The defense of antitrust litigation investigation and claims are generally expensive and time
consuming, and we can give no assurance as to the timing or outcome of such investigation or claims or of any future private litigation or government action alleging
that one of our settlement agreements violates antitrust laws.
Our ability to develop or license, or otherwise acquire, and introduce new products on a timely basis in relation to our competitors’ product introductions
involves inherent risks and uncertainties.
Product development is inherently risky, especially for new drugs for which safety and efficacy have not been established and the market is not yet proven.
Likewise, product licensing involves inherent risks including uncertainties due to matters that may affect the achievement of milestones, as well as the possibility of
contractual disagreements with regard to terms such as license scope or termination rights. The development and commercialization process, particularly with regard to
new drugs, also requires substantial time, effort and financial resources. The process of obtaining FDA approval to manufacture and market new pharmaceutical
products is rigorous, time consuming, costly and largely unpredictable. We, or a partner, may not be successful in obtaining FDA approval or in commercializing any of
the products that we are developing or licensing.
Our approved products may not achieve expected levels of market acceptance.
Even if we are able to obtain regulatory approvals for our new products, the success of those products is dependent upon market acceptance. Levels of
market acceptance for our new products could be affected by several factors, including:
●
●
●
●
●
●
the availability of alternative products from our competitors;
the prices of our products relative to those of our competitors;
the timing of our market entry;
the ability to market our products effectively at the retail level;
the perception of patients and the healthcare community, including third-party payers, regarding the safety, efficacy and benefits of our drug
products compared to those of competing products; and
the acceptance of our products by government and private formularies.
Some of these factors are not within our control, and our products may not achieve expected levels of market acceptance. Additionally, continuing and
increasingly sophisticated studies of the proper utilization, safety and efficacy of pharmaceutical products are being conducted by the industry, government agencies
and others which can call into question the utilization, safety and efficacy of previously marketed products. In some cases, studies have resulted, and may in the future
result, in the discontinuance of product marketing or other risk management programs such as the need for a patient registry.
Our business is highly dependent on market perceptions of us and the safety and quality of our products. Our business or products could be subject to negative
publicity, which could have a material adverse effect on our business, results of operations and financial condition.
Market perceptions of our business are very important to us, especially market perceptions of the safety and quality of our products. If any of our products or
similar products that other companies distribute are subject to market withdrawal or recall or are proven to be, or are claimed to be, harmful to consumers, then this
could have a material adverse effect on our business, results of operations and financial condition. Also, because our business is dependent on market perceptions,
negative publicity associated with product quality, illness or other adverse effects resulting from, or perceived to be resulting from, our products could have a material
adverse impact on our business, results of operations and financial condition.
28
We may discontinue the manufacture and distribution of certain existing products, which may adversely impact our business, results of operations and financial
condition.
We continually evaluate the performance of our products, and may determine that it is in our best interest to discontinue the manufacture and distribution of
certain of our products. For example, during 2013, we decided to discontinue the manufacture and distribution of certain products after we conducted a strategic review
of our then currently manufactured generic product portfolio. We cannot guarantee that we have correctly forecasted, or will correctly forecast in the future, the
appropriate products to discontinue or that our decision to discontinue various products is prudent if market conditions change. In addition, there are no assurances
that the discontinuance of products will reduce our operating expenses or will not cause us to incur material charges associated with such a decision. Furthermore, the
discontinuance of existing products entails various risks, including, in the event that we decide to sell the discontinued product, the risk that we will not be able to find
a purchaser for such products or that the purchase price obtained will not be equal to at least the book value of the net assets for such products. Other risks include
managing the expectations of, and maintaining good relations with, our customers who previously purchased products from our discontinued products, which could
prevent us from selling other products to them in the future. Moreover, we may incur other significant liabilities and costs associated with our discontinuance of
products, which could have a material adverse effect on our business, results of operations and financial condition.
We expend a significant amount of resources on research and development efforts that may not lead to successful product introductions or the recovery of our
research and development expenditures.
We conduct research and development primarily to enable us to manufacture and market pharmaceuticals in accordance with FDA regulations. We spent
approximately $79.1 million, $68.9 million, $81.3 million on research and development activities during the years ended December 31, 2014, 2013 and 2012, respectively.
We are required to obtain FDA approval before marketing our drug products. The FDA approval process is costly and time consuming. Typically, research expenses
related to the development of innovative compounds and the filing of NDAs are significantly greater than those expenses associated with ANDAs. As we continue to
develop new products, our research expenses will likely increase. Because of the inherent risk associated with research and development efforts in our industry, our
research and development expenditures may not result in the successful introduction of FDA-approved pharmaceuticals.
Our bioequivalence studies, other clinical studies and/or other data may not result in FDA approval to market our new drug products. While we believe that
the FDA’s ANDA procedures will apply to our bioequivalent versions of branded drugs, these drugs may not be suitable for, or approved as part of, these abbreviated
applications. In addition, even if our drug products are suitable for FDA approval by filing an ANDA, the abbreviated applications are costly and time consuming to
complete. After we submit an NDA or ANDA, the FDA may require that we conduct additional studies, and as a result, we may be unable to reasonably determine the
total research and development costs to develop a particular product. Also, for products pending approval, we may obtain raw materials or produce batches of
inventory to be used in anticipation of the product’s launch. In the event that FDA approval is denied or delayed, we could be exposed to the risk of this inventory
becoming obsolete. Finally, we cannot be certain that any investment made in developing products or product-delivery technologies will be recovered, even if we are
successful in commercialization. To the extent that we expend significant resources on research and development efforts and are not able, ultimately, to introduce
successful new products or new delivery technologies as a result of those efforts, we will be unable to recover those expenditures.
The time necessary to develop generic drugs may adversely affect whether, and the extent to which, we receive a return on our capital.
We generally begin our development activities for a new generic drug product several years in advance of the patent expiration date of the brand-name drug
equivalent. The development process, including drug formulation, testing, and FDA review and approval, often takes three or more years. This process requires that
we expend considerable capital to pursue activities that do not yield an immediate or near-term return. Also, because of the significant time necessary to develop a
product, the actual market for a product at the time it is available for sale may be significantly less than the originally projected market for the product. If this were to
occur, our potential return on our investment in developing the product, if approved for marketing by the FDA, would be adversely affected and we may never receive
a return on our investment in the product. It is also possible for the manufacturer of the brand-name product for which we are developing a generic drug to obtain
approvals from the FDA to switch the brand-name drug from the prescription market to the OTC market. If this were to occur, we would be prohibited from marketing
our product other than as an OTC drug, in which case revenues could be substantially less than we anticipated.
29
Research and development efforts invested in our branded pharmaceutical products may not achieve expected results.
We invest increasingly significant resources to develop our branded products, both through our own efforts and through collaborations, in-licensing and
acquisition of products from or with third parties. The development of proprietary branded drugs involves processes and expertise different from those used in the
development of generic products, which increases the risks of failure that we face. For example, the time from discovery to commercial launch of a branded product can
be 15 years or even longer, and involves multiple stages: not only intensive preclinical and clinical testing, but also highly complex, lengthy and expensive approval
processes which can vary from country to country. The longer it takes to develop a product, the longer time it may take for us to recover our development costs and
generate profits, if at all.
During each development stage, we may encounter obstacles that delay the process or approval and increase expenses, leading to significant risks that we
will not achieve our goals and may be forced to abandon a potential product in which we have invested substantial amounts of time and money. These obstacles may
include: preclinical failures; difficulty enrolling patients in clinical trials; delays in completing formulation and other work needed to support an application for
approval; adverse reactions or other safety concerns arising during clinical testing; insufficient clinical trial data to support the safety or efficacy of the product
candidate; and failure to obtain, or delays in obtaining, the required regulatory approvals for the product candidate or the facilities in which it is manufactured. For
instance, during 2013, we discontinued our branded pharmaceutical development programs for the potential treatment of moderate to severe Restless Leg Syndrome
(“RLS”) after the results from the study did not achieve the statistical criteria for its primary efficacy endpoints compared to placebo and our program for the potential
treatment of epilepsy as a result of technical and competitive factors. As a result of the obstacles noted above, our investment in research and development of branded
products can involve significant costs with no assurances of future revenues or profits.
Approvals for our new generic drug products may be delayed or become more difficult to obtain if the FDA institutes changes to its approval requirements.
The FDA may institute changes to its ANDA approval requirements, which may make it more difficult or expensive for us to obtain approval for our new
generic products. For instance, in July 2012, the Generic Drug Fee User Amendments of 2012 (“GDUFA”) was enacted into law. The GDUFA legislation implemented
fees for new ANDAs, Drug Master Files, product and establishment fees and a one-time fee for back-logged ANDAs pending approval as of October 1, 2012. In return,
the program is intended to provide faster and more predictable ANDA reviews by the FDA and increased inspections of drug facilities. Under GDUFA, generic product
companies face significant penalties for failure to pay the new user fees, including rendering an ANDA not “substantially complete” until the fee is paid. It is currently
uncertain the effect the new fees and new review procedures will have on our ANDA process and business, however, any failure by us or our suppliers to pay the fees
or to comply with the other provisions of GDFUA may impact or delay our ability to file ANDAs, obtain approvals for new generic products, generate revenues and
thus may have a material adverse effect on our business, results of operations and financial condition.
In addition to the implementation of new fees and review procedures by the FDA, the FDA may also implement other changes that may directly affect some of
our ANDA filings pending approval from the FDA, such as changes to guidance from the FDA regarding bioequivalency requirements for particular drugs. Such
changes may cause our development of such generic drugs to be significantly more difficult or result in delays in FDA approval or result in our decision to abandon or
terminate certain projects. Any changes in FDA requirements may make it more difficult for us to file ANDAs or obtain approval of our ANDAs and generate revenues
and thus have a material adverse effect on our business, results of operations and financial condition.
The risks and uncertainties inherent in conducting clinical trials could delay or prevent the development and commercialization of our own branded products,
which could have a material adverse effect on our business, results of operations and financial condition.
With respect to our branded products which do not qualify for the FDA’s abbreviated application procedures, we must demonstrate through clinical trials that
these products are safe and effective for use. We have only limited experience in conducting and supervising clinical trials. The process of completing clinical trials
and preparing an NDA may take several years and requires substantial resources. Our studies and filings may not result in FDA approval to market our new drug
products and, if the FDA grants approval, we cannot predict the timing of any approval. There are substantial filing fees for NDAs that are not refundable if FDA
approval is not obtained.
30
There are a number of risks and uncertainties associated with clinical trials. The results of clinical trials may not be indicative of results that would be obtained
from large scale testing. Clinical trials are often conducted with patients having advanced stages of disease and, as a result, during the course of treatment these
patients can die or suffer adverse medical effects for reasons that may not be related to the pharmaceutical agents being tested, but which nevertheless affect the
clinical trial results. In addition, side effects experienced by the patients may cause delay of approval or limit the profile of an approved product. Moreover, our clinical
trials may not demonstrate sufficient safety and efficacy to obtain approval from the FDA or foreign regulatory authorities. The FDA or foreign regulatory authorities
may not agree with our assessment of the clinical data or they may interpret it differently. Such regulatory authorities may require additional or expanded clinical trials.
Even if the FDA or foreign regulatory authorities approve certain products developed by us, there is no assurance that such regulatory authorities will not subject
marketing of such products to certain limits on indicated use.
Failure can occur at any time during the clinical trial process and, in addition, the results from early clinical trials may not be predictive of results obtained in
later and larger clinical trials, and product candidates in later clinical trials may fail to show the desired safety or efficacy despite having progressed successfully
through earlier clinical testing. A number of companies in the pharmaceutical industry, including us, have suffered significant setbacks in clinical trials, even in
advanced clinical trials after showing positive results in earlier clinical trials. For example, we had previously sought to develop an earlier product formulation
containing carbidopa/levodopa for the treatment of Parkinson’s disease. Following completion of the clinical trials and submission of the NDA, the NDA was not
approved due to the FDA’s concerns over product nomenclature and the potential for medication errors. In early 2013, we discontinued our branded pharmaceutical
development program for IPX159, an oral controlled-release formulation for the potential treatment of moderate to severe RLS, after the results from the clinical study in
patients did not achieve the statistical criteria for its primary efficacy endpoints compared to placebo. In the future, the completion of clinical trials for our product
candidates may be delayed or halted for the reasons noted above in addition to many other reasons, including:
●
●
●
●
●
●
●
●
●
●
●
delays in patient enrollment, and variability in the number and types of patients available for clinical trials;
regulators or institutional review boards may not allow us to commence or continue a clinical trial;
our inability, or the inability of our partners, to manufacture or obtain from third parties materials sufficient to complete our clinical trials;
delays or failure in reaching agreement on acceptable clinical trial contracts or clinical trial protocols with prospective clinical trial sites;
risks associated with trial design, which may result in a failure of the trial to show statistically significant results even if the product candidate is
effective;
difficulty in maintaining contact with patients after treatment commences, resulting in incomplete data;
poor effectiveness of product candidates during clinical trials;
safety issues, including adverse events associated with product candidates;
the failure of patients to complete clinical trials due to adverse side effects, dissatisfaction with the product candidate, or other reasons;
governmental or regulatory delays or changes in regulatory requirements, policy and guidelines; and
varying interpretation of data by the FDA or foreign regulatory authorities.
In addition, our product candidates could be subject to competition for clinical study sites and patients from other therapies under development which may
delay the enrollment in or initiation of our clinical trials.
The FDA or foreign regulatory authorities may require us to conduct unanticipated additional clinical trials, which could result in additional expense and
delays in bringing our product candidates to market. Any failure or delay in completing clinical trials for our product candidates would prevent or delay the
commercialization of our product candidates. We cannot assure that our expenses related to clinical trials will lead to the development of brand-name drugs that will
generate revenues in the near future. Delays or failure in the development and commercialization of our own branded products could have a material adverse effect on
our business, results of operations and financial condition.
31
We rely on third parties to conduct clinical trials and testing for our product candidates, and if they do not properly and successfully perform their legal and
regulatory obligations, as well as their contractual obligations to us, we may not be able to obtain regulatory approvals for our product candidates.
We design the clinical trials for our product candidates, but rely on contract research organizations and other third parties to assist us in managing,
monitoring and otherwise carrying out these trials, including with respect to site selection, contract negotiation, analytical testing and data management. We do not
control these third parties and, as a result, they may not treat our clinical studies as their highest priority, or in the manner in which we would prefer, which could result
in delays.
Although we rely on third parties to conduct our clinical trials and related activities, we are responsible for confirming that each of our clinical trials is
conducted in accordance with our general investigational plan and protocol. Moreover, the FDA and foreign regulatory agencies require us to comply with regulations
and standards, commonly referred to as good clinical practices and good laboratory practices, for conducting, recording and reporting the results of clinical trials to
ensure that the data and results are credible and accurate and that the trial participants are adequately protected. Our reliance on third parties does not relieve us of
these responsibilities and requirements. The FDA enforces good clinical practices and good laboratory practices through periodic inspections of trial sponsors,
principal investigators and trial sites. If we, our contract research organizations or our study sites fail to comply with applicable good clinical practices and good
laboratory practices, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before
approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with good clinical
practices and good laboratory practices. In addition, our clinical trials must be conducted with product manufactured under the FDA’s current Good Manufacturing
Practices, or cGMP, regulations. Our failure or the failure of our contract manufacturers if any are involved in the process, to comply with these regulations may require
us to repeat clinical trials, which would delay the regulatory approval process.
If third parties do not successfully carry out their duties under their agreements with us, if the quality or accuracy of the data they obtain is compromised due
to failure to adhere to our clinical protocols or regulatory requirements, or if they otherwise fail to comply with clinical trial protocols or meet expected deadlines, our
clinical trials may not meet regulatory requirements. If our clinical trials do not meet regulatory requirements or if these third parties need to be replaced, our clinical
trials may be extended, delayed, suspended or terminated. If any of these events occur, we may not be able to obtain regulatory approval of our product candidates,
which could have a material adverse effect on our business, results of operations and financial condition.
We currently do not have a license partner for commercialization of IPX066 outside of the United States.
In December 2010, we entered into a License, Development and Commercialization Agreement with Glaxo Group Limited (“GSK”) whereby GSK received an
exclusive license to develop and commercialize IPX066 (brand name RYTARY™ in the United States) throughout the world, except in the United States and Taiwan, and
certain follow-on products at the option of GSK. In April 2013, we announced with GSK that we were terminating our collaboration as a result of delays in the
anticipated regulatory approval and launch dates in countries in which GSK had rights to commercialize the product and the License, Development and
Commercialization Agreement was terminated. At the end of July 2013, GSK’s rights to develop and commercialize IPX066 outside the United States and Taiwan were
transferred back to us.
In November 2014, we submitted a Market Authorization Application (“MAA”) to the European Medicines Agency (“EMA”) for IPX066, which was accepted
for filing by the EMA later that month. We are, however, also seeking a license partner for the development and commercialization of IPX066 outside of the United
States. No assurances, however, can be made that we will be able to receive regulatory approval from the EMA or that we will find a license partner for the development
and commercialization of IPX066 outside of the United States. If we are unsuccessful in entering into a third party collaboration arrangement for the development and
commercialization activities for IPX066 outside of the United States and/or are unable to satisfy our regulatory obligations with respect to IPX066 in such territories, we
will be unable to obtain regulatory approval for IPX066 in certain jurisdictions outside of the United States, which could have a material adverse effect on our business,
results of operations and financial condition.
32
The illegal distribution and sale by third parties of counterfeit versions of our products or of stolen products could have a negative impact on our reputation and
a material adverse effect on our business, results of operations and financial condition.
Third parties could illegally distribute and sell counterfeit versions of our products, which do not meet the rigorous manufacturing and testing standards that
our products undergo. Counterfeit products are frequently unsafe or ineffective, and can be life-threatening. Counterfeit medicines may contain harmful substances,
the wrong dose of the active pharmaceutical ingredient or no active pharmaceutical ingredients at all. However, to distributors and users, counterfeit products may be
visually indistinguishable from the authentic version.
Reports of adverse reactions to counterfeit drugs or increased levels of counterfeiting could materially affect patient confidence in the authentic product. It is
possible that adverse events caused by unsafe counterfeit products will mistakenly be attributed to the authentic product. In addition, thefts of inventory at
warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels could adversely impact patient safety, our
reputation and our business.
Public loss of confidence in the integrity of pharmaceutical products as a result of counterfeiting or theft could have a material adverse effect on our business,
results of operations and financial condition.
We are dependent on a small number of suppliers for our raw materials that we use to manufacture our products and interruptions in our supply chain could
materially and adversely affect our business.
We typically purchase the ingredients, other materials and supplies that we use in the manufacturing of our products, as well as certain finished products,
from a small number of foreign and domestic suppliers. The FDA requires identification of raw material suppliers in applications for approval of drug products. If raw
materials were unavailable from a specified supplier or the supplier was not in compliance with FDA or other applicable requirements, the FDA approval of a new
supplier could delay the manufacture of the drug involved. As a result, there is no guarantee we will always have timely and sufficient access to a required raw material
or other product. In addition, some materials used in our products are currently available from only one supplier or a limited number of suppliers. Generally, we would
need as much as 18 months to find and qualify a new sole-source supplier. If we receive less than one year’s termination notice from a sole-source supplier that it
intends to cease supplying raw materials, it could result in disruption of our ability to produce the drug involved. Further, a significant portion of our raw materials may
be available only from foreign sources. Foreign sources can be subject to the special risks of doing business abroad, including:
●
●
●
●
greater possibility for disruption due to transportation or communication problems;
the relative instability of some foreign governments and economies;
interim price volatility based on labor unrest, materials or equipment shortages, export duties, restrictions on the transfer of funds, or fluctuations in
currency exchange rates; and
uncertainty regarding recourse to a dependable legal system for the enforcement of contracts and other rights.
Those of our raw materials that are available from a limited number of suppliers include Bendroflumethiazide, Chloroquine, Colestipol, Digoxin, Fenofibrate,
Methyltestosterone, Nadolol, Pyridostigmine and Klucel®, all of which are active pharmaceutical ingredients except Klucel®, which is an excipient used in several
product formulations. The manufacturers of several of these products are sole-source suppliers. While none of the active ingredients is individually significant to our
business, the excipient, which is not covered by a supply agreement, is utilized in a number of significant products. Only a couple of the active ingredients are covered
by long-term supply agreements and, although we have to date only experienced occasional interruptions in supplies, no assurance can be given that we will continue
to receive uninterrupted or adequate supplies of such raw materials.
Many third-party suppliers are subject to governmental regulation and, accordingly, we are dependent on the regulatory compliance of these third parties. We
also depend on the strength, enforceability and terms of our various contracts with these third-party suppliers. We also rely on complex shipping arrangements
throughout the various facilities of our supply chain spectrum. Customs clearance and shipping by land, air or sea routes rely on and may be affected by factors that
are not in our full control or are hard to predict.
Any inability to obtain raw materials on a timely basis, or any significant price increases which cannot be passed on to customers, could have a material
adverse effect on our business, results of operations and financial condition.
33
Our policies regarding returns, rebates, allowances and chargebacks, and marketing programs adopted by wholesalers may reduce our revenues in future fiscal
periods.
Based on industry practice, generic drug manufacturers have liberal return policies and have been willing to give customers post-sale inventory allowances.
Under these arrangements, from time to time, we give our customers credits on our generic products that our customers hold in inventory after we have decreased the
market prices of the same generic products due to competitive pricing. Therefore, if new competitors enter the marketplace and significantly lower the prices of any of
their competing products, we would likely reduce the price of our product. As a result, we would be obligated to provide credits to our customers who are then holding
inventories of such products, which could reduce sales revenue and gross margin for the period the credit is provided. Like our competitors, we also give credits for
chargebacks to wholesalers that have contracts with us for their sales to hospitals, group purchasing organizations, pharmacies or other customers. A chargeback is
the difference between the price the wholesaler pays and the price that the wholesaler’s end-customer pays for a product. Although we establish reserves based on
our prior experience and our best estimates of the impact that these policies may have in subsequent periods, we cannot ensure that our reserves are adequate or that
actual product returns, rebates, allowances and chargebacks will not exceed our estimates.
Certain of our products use controlled substances, the availability of which may be limited by the DEA and other regulatory agencies.
We utilize controlled substances in certain of our current products and products in development and therefore must meet the requirements of the Controlled
Substances Act of 1970 and the related regulations administered by the DEA in the United States. These laws relate to the manufacture, shipment, storage, sale and
use of controlled substances. The DEA and other regulatory agencies limit the availability of the active ingredients used in certain of our current products and
products in development and, as a result, our procurement quota of these active ingredients may not be sufficient to meet commercial demand or complete clinical
trials. We must annually apply to the DEA for procurement quota in order to obtain these substances. Any delay or refusal by the DEA in establishing our
procurement quota for controlled substances could delay or stop our clinical trials or product launches, or could cause trade inventory disruptions for those products
that have already been launched, which could have a material adverse effect on our business, results of operations and financial condition.
Unstable economic conditions may adversely affect our industry, business, results of operations and financial condition.
The global economy has undergone a period of significant volatility which has led to diminished credit availability, declines in consumer confidence and
increases in unemployment rates. There remains caution about the stability of the U.S. economy due to the global financial crisis, and we cannot assure that further
deterioration in the financial markets will not occur. These economic conditions have resulted in, and could lead to further, reduced consumer spending related to
healthcare in general and pharmaceutical products in particular.
In addition, we have exposure to many different industries and counterparties, including our partners under our alliance and collaboration agreements,
suppliers of raw chemical materials, drug wholesalers and other customers that may be affected by an unstable economic environment. Any economic instability may
affect these parties’ ability to fulfill their respective contractual obligations to us, cause them to limit or place burdensome conditions upon future transactions with us
or drive us and our competitors to decrease prices, each of which could materially and adversely affect our business, results of operations and financial condition.
Furthermore, the capital and credit markets have experienced extreme volatility. Disruptions in the credit markets make it harder and more expensive to obtain
funding. In the event current resources do not satisfy our needs, we may have to seek additional financing. The availability of additional financing will depend on a
variety of factors such as market conditions and the general availability of credit. Future debt financing may not be available to us when required or may not be
available on acceptable terms, and as a result we may be unable to grow our business, take advantage of business opportunities, or respond to competitive pressures.
34
We may be subject to disruptions or failures in our information technology systems and network infrastructures that could have a material adverse effect on our
business.
We rely on the efficient and uninterrupted operation of complex information technology systems and network infrastructures to operate our business. We
also hold data in various data center facilities upon which our business depends. A disruption, infiltration or failure of our information technology systems or any of
our data centers as a result of software or hardware malfunctions, system implementations or upgrades, computer viruses, third-party security breaches, employee
error, theft or misuse, malfeasance, power disruptions, natural disasters or accidents could cause breaches of data security, loss of intellectual property and critical data
and the release and misappropriation of sensitive competitive information. Any of these events could result in the loss of key information, impair our production and
supply chain processes, harm our competitive position, cause us to incur significant costs to remedy any damages and ultimately materially and adversely affect our
business, results of operations and financial condition.
While we have implemented a number of protective measures, including firewalls, antivirus, patches, data encryption, log monitors, routine back-ups with
offsite retention of storage media, system audits, data partitioning, routine password modifications and disaster recovery procedures, such measures may not be
adequate or implemented properly to prevent or fully address the adverse effect of such events.
We may be adversely affected by alliance, collaboration, supply, or license and distribution agreements we enter into with other companies.
We have entered into several alliance, collaboration, supply or license and distribution agreements with respect to certain of our products and services and
may enter into similar agreements in the future. These arrangements may require us to relinquish rights to certain of our technologies or product candidates, or to grant
licenses on terms that ultimately may prove to be unfavorable to us. Relationships with alliance partners may also include risks due to regulatory requirements,
incomplete marketplace information, inventories, and commercial strategies of our partners, and our agreements may be the subject of contractual disputes. If we or our
partners are not successful in commercializing the products covered by the agreements, such commercial failure could adversely affect our business.
Pursuant to license and distribution agreements with unrelated third party pharmaceutical companies, we are dependent on such companies to supply us with
product that we market and sell, and we may enter into similar agreements in the future. Any delay or interruption in the supply of product under such agreements
could curtail or delay our product shipment and adversely affect our revenues, as well as jeopardize our relationships with our customers.
From time to time we may need to rely on licenses to proprietary technologies, which may be difficult or expensive to obtain.
We may need to obtain licenses to patents and other proprietary rights held by third parties to develop, manufacture and market products. If we are unable to
timely obtain these licenses on commercially reasonable terms, our ability to commercially market our products may be inhibited or prevented, which could have a
material adverse effect on our business, results of operations and financial condition.
35
We depend on qualified scientific and technical employees and are increasingly dependent on our direct sales force, and our limited resources may make it more
difficult to attract and retain these personnel.
Because of the specialized scientific nature of our business, we are highly dependent upon our ability to continue to attract and retain qualified scientific and
technical personnel. We are not aware of any pending, significant losses of scientific or technical personnel. Loss of the services of, or failure to recruit, key scientific
and technical personnel, however, would be significantly detrimental to our product-development programs. As a result of our small size and limited financial and other
resources, it may be difficult for us to attract and retain qualified officers and qualified scientific and technical personnel.
In addition, marketing of the Zomig® products pursuant to our AZ Agreement with AstraZeneca and future marketing of our internally developed branded
products approved by the FDA, including RYTARY™, requires and will continue to require much greater use of a direct sales force compared to marketing of our
Global products. Our ability to realize significant revenues from marketing and sales activities depends on our ability to attract and retain qualified sales personnel.
Competition for qualified sales personnel is intense. Any failure to attract or retain qualified sales personnel or to enter into third party arrangements on favorable
terms for a contract sales force could negatively impact our sales revenue and have a material adverse effect on our business, results of operations and financial
condition.
We have entered into employment agreements with our executive officers and certain other key employees. Under the employment agreements, the employee
may terminate his or her employment upon 60 days prior written notice to us. All of our other key personnel are employed on an at-will basis with no formal
employment agreements. We do not maintain “Key Man” life insurance on any executives.
We are subject to significant costs and uncertainties related to compliance with the extensive regulations that govern the manufacturing, labeling, distribution,
and promotion of pharmaceutical products as well as environmental, safety and health regulations.
The manufacturing, distribution, processing, formulation, packaging, labeling and advertising of our products are subject to extensive regulation by federal
agencies, including the FDA, DEA, FTC, Consumer Product Safety Commission and Environmental Protection Agency, among others. We are also subject to state and
local laws, regulations and agencies in California, Pennsylvania and elsewhere, as well as the laws and regulations of Taiwan. Such regulations are also subject to
change by the relevant federal, state and international agencies. For instance, beginning on January 1, 2015, manufacturers, wholesale distributors, and repackagers of
certain prescription drugs must provide and capture certain product tracing information under the Drug Quality and Security Act (“DQSA”). Title II of the DQSA, the
Drug Supply Chain Security Act, requires companies in certain prescription drugs’ chain of distribution to build electronic, interoperable systems to identify and trace
the products as they are distributed in the United States. Compliance with the DQSA or any future federal or state electronic pedigree requirements may increase the
Company's operational expenses and impose significant administrative burdens. Compliance with other federal and state and local law regulations, including
compliance with any newly enacted regulations, requires substantial expenditures of time, money and effort to ensure full technical compliance. Failure to comply with
the FDA and other governmental regulations can result in fines, disgorgement, unanticipated compliance expenditures, recall or seizure of products, exposure to
product liability claims, total or partial suspension of production or distribution, suspension of the FDA’s review of NDAs or ANDAs, enforcement actions,
injunctions and civil or criminal prosecution.
As discussed above, we received a warning letter in late May 2011 from the FDA related to an on-site FDA inspection of our Hayward, California
manufacturing facility citing deviations from cGMP. During 2012, 2013 and 2014, the FDA conducted inspections of our Hayward manufacturing facility and at the
conclusion of each inspection, we received a Form 483. In July 2014, the FDA conducted an inspection of our Taiwan manufacturing facility and at the conclusion of
the inspection, we received a Form 483 with ten observations. We have taken a number of steps to review our quality control and manufacturing systems and
standards and are working with third-party experts to assist us with our review and in enhancing such systems and standards. We cannot be assured, however, that
the FDA will be satisfied with our corrective actions and as such, we cannot be assured of when the warning letter will be closed out. Unless and until the warning
letter is closed out and the Form 483 observations resolved, it is possible we may be subject to additional regulatory action by the FDA as a result of the current or
future FDA observations, including, among others, monetary sanctions or penalties, product recalls or seizure, injunctions, total or partial suspension of production
and/or distribution, and suspension or withdrawal of regulatory approvals. Additionally, the FDA has withheld and may continue to withhold approval of pending
drug applications currently or previously listing our Hayward, California facility as a manufacturing location of finished dosage forms until the warning letter is closed
out and the Form 483 observations on our Hayward facility are resolved. Further, other federal agencies, our customers and partners in our alliance, development,
collaboration and other partnership agreements with respect to our products and services may take the warning letter and the Form 483 observations into account
when considering the award of contracts or the continuation or extension of such partnership agreements. Any such actions could significantly disrupt our business
and harm our reputation, resulting in a material adverse effect on our business, results of operations and financial condition.
36
With respect, to environmental, safety and health laws and regulations, we cannot accurately predict the outcome or timing of future expenditures that we
may be required to make in order to comply with such laws as they apply to our operations and facilities. We are also subject to potential liability for the remediation of
contamination associated with both present and past hazardous waste generation, handling, and disposal activities. We are subject periodically to environmental
compliance reviews by environmental, safety, and health regulatory agencies. Environmental laws are subject to change and we may become subject to stricter
environmental standards in the future and face larger capital expenditures in order to comply with environmental laws.
We may experience reductions in the levels of reimbursement for pharmaceutical products by governmental authorities, HMOs or other third-party payers. Any
such reductions could have a material adverse effect on our business, results of operations and financial condition.
Various governmental authorities and private health insurers and other organizations, such as HMOs, provide reimbursement to consumers for the cost of
certain pharmaceutical products. Demand for our products depends in part on the extent to which such reimbursement is available. In addition, third-party payers are
attempting to control costs by limiting the level of reimbursement for medical products, including pharmaceuticals, and increasingly challenge the pricing of these
products which may adversely affect the pricing of our products. Moreover, health care reform has been, and is expected to continue to be, an area of national and
state focus, which could result in the adoption of measures that could adversely affect the pricing of pharmaceuticals or the amount of reimbursement available from
third-party payers for our products.
Reporting and payment obligations under the Medicaid rebate program and other government programs are complex, and failure to comply could result in
sanctions and penalties or we could be required to reimburse the government for underpayments, which could have a material adverse effect on our business.
Medicaid and other government reporting and payment obligations are highly complex and somewhat ambiguous. State attorneys general and the U.S.
Department of Justice have brought suits or instituted investigations against a number of other pharmaceutical companies for failure to comply with Medicaid and
other government reporting obligations. Our methodologies for making these calculations are complex and the judgments involved require us to make subjective
decisions, such that these calculations are subject to the risk of errors. Government agencies may impose civil or criminal sanctions, including fines, penalties and
possible exclusion from federal health care programs, including Medicaid and Medicare. Any such penalties or sanctions could have a material adverse effect on our
business, results of operations and financial condition.
Legislative or regulatory programs that may influence prices of prescription drugs could have a material adverse effect on our business.
Current or future federal or state laws and regulations may influence the prices of drugs and, therefore, could adversely affect the prices that we receive for
our products. Programs in existence in certain states seek to set prices of all drugs sold within those states through the regulation and administration of the sale of
prescription drugs. Expansion of these programs, in particular, state Medicaid programs, or changes required in the way in which Medicaid rebates are calculated under
such programs, could adversely affect the price we receive for our products and could have a material adverse effect on our business, results of operations and
financial condition. Further, prescription drug prices have been the focus of increased scrutiny by certain state attorneys general and the U.S. Department of Justice.
Decreases in health care reimbursements or prices of our prescription drugs could limit our ability to sell our products or decrease our revenues, which could have a
material adverse effect on our business, results of operations and financial condition.
37
Our failure to comply with the legal and regulatory requirements governing the healthcare industry may result in substantial fines, sanctions and restrictions on
our business activities.
Our practices and activities related to the sales and marketing of our products, as well as the pricing of our products, are subject to extensive regulation under
U.S. federal and state healthcare statutes and regulations intended to combat fraud and abuse to federal and state healthcare payment programs, such as Medicare and
Medicaid, Tri-Care, CHAMPUS, and Department of Defense programs. These laws include the federal Anti-Kickback Statute, the federal False Claims Act, and similar
state laws and implementing regulations. For example, the payment of any incentive to a healthcare provider to induce the recommendation of our product or the
purchase of our products reimbursable under a federal or state program is prohibited under these laws. Likewise, knowingly presenting or causing to be presented a
false claim for payment to a federal or state health care program would expose a company to sanctions and penalties. Similarly, the inaccurate reporting of prices
leading to inflated reimbursement rates would also be considered a violation of these laws. These laws and regulations are enforced by the U.S. Department of Justice,
the U.S. Department of Health and Human Services, Office of Inspector General, state Medicaid Fraud Units and other state enforcement agencies.
Violations of these laws and regulations are punishable by criminal and civil sanctions, including substantial fines and penal sanctions, such as imprisonment.
It is common for enforcement agencies to initiate investigations into sales and marketing practices, as well as pricing practices, regardless of merit. These types of
investigations and any related litigation can result in: (i) large expenditures of cash for legal fees, payment for penalties, and compliance activities; (ii) limitations on
operations; (iii) diversion of management resources; (iv) injury to our reputation; and (v) decreased demand for our products.
While we believe that our practices and activities related to sales and marketing, and the pricing of our products, are in compliance with these fraud and abuse
laws, the criteria for compliance are often complex and subject to change and interpretation. An investigation by an enforcement agency could have a material and
adverse effect on our business, results of operations and financial condition.
38
We have entered into, and anticipate entering into, contracts with various U.S. government agencies. Unfavorable provisions in government contracts, some of
which may be customary, may harm our business, financial condition and operating results.
Government contracts customarily contain provisions that give the government substantial rights and remedies, many of which are not typically found in
commercial contracts, including provisions that allow the government to:
●
●
●
●
●
●
●
●
●
suspend or debar the contractor from doing business with the government or a specific government agency;
terminate existing contracts, in whole or in part, for any reason or no reason;
reduce the scope and value of contracts;
change certain terms and conditions in contracts;
claim rights to products, including intellectual property, developed under the contract;
take actions that result in a longer development timeline than expected;
direct the course of a development program in a manner not chosen by the government contractor;
audit and object to the contractor’s contract-related costs and fees, including allocated indirect costs; and
control and potentially prohibit the export of the contractor’s products.
Generally, government contracts contain provisions permitting unilateral termination or modification, in whole or in part, at the government’s convenience.
Under general principles of government contracting law, if the government terminates a contract for convenience, the terminated company may recover only its
incurred or committed costs, settlement expenses and profit on work completed prior to the termination.
If the government terminates a contract for default, the defaulting company is entitled to recover costs incurred and associated profits on accepted items only
and may be liable for excess costs incurred by the government in procuring undelivered items from another source. Some government contracts grant the government
the right to use, for or on behalf of the U.S. government, any technologies developed by the contractor under the government contract. If we were to develop
technology under a contract with such a provision, we might not be able to prohibit third parties, including our competitors, from using that technology in providing
products and services to the government.
As a government contractor, we may also become subject to periodic audits and reviews. As part of any such audit or review, the government may review the
adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, compensation and/or
management information systems. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and
administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing
business with the government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us.
39
Legislative or regulatory reform of the healthcare system in the United States may harm our future business.
Healthcare costs have risen significantly over the past decade. On March 23, 2010, President Obama signed the “Patient Protection and Affordable Care Act”
(P.L. 111-148) and on March 30, 2010, the President signed the "Health Care and Education Reconciliation Act" (P.L. 111-152), collectively commonly referred to as the
“Healthcare Reform Act” which, among other things, requires most individuals to have health insurance, effective January 1, 2014, establishes new regulations on
health plans (with the earliest changes for certain benefits beginning with plan years commencing after September 23, 2010), creates insurance exchanges (effective
January 2014) and imposes new requirements and changes in reimbursement or funding for healthcare providers, device manufacturers and pharmaceutical companies
(with the earliest changes effective on March 23, 2010) and other changes staged in thereafter. The Health Care Reform Act also added substantial new provisions
affecting compliance, some of which may require us to modify our business practices with health care practitioners. Pharmaceutical manufacturers are required,
beginning from 2013, to comply with the federal Physician Payments Sunshine Act, which was passed as part of the Health Care Reform Act and requires
pharmaceutical companies to monitor and report payments, gifts, the provision of samples and other remuneration made to physicians and other health care
professionals and teaching hospitals. The Healthcare Reform Act imposes additional requirements and obligations upon our company, which, to a certain extent, will
depend upon the mix of products we sell. These changes include, among other things:
●
●
●
●
●
revisions to the Medicaid rebate program by: (a) increasing the rebate percentage for branded drugs and authorized generics dispensed after December
31, 2009 to 23.1% of the average manufacturer price ("AMP"), with limited exceptions, (b) increasing the rebate for outpatient generic, multiple source
drugs dispensed after December 31, 2009 to 13% of AMP; (c) changing the definition of AMP; and (d) extending the Medicaid rebate program effective
January 1, 2011 to Medicaid managed care plans, with limited exception;
the imposition of annual fees upon manufacturers or importers of branded prescription drugs, which fees will be in amounts determined by the Secretary
of Treasury based upon market share and other data;
providing a 50% discount on brand-name prescriptions filled in the Medicare Part D coverage gap beginning in 2011;
imposing increased penalties for the violation of fraud and abuse laws and funding for anti-fraud activities; and
expands the definition of “covered entities” that purchase certain outpatient drugs in the 340B Drug Pricing Program of Section 340B of the Public Health
Service Act.
Further, the Healthcare Reform Act also amends the intent requirement of the federal Anti-Kickback Statute. In particular, a person or entity no longer needs
to have actual knowledge of the Anti-Kickback Statute or specific intent to violate it. In addition, the Healthcare Reform Act provides that the government may assert
that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False
Claims Act. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions
and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing, or recommending may be subject to scrutiny
if they do not qualify for an exemption or safe harbor. From time to time we may enter into business arrangements (e.g., loans or investments) involving our customers
and those arrangements may be reviewed by federal and state regulators. Although we believe that we are in compliance, our practices may be determined to fail to
meet all of the criteria for safe harbor protection from anti-kickback liability.
The Healthcare Reform Act contemplates the promulgation of significant future regulatory action which may also further affect our business. The Act and
any further changes to health care laws or regulatory framework that reduce our revenues or increase our costs could also have a material adverse effect on our
business, results of operations and financial condition.
40
We depend on our intellectual property, and our future success is dependent on our ability to protect our intellectual property and not infringe on the rights of
others.
We believe intellectual property protection is important to our business and that our future success will depend, in part, on our ability to obtain patent
protection, maintain trade secret protection and operate without infringing on the rights of others. We cannot assure you that:
any of our future processes or products will be patentable;
our processes or products will not infringe upon the patents of third parties; or
●
●
● we will have the resources to defend against charges of patent infringement by third parties or to protect our own rights against infringement by third
parties.
We rely on trade secrets and proprietary knowledge related to our products and technology which we generally seek to protect by confidentiality and non-
disclosure agreements with employees, consultants, licensees and pharmaceutical companies. If these agreements are breached, we may not have adequate remedies
for any breach, and our trade secrets may otherwise become known by our competitors.
We are subject to potential product liability claims that can result in substantial litigation costs and liability.
The design, development and manufacture of pharmaceutical products involve an inherent risk of product liability claims and associated adverse publicity.
Product liability insurance coverage is expensive, difficult to obtain, and may not be available in the future on acceptable terms, or at all. Although we currently carry
$50.0 million of such insurance, we believe that no reasonable amount of insurance can fully protect against all such risks because of the potential liability inherent in
the business of producing pharmaceutical products for human consumption.
We face risks relating to our goodwill and intangibles.
®
At December 31, 2014, our goodwill, which was originally generated as a result of the December 1999 merger of Global Pharmaceuticals Corporation and Impax
Pharmaceuticals, Inc., was approximately $27.6 million, or approximately 3% of our total assets, and the carrying value of our intangible assets, composed primarily of
the Zomig
, Actavis, Perrigo and Tolmar product rights acquired by us pursuant to agreements with the respective parties, was approximately $26.7 million, or
approximately 2% of our total assets. We may never realize the value of our goodwill and intangibles. We regularly evaluate and will continue to regularly evaluate
whether events or circumstances have occurred to indicate all, or a portion, of the carrying amount of goodwill or intangible assets may no longer be recoverable, in
which case an impairment charge to earnings would become necessary. During the three month period ended September 30, 2013, we recorded a $13.2 million
impairment charge to cost of revenues for our Global Division as a result of deteriorating market conditions. During the same period in 2013, we also recorded an
intangible asset impairment charge of $0.8 million in research and development expenses as a result of a decision by management to withdraw one of our ANDAs and
no longer seek FDA approval. The impairment charge represented the full carrying value of the ANDA. During the three month period ended March 31, 2014, as a
result of a further decline in pricing, we revised our projections and performed an intangible asset impairment analysis. Based on the results of this analysis, we
recorded a $2.9 million charge to cost of revenues for the Global Pharmaceuticals Division. Other than the impairment charges discussed above, as of December 31,
2014, the carrying value of our goodwill and intangible assets was not impaired based on our assessment performed in accordance with accounting principles generally
accepted in the United States (“GAAP”). Further, any future acquisitions or investments in businesses could also result in an increase in goodwill, intangible assets
and amortization expenses that could ultimately negatively impact our profitability. If the fair value of our goodwill or intangible assets is determined at some future
date to be less than its recorded value, a change to earnings may be required. Any such charge or future determination requiring the write-off of a significant portion of
the carrying value of our goodwill or intangible assets could have a material adverse effect on our business, results of operations and financial condition.
41
Changes in tax regulations and varying application and interpretations of these regulations could result in an increase in our existing and future tax liabilities.
We have potential tax exposures resulting from the varying application of statutes, regulations and interpretations, including exposures with respect to
manufacturing, research and development, marketing, sales and distribution functions. Although our arrangements are based on accepted tax standards, tax authorities
in various jurisdictions including the United States may disagree with and subsequently challenge the amount of profits taxed, which may increase our tax liabilities
and could have a material adverse effect on our business, results of our operations and financial condition.
If we are unable to manage our growth, our business will suffer.
We have experienced rapid growth in the past several years and anticipate continued rapid expansion in the future. This growth has required us to expand,
upgrade, and improve our administrative, operational, and management systems, internal controls and resources. We anticipate additional growth in connection with
the expansion of our manufacturing operations, development of our brand-name products, and our marketing and sales efforts for the products we develop. Although
we cannot assure you that we will, in fact, grow as we expect, if we fail to manage growth effectively or to develop a successful marketing approach, our business and
financial results will be materially harmed. We may also seek to expand our business through complementary or strategic acquisitions of other businesses, products or
assets, or through joint ventures, strategic agreements or other arrangements. Any such acquisitions, joint ventures or other business combinations may involve
significant integration challenges, operational complexities and time consumption and require substantial resources and effort. It may also disrupt our ongoing
businesses, which may adversely affect our relationships with customers, employees, regulators and others with whom we have business or other dealings. Further, if
we are unable to realize synergies or other benefits expected to result from any acquisitions, joint ventures or other business combinations, or to generate additional
revenue to offset any unanticipated inability to realize these expected synergies or benefits, our growth and ability to compete may be impaired, which would require
us to focus additional resources on the integration of operations rather than other profitable areas of our business, and may otherwise cause a material adverse effect
on our business, results of operations and financial condition.
42
We may make acquisitions of, or investments in, complementary technologies, businesses or products, which may be on terms that are not commercially
advantageous, may require additional debt or equity financing, and may involve numerous risks, including the risks that we may be unable to integrate the
acquired business successfully and that we may assume liabilities that adversely affect us.
We regularly review the potential acquisition of technologies, products, product rights and complementary businesses. We may choose to enter into such
transactions at any time. Nonetheless, we cannot provide assurance that we will be able to identify suitable acquisition or investment candidates. To the extent that we
do identify candidates that we believe to be suitable, we cannot provide assurance that we will be able to make such acquisitions or investments on commercially
advantageous terms or at all.
If we make any acquisitions or investments, we may finance such acquisitions or investments through our cash reserves, debt financing, or by issuing
additional equity securities, which could dilute the holdings of our then-existing stockholders. If we require financing, we cannot provide assurance that we will be
able to obtain required financing when needed on acceptable terms or at all. Any such acquisitions or investments could also result in an increase in goodwill,
able to obtain required financing when needed on acceptable terms or at all. Any such acquisitions or investments could also result in an increase in goodwill,
intangible assets and amortization expenses that could ultimately negatively impact our profitability. If the fair value of our goodwill or intangible assets is determined
at some future date to be less than its recorded value, a charge to earnings may be required. Further, our consolidated financial statements may also be impacted in
future periods based on the accuracy of our valuations of any businesses we acquire. Such a charge to earnings or impact on our consolidated financial statements
could be in amounts that are material to our business, results of operations and financial condition.
Additionally, acquisitions involve numerous risks, including difficulties in assimilating the personnel, operations and products of the acquired companies, the
diversion of management’s attention from other business concerns, risks of entering markets in which we have limited or no prior experience, and the potential loss of
key employees of the acquired company. There may be overlap between our products or customers and those of an acquired entity that may create conflicts in
relationships or other commitments detrimental to the integrated businesses. As a result of acquiring businesses, we may incur significant transaction costs, including
substantial fees for investment bankers, attorneys, accountants and financial printing. Any acquisition could result in our assumption of unknown and/or unexpected,
perhaps material liabilities. Additionally, in any acquisition agreement, the negotiated representations, warranties and agreements of the selling parties may not entirely
protect us, and liabilities resulting from any breaches could exceed negotiated indemnity limitations.
43
We may not complete the proposed acquisition of Tower Holdings, Inc. (“Tower”) and Lineage Therapeutics Inc. (“Lineage”) within the time frame we anticipate
or at all, which could have a material adverse effect on our business.
On October 8, 2014, we entered into a Stock Purchase Agreement pursuant to which we will acquire all the outstanding shares of common stock of Tower and
Lineage, and the options and warrants to purchase or acquire shares of Tower common stock and shares of Lineage common stock will be cancelled, for a purchase
price of $700 million in cash, subject to customary adjustments for working capital, net debt and transaction expenses. The closing of the transaction is subject to the
satisfaction or waiver of certain customary closing conditions, including approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the accuracy of
the representations and warranties, and performance of covenants. In connection with the Stock Purchase Agreement, on January 2, 2015, we entered into a second
amended and restated commitment letter (the “Commitment Letter”), which amended and restated the commitment letter dated as of October 8, 2014, as first amended
and restated on October 22, 2014 with Barclays Bank plc (“Barclays”), Royal Bank of Canada (“Royal Bank”), Wells Fargo Bank, National Association (“Wells Fargo”)
and Wells Fargo Securities, LLC (“Wells Fargo Securities” and together with Barclays, Royal Bank and Wells Fargo, the “Lenders”) pursuant to which the Lenders
have severally but not jointly committed to provide a $50.0 million senior secured revolving credit facility and a $435.0 million senior secured term loan facility in an
aggregate principal amount of up to $485.0 million for the purposes of financing the proposed acquisition of Tower and Lineage and the fees and expenses in
connection therewith, on the terms and subject to the conditions set forth in the Commitment Letter. The obligations of the Lenders to provide debt financing under
the Commitment Letter is subject to a number of conditions, including (i) absence of a Material Adverse Effect (as defined in the Stock Purchase Agreement) that
would result in a failure of a condition under the Stock Purchase Agreement, (ii) execution and delivery by us of definitive documentation with respect to the debt
financing consistent with the term sheet attached to the Commitment Letter; (iii) the accuracy of certain specified representations and warranties in the debt
documents; (iv) concurrent consummation of the proposed transaction in accordance with the Stock Purchase Agreement (v) delivery of certain customary closing
documents (including, among others, a customary solvency certificate), specified items of collateral (where applicable) and certain Tower and Lineage financial
statements; and (vi) payment of applicable costs, fees and expenses. The final termination date of the Commitment Letter is March 30, 2015.
The proposed transaction is also subject to other risks and uncertainties, such as the possibility that we do not satisfy the conditions to obtain the debt
financing under the Commitment Letter or that either we or the Sellers (as defined in the Stock Purchase Agreement) could exercise our respective termination rights. In
the event that the transaction is not consummated or is materially delayed for any reason, we will have spent considerable time and resources and incurred substantial
costs related to the acquisition, many of which must be paid even if the transaction is not completed. We cannot provide any assurance that the proposed transaction
will be completed or that there will not be a delay in the completion of the transaction. If the acquisition is not consummated, our reputation in our industry and in the
investment community could be damaged, and the market price of our common stock could decline.
Failure to consummate the acquisition of Tower and Lineage could negatively impact the share price of our common stock.
If the proposed acquisition of Tower and Lineage is not consummated, the stock price of our common stock may be materially and adversely affected.
Without realizing any of the benefits of having consummated the transactions, we will be subject to a number of risks, including that the current price of our common
stock may reflect a market assumption that the proposed acquisition of Tower and Lineage will occur. A failure to complete the acquisition could therefore result in a
material decline in the price of our common stock.
We may experience difficulties in integrating the operations of Tower and Lineage into our business and in realizing the expected benefits of the proposed
acquisition.
The success of the proposed acquisition of Tower and Lineage, if completed, will depend in part on our ability to realize the anticipated business
opportunities and growth prospects from combining the operations of Tower and Lineage with our business in an efficient and effective manner. We may never realize
these business opportunities and growth prospects. Further, our management might have its attention diverted while trying to integrate operations and corporate and
administrative infrastructures.
44
Tower and Lineage will continue to operate independently of us until the closing of the transaction. The integration process could take longer than
anticipated and could result in the loss of key employees, the disruption of each company’s ongoing businesses, tax costs or inefficiencies, or inconsistencies in
standards, controls, information technology systems, procedures and policies, any of which could adversely affect our ability to maintain relationships with
customers, employees or other third parties, or our ability to achieve the anticipated benefits of the transaction, and could harm our financial performance. If we are
unable to successfully or timely integrate the operations of Tower and Lineage with our business, we may incur unanticipated liabilities and be unable to realize the
revenue growth, synergies and other anticipated benefits resulting from the proposed transaction, and our business, results of operations and financial condition
could be materially and adversely affected.
There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with GAAP. Any
future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions could lead to a restatement of
our results.
The consolidated financial statements included in this Annual Report on Form 10-K are prepared in accordance with GAAP. This involves making estimates,
judgments and assumptions that affect reported amounts of assets (including intangible assets), liabilities, revenues, expenses and income. Estimates, judgments and
assumptions are inherently subject to change in the future and any necessary revisions to prior estimates, judgments or assumptions could lead to a restatement. Any
such changes could result in corresponding changes to the amounts of assets (including goodwill and other intangible assets), liabilities, revenues, expenses and
income.
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results, timely file our
periodic reports, maintain our reporting status or prevent fraud.
Our management or our independent registered public accounting firm may identify material weaknesses in our internal control over financial reporting in the
future. The existence of internal control material weaknesses may result in current and potential stockholders and alliance and collaboration agreements’ partners
losing confidence in our financial reporting, which could harm our business, the market price of our common stock, and our ability to retain our current, or obtain new,
alliance and collaboration agreements’ partners.
In addition, the existence of material weaknesses in our internal control over financial reporting may affect our ability to timely file periodic reports under the
Exchange Act. Although we remedied any past accounting issues and do not believe similar accounting problems are likely to recur, an internal control material
weakness may develop in the future and affect our ability to timely file our periodic reports. The inability to timely file periodic reports under the Exchange Act could
result in the SEC revoking the registration of our common stock, which would prohibit us from listing or having our stock quoted on any public market. This would
have an adverse effect on our business and stock price by limiting the publicly available information regarding us and greatly reducing the ability of our stockholders
to sell or trade our common stock.
Terrorist attacks and other acts of violence or war may adversely affect our business.
Terrorist attacks at or nearby our facilities in Hayward, California, Philadelphia, Pennsylvania, or our manufacturing facility in Taiwan may negatively affect
our operations. While we do not believe that we are more susceptible to such attacks than other companies, such attacks could directly affect our physical facilities or
those of our suppliers or customers and could make the transportation of our products more difficult and more expensive and ultimately affect our sales.
We carry insurance coverage on our facilities of types and in amounts that we believe are in line with coverage customarily obtained by owners of similar
properties. We continue to monitor the state of the insurance market in general and the scope and cost of coverage for acts of terrorism in particular, but we cannot
anticipate what coverage will be available on commercially reasonable terms in future policy years. Currently, we carry terrorism insurance as part of our property and
casualty and business interruption coverage. If we experience a loss that is uninsured or that exceeds policy limits, we could lose the capital invested in the damaged
facilities, as well as the anticipated future net sales from those facilities.
45
Because of the location of our manufacturing and research and development facilities, our operations could be interrupted by an earthquake or be susceptible to
climate changes.
Our corporate headquarters in California, manufacturing operations in California and Taiwan, and research and development activities related to process
technologies are located near major earthquake fault lines. Although we have other facilities, we produce a substantial portion of our products at our California facility.
A disruption at these California facilities due to an earthquake, other natural disaster, or due to climate changes, even on a short-term basis, could impair our ability to
produce and ship products to the market on a timely basis. In addition, we could experience a destruction of facilities which would be costly to rebuild, or loss of life,
all of which could materially adversely affect our business and results of operations.
We presently carry $10.0 million of earthquake coverage which covers all of our facilities on a worldwide basis. We carry an additional $40.0 million of
earthquake coverage specifically for our California facilities. We believe the aggregate amount of earthquake coverage we currently carry is appropriate in light of the
risks; however, the amount of our earthquake insurance coverage may not be sufficient to cover losses from earthquakes. We may discontinue some or all of this
insurance coverage in the future if the cost of premiums exceeds the value of the coverage discounted for the risk of loss. If we experience a loss that is uninsured or
that exceeds policy limits, we could lose the capital invested in the damaged facilities, as well as the anticipated future net sales from those facilities.
The expansion of social media platforms present new risks and challenges, which could cause a material adverse effect on our business, results of operations and
financial condition.
The inappropriate use of certain media vehicles could cause brand damage or information leakage or could lead to legal implications from the improper
collection and/or dissemination of personally identifiable information. In addition, negative posts or comments about us on any social networking website could
seriously damage our reputation. Further, the disclosure of non-public company sensitive information through external media channels could lead to information loss
as there might not be structured processes in place to secure and protect information. If our non-public sensitive information is disclosed or if our reputation is
seriously damaged through social media, it could have a material adverse effect on our business, results of operations and financial condition.
46
Item 1B. Unresolved Staff Comments
Not applicable.
Item 2.
Properties
Our primary properties consist of a leased 45,000 sq. ft. corporate headquarter facility, an owned 35,000 sq. ft. research and development center and an owned
50,000 sq. ft. manufacturing facility, all located in Hayward, California; a 113,000 sq. ft. packaging and warehousing facility located in Philadelphia, Pennsylvania, also
owned by us, and a leased 44,000 sq. ft. facility located in New Britain, Pennsylvania, which houses sales, marketing and administration personnel and also serves as
our distribution center. In addition, we own a 19,000 sq. ft. office building containing additional administrative and laboratory facilities in Hayward, a 50,400 sq. ft.
warehouse building in Hayward, and a 13,300 sq. ft. building in Hayward which houses additional administrative support staff. We also lease two additional facilities
aggregating 76,180 sq. ft. in Hayward, California, which are utilized for additional research and development, administrative services and equipment storage, one 9,250
sq. ft. facility in Hayward, California used to support manufacturing and quality assurance and one 40,000 sq. ft. facility in Montgomeryville, Pennsylvania. The
expiration dates of these lease agreements range between June 30, 2015 and January 31, 2020. We also own a 388,000 sq. ft. manufacturing facility in Taiwan. Our
properties are generally used to support the operations of both the Global Division and the Impax Division.
In our various facilities we maintain an extensive equipment base that includes new or recently reconditioned equipment for the manufacturing and packaging
of compressed tablets, coated tablets and capsules. The manufacturing and research and development equipment includes mixers and blenders for capsules and
tablets, automated capsule fillers, tablet presses, particle reduction, sifting equipment, and tablet coaters. The packaging equipment includes fillers, cottoners, cappers,
and labelers. We also maintain two well equipped, modern laboratories used to perform all the required physical and chemical testing of our products. We also maintain
a broad variety of material handling and cleaning, maintenance, and support equipment. We own substantially all of our manufacturing equipment and believe it is well
maintained and suitable for its requirements.
We maintain property and casualty and business interruption insurance in amounts we believe are sufficient and consistent with practices for companies of
comparable size and business.
Item 3.
Legal Proceedings
Information pertaining to legal proceedings can be found in “Item 15. Exhibits and Financial Statement Schedules – Note 19. Legal and Regulatory Matters”
and is incorporated by reference herein.
Item 4.
Mine Safety Disclosures
Not applicable.
47
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Stock Price
Our common stock is traded on the NASDAQ Global Market under the symbol "IPXL". The following table sets forth the high and low sales prices for our
common stock as reported by the NASDAQ Global Market, as follows:
PART II
Year Ending December 31, 2014
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
Year Ending December 31, 2013
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
Price Range
per Share
High
Low
$
$
$
$
$
$
$
$
28.50 $
30.74 $
31.04 $
33.05 $
22.38 $
19.98 $
22.01 $
25.50 $
21.34
23.02
22.12
23.31
14.41
15.05
19.79
19.39
48
This performance graph shall not be deemed "soliciting material" or to be "filed" with the Securities and Exchange Commission for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be
incorporated by reference into any filing of Impax Laboratories, Inc. under the Securities Act of 1933, as amended, or the Exchange Act.
Holders
As of February 13, 2015, there were approximately 242 holders of record of our common stock, solely based upon the count our transfer agent provided us as
of that date.
Dividends
We have never paid cash dividends on our common stock and have no present plans to do so. Our current policy is to retain all earnings, if any, for use in the
operation of our business. The payment of future cash dividends, if any, will be at the discretion of the Board of Directors and will be dependent upon our earnings,
financial condition, capital requirements and other factors as the Board of Directors may deem relevant.
Unregistered Sales of Securities
There were no sales of unregistered securities during the year ended December 31, 2014.
49
Purchases of Equity Securities by the Issuer
The following table provides information regarding the purchases of our equity securities by us during the quarter ended December 31, 2014.
Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
Total Number of
Shares (or Units)
Purchased as
Part of Publicly
Announced Plans
or Programs
Total Number of
Shares (or Units)
Purchased(1)
Average Price
Paid Per Share
(or Unit)
200,099 $
27.90
October 1, 2014 to October 31, 2014
Period
November 1, 2014 to November 30, 2014
0
0
December 1, 2014 to December 31, 2014
3,853 $
29.94
Total
203,952 $
27.94
---
---
---
---
---
---
---
---
(1) Represents shares of our common stock that we accepted during the indicated periods as a tax withholding from certain of our employees in connection with the
vesting of shares of restricted stock pursuant to the terms of our Second Amended and Restated 2002 Equity Incentive Plan (the “2002 Plan”).
50
Equity Compensation Plans
The following table details information regarding our existing equity compensation plans as of December 31, 2014:
Plan Category
Equity compensation plans approved by security holders
Equity compensation plans not approved by security holders
Total:
Number of Securities
to be Issued Upon
Exercise of
Outstanding Options,
Warrants and Rights
(a)
Weighted Average
Exercise Price of
Outstanding Options,
Warrants and Rights
(b)
Number of Securities
Remaining Available
for Future Issuance
Under Equity
Compensation Plans
(Excluding Securities
reflected in
Column (a))
(c)
3,042,180(1) $
---
3,042,180
$
14.78
---
14.78
2,595,124
116,525(2)
2,711,649
(1) Represents options issued pursuant to the 2002 Plan, and the Impax Laboratories, Inc. 1999 Equity Incentive Plan.
(2) Represents 116,525 shares of common stock available for future issuance under the Impax Laboratories, Inc. 2001 Non-Qualified Employee Stock Purchase
Plan.
See “Item 15. Exhibits and Financial Statement Schedules — Note 13. Employee Benefit Plans” and “Note 14. Share-Based Compensation” for information
concerning our employee benefit plans and equity compensation plans.
51
Item 6.
Selected Financial Data
The following selected financial data should be read together with our consolidated financial statements and accompanying consolidated financial statement
footnotes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this Annual Report on Form 10-K.
The selected consolidated financial statement data in this section are not intended to replace our consolidated financial statements and the accompanying
consolidated financial statement footnotes. Our historical consolidated financial results are not necessarily indicative of our future consolidated financial results.
The selected financial data set forth below are derived from our consolidated financial statements. The consolidated statements of operations data for the
years ended December 31, 2014, 2013 and 2012 and the consolidated balance sheet data as of December 31, 2014 and 2013 are derived from our audited consolidated
financial statements included elsewhere in this Annual Report on Form 10-K. These audited consolidated financial statements include, in the opinion of management,
all adjustments necessary for the fair presentation of our financial position and results of operations for these periods.
($ in 000s, except per share data)
Statements of Operations Data:
Total revenues
Research and development
Total operating expenses
Income (loss) from operations
Net income
Net income per share — basic
Net income per share — diluted
($ in 000s)
Balance Sheet Data:
Cash, cash equivalents and short-term investments
Working capital
Total assets
Long-term debt
Total liabilities
Retained earnings
Total stockholders’ equity
$
$
2014
For the Years Ended December 31,
2012
2013
2011
2010
596,049 $
79,114
223,837
88,816
57,353
0.84
0.81
511,502 $
68,854
205,687
(6,387)
101,259
1.51
1.47
581,692 $
81,320
199,562
82,992
55,873
0.85
0.82
512,919 $
82,701
158,684
99,611
65,495
1.02
0.97
879,509
86,223
145,939
393,324
250,418
4.04
3.82
2014
2013
As of December 31,
2012
2011
2010
413,133 $
505,852
996,923
--
186,720
473,873
810,203
298,918 $
400,248
863,970
--
172,867
372,614
691,103
346,414 $
443,074
793,859
--
190,918
316,741
602,941
348,401
394,278
693,318
--
185,331
251,246
507,987
414,856 $
571,752
1,079,197
--
191,320
531,226
887,877
52
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis, as well as other sections in this report, should be read in conjunction with the consolidated financial statements and
related Notes to Consolidated Financial Statements included elsewhere herein. All references to years mean the relevant 12-month period ended December 31.
Overview
General
We are a technology based, specialty pharmaceutical company applying formulation and development expertise, as well as our drug delivery technology, to
the development, manufacture and marketing of controlled-release and niche generics, in addition to the development of branded products. As of February 6, 2015, we
marketed 96 generic pharmaceuticals, which represent dosage variations of 29 different pharmaceutical compounds through our own Global Pharmaceuticals division;
another five of our generic pharmaceuticals representing dosage variations of two different pharmaceutical compounds are marketed by our alliance and collaboration
agreement partners. As of February 6, 2015, we had 21 applications pending at the FDA and 21 other products in various stages of development for which applications
have not yet been filed.
In the generic pharmaceuticals market, we focus our efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a broad
range of therapeutic areas and having technically challenging drug-delivery mechanisms or unique product formulations. We employ our technologies and formulation
expertise to develop generic products that will reproduce the brand-name product’s physiological characteristics but not infringe any valid patents relating to the
brand-name product. We generally focus on brand-name products as to which the patents covering the active pharmaceutical ingredient have expired or are near
expiration, and we employ our formulation expertise to develop controlled-release versions that do not infringe valid patents covering the brand-name products. We
develop specialty generic pharmaceuticals that we believe present certain competitive advantages, such as difficulty in raw materials sourcing, complex formulation or
development characteristics or special handling requirements. We have also recently expanded our generic pharmaceutical products portfolio to include alternative
dosage form products primarily through alliance and collaboration agreements with third parties.
In the brand-name pharmaceuticals market, we are developing products for the treatment of central nervous system (“CNS”) disorders. Our brand-name
product portfolio currently consists of one internally developed branded pharmaceutical product, RYTARY™, for the treatment of Parkinson’s disease, post-
encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the FDA on
January 7, 2015 in addition to development-stage projects to which we are applying our formulation and development expertise to develop differentiated, modified, or
controlled-release versions of currently marketed (either in the U.S. or outside the U.S.) drug substances. We also sell and promote branded pharmaceutical products
developed by an unrelated third-party pharmaceutical company through our direct sales force. We intend to expand our brand-name products portfolio primarily
through internal development and also through licensing and acquisition.
We operate in two segments, referred to as the “Global Pharmaceuticals Division” or “Global Division” and the “Impax Pharmaceuticals Division” or “Impax
Division.”
53
The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products primarily through the following sales channels: the Global
Products sales channel, for sales of generic prescription products we sell directly to wholesalers, large retail drug chains, and others; the Private Label Product sales
channel, for generic pharmaceutical over-the-counter and prescription products we sell to unrelated third-party customers who in-turn sell the product to third parties
under their own label; the Rx Partner sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under their own label
pursuant to alliance agreements; and the OTC Partner sales channel, for sales of generic pharmaceutical over-the-counter products sold through unrelated third-party
pharmaceutical entities under their own label pursuant to alliance agreements. We sell our Global Division products within the continental United States and the
Commonwealth of Puerto Rico. We have no sales in foreign countries. Revenues from Global Product sales channel and the Private Label Product sales channel are
reported under the caption “Global Product Sales, net” in our consolidated results of operations. We also generate revenue in our Global Division from research and
development services provided under a joint development agreement with another pharmaceutical company, and we report such revenue under the caption “Other
Revenues” in “Item 15. Exhibits and Financial Statement Schedules – Note 20 - Supplementary Financial Information.”
The Impax Division is engaged in the development of proprietary branded pharmaceutical products through improvements to already-approved
pharmaceutical products to address CNS disorders. We have one internally developed branded pharmaceutical product, RYTARY™, for the treatment of Parkinson’s
disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the
FDA on January 7, 2015 and for which we currently plan to fully launch our sales and marketing efforts for the product in early April 2015. The Impax Division also has
a number of other product candidates that are in varying stages of development. In addition, the Impax Division is engaged in product sales through a direct sales
force focused on selling to physicians, primarily in the CNS community, pharmaceutical products developed by an unrelated third-party pharmaceutical company
pursuant to a Distribution, License, Development and Supply Agreement. Additionally, we generate revenue in the Impax Division from research and development
services provided under a development and license agreement with another unrelated third-party pharmaceutical company, and we report such revenue in the line item
“Research Partner” in our consolidated results of operations.
We have entered into several alliance, collaboration or license and distribution agreements with respect to certain of our products and services and may enter
into similar agreements in the future. These agreements may require us to relinquish rights to certain of our technologies or product candidates, or to grant licenses on
terms which ultimately may prove to be unfavorable to us. Relationships with alliance and collaboration partners may also include risks due to the failure of a partner to
perform under the agreement, incomplete marketplace information, inventories, development capabilities, regulatory compliance and commercial strategies of our
partners and our agreements may be the subject of contractual disputes. For instance, we were previously dependent on an unrelated third-party pharmaceutical
company to supply us with our authorized generic Adderall XR®, which we market and sell. We experienced disruptions related to the supply of such product during
each of the years ended December 31, 2012, 2011 and 2010 and we filed suit against such third party supplier for breach of contract and other related claims due to a
failure to fill our orders as required by the license and distribution agreement. We entered into a settlement agreement with the third party supplier in February 2013. If
we suffer similar supply failures on our significant products in the future, or if we or our partners are not successful in commercializing the products covered by such
alliance, collaboration or license and distribution agreements, our revenues and relationships with our customers may be materially adversely affected.
54
Critical Accounting Policies and Use of Estimates
The preparation of our consolidated financial statements in accordance with accounting principles generally accepted in the United States (GAAP) and the
rules and regulations of the U.S. Securities & Exchange Commission (SEC) require the use of estimates and assumptions, based on complex judgments considered
reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant judgments are employed in estimates used
in determining values of tangible and intangible assets, legal contingencies, tax assets and tax liabilities, fair value of share-based compensation related to equity
incentive awards issued to employees and directors, and estimates used in applying the Company’s revenue recognition policy including those related to accrued
chargebacks, rebates, distribution service fees, product returns, Medicare, Medicaid, and other government rebate programs, shelf-stock adjustments, and the timing
and amount of deferred and recognized revenue under the Company's several alliance and collaboration agreements. Actual results may differ from estimated results.
Certain prior year amounts have been reclassified to conform to the presentation for the year ended December 31, 2014.
Although we believe our estimates and assumptions are reasonable when made, they are based upon information available to us at the time they are made.
We periodically review the factors having an influence on our estimates and, if necessary, adjust such estimates. Although historically our estimates have generally
been reasonably accurate, due to the risks and uncertainties involved in our business and evolving market conditions, and given the subjective element of the
estimates made, actual results may differ from estimated results. This possibility may be greater than normal during times of pronounced economic volatility.
Global Product sales, net, and Impax Product sales, net. Revenue from the sale of products is recognized when title and risk of loss of the product is
transferred to the customer and the sales price is fixed and determinable. Provisions for discounts, early payments, rebates, sales returns and distributor chargebacks
under terms customary in the industry are provided for in the same period the related sales are recorded. We record estimated reductions to revenue at the time of the
initial sale and these estimates are based on the sales terms, historical experience and trend analysis.
Gross to Net Sales Accruals. We base our sales returns allowance on estimated on-hand inventories at our customers, measured end-customer demand as
reported by third-party sources, actual returns history and other factors, such as the trend experience for lots where product is still being returned or inventory
centralization and rationalization initiatives conducted by major pharmacy chains, as applicable. If the historical data we use to calculate these estimates do not
properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be
materially affected. Under this methodology, we track actual returns by individual production lots. Returns on closed lots, that is, lots no longer eligible for return
credits, are analyzed to determine historical returns experience. Returns on open lots, that is, lots still eligible for return credits, are monitored and compared with
historical return trend rates. Any changes from the historical trend rates are considered in determining the current sales return allowance.
Sales discount accruals are based on payment terms extended to customers.
Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental
programs. U.S. Medicaid rebate accruals are generally based on historical payment data and estimates of future Medicaid beneficiary utilization applied to the
Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicaid rebate percentage was increased and extended to Medicaid
Managed Care Organizations in March 2010. The accrual of the rebates associated with Medicaid Managed Care Organizations is calculated based on actual billings
received from the states. We adjust the rebate accruals as more information becomes available and to reflect actual claims experience. Effective January 1, 2011,
manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In
order to estimate the cost to us of this coverage gap responsibility, we analyze the historical invoices. This expense is recognized throughout the year as costs are
incurred.
Rebates or administrative fees are offered to certain customers, group purchasing organizations and pharmacy benefit managers, consistent with
pharmaceutical industry practices. Settlement of rebates and fees may generally occur from one to 15 months from the date of sale. We provide a provision for rebates
at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of customer inventories,
contract sales mix and average contract pricing. We regularly review the information related to these estimates and adjust the provision accordingly.
55
Chargeback accruals are based on the differentials between product acquisition prices paid by wholesalers and lower contract pricing paid by eligible
customers.
Distributor service fee accruals are based on contractual fees to be paid to the wholesale distributor for services provided. TRICARE is a health care program
of the U.S. Department of Defense Military Health System that provides civilian health benefits for military personnel, military retirees and their dependents. TRICARE
rebate accruals are included in chargeback accruals and are based on estimated Department of Defense eligible sales multiplied by the TRICARE rebate formula.
A significant majority of our gross to net accruals are the result of chargebacks and rebates, with the majority of those programs having an accrual to payment
cycle of approximately three months. In addition to this relatively short accrual to payment cycle, we receive monthly information from the wholesalers regarding their
sales of our products and actual on hand inventory levels of our products. The three large wholesalers account for approximately 97% of our chargebacks and
approximately 80% of our indirect sales rebates. This enables us to execute accurate provisioning procedures. Consistent with the pharmaceutical industry, the accrual
to payment cycle for returns is longer and can take several years depending on the expiration of the related products. However, returns represent the smallest gross to
net adjustment. We have not experienced any significant changes in our estimates as it relates to our chargebacks, rebates or returns in each of the years in the three
year period ended December 31, 2014.
The following tables are roll-forwards of the activity in the reserves for the years ended December 31, 2014, 2013 and 2012 with an explanation for any
significant changes in the accrual percentages:
Chargeback reserve
Beginning balance
Provision recorded during the period
Credits issued during the period
Ending balance
2014
As of December 31,
2013
($ in 000s)
2012
$
$
$
37,066
487,377
(481,318)
$
43,125
$
18,410
389,707
(371,051)
$
37,066
22,161
209,452
(213,203)
18,410
Provision as a percent of gross product sales
35%
34%
22%
The aggregate provision for chargebacks, as a percent of gross product sales, increased to 35% in 2014 from 34% in 2013 primarily as a result of an increase in
the estimated provision for chargebacks related to our authorized generic Trilipix® and branded Zomig® products during the year ended December 31, 2014 due to
price erosion resulting from increased competition, partially offset by lower chargeback rates on our authorized generic Renvela® tablets and generic Solaraze®, both
launched during 2014.
The aggregate provision for chargebacks, as a percent of gross product sales, increased to 34% in 2013 from 22% in 2012 primarily as a result of an increase in
the estimated provision for chargebacks related to our authorized generic Adderall XR® products during the year ended December 31, 2013 due to price erosion
resulting from increased competition. In June 2012, an unrelated pharmaceutical company received FDA approval for a competitor product to our authorized generic
Adderall XR® products and began marketing their product. See “Results of Operations” below for additional discussion on the impact of our authorized generic of
Adderall XR® product sales on our financial condition.
56
Rebate reserve
Beginning balance
Provision recorded during the period
Credits issued during the period
Ending balance
2014
As of December 31,
2013
($ in 000s)
2012
$
$
$
88,449
260,747
(260,384)
$
88,812
$
46,011
193,288
(150,850)
$
88,449
29,164
111,099
(94,252)
46,011
Provision as a percent of gross product sales
19%
17%
12%
As noted in the table above, the provision for rebates, as a percent of gross product sales, increased from 17% during the year ended December 31, 2013 to
19% during the year ended December 31, 2014 as a result of product sales mix, as well as the impact of additional rebates resulting from the recent formation of new
alliances between major wholesalers and major retailers.
The increase in the provision for rebates as a percent of gross product sales from 2012 to 2013 was principally the result of product sales mix, as well as higher
levels of rebates offered on our authorized generic Adderall XR® products.
Returns reserve
Beginning balance
Provision recorded during the period
Credits issued during the period
Ending balance
2014
As of December 31,
2013
($ in 000s)
2012
$
$
$
28,089
12,016
(12,931)
$
27,174
$
23,440
11,015
(6,366)
$
28,089
24,101
3,003
(3,664)
23,440
Provision as a percent of gross product sales
1.0%
1.0%
0.3%
The provision for returns as a percent of gross product sales remained at 1.0% in 2014 compared to 2013.
The provision for returns as a percent of gross product sales increased to 1.0% in 2013 as compared to 0.3% in 2012. The primary factor driving the 2013 rate
was due to a shifting sales mix within both the generic and brand product divisions.
57
Rx Partner and OTC Partner. Each of our Rx Partner and OTC Partner agreements contain multiple deliverables in the form of products, services and/or
licenses over extended periods. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification
(“ASC”) Topic 605-25 supplemented SAB 104
and provides guidance for accounting for such multiple-element revenue arrangements. With respect to our multiple-element revenue arrangements that are material to
our financial results, we determine whether any or all of the elements of the arrangement should be separated into individual units of accounting under FASB ASC
Topic 605-25. If separation into individual units of accounting is appropriate, we recognize revenue for each deliverable when the revenue recognition criteria specified
by SAB 104 are achieved for the deliverable. If separation is not appropriate, we recognize revenue and related direct manufacturing costs over the estimated life of the
agreement or our estimated expected period of performance using either the straight-line method or a modified proportional performance method.
T M
The Rx Partners and OTC Partners agreements obligate us to deliver multiple goods and/or services over extended periods. Such deliverables include
manufactured pharmaceutical products, exclusive and semi-exclusive marketing rights, distribution licenses, and research and development services. In exchange for
these deliverables, we receive payments from our agreement partners for product shipments and research and development services, and may also receive other
payments including royalty, profit sharing, upfront payments, and periodic milestone payments. Revenue received from our partners for product shipments under
these agreements is generally not subject to deductions for chargebacks, rebates, product returns, and other pricing adjustments. Royalty and profit sharing amounts
we receive under these agreements are calculated by the respective agreement partner, with such royalty and profit share amounts generally based upon estimates of
net product sales or gross profit which include estimates of deductions for chargebacks, rebates, product returns, and other adjustments the alliance agreement
partners may negotiate with their customers. We record the agreement partner's adjustments to such estimated amounts in the period the agreement partner reports the
amounts to us.
We apply the updated guidance of ASC 605-25, “Multiple Element Arrangements”, to the Strategic Alliance Agreement with Teva Pharmaceuticals Curacao
N.V., a subsidiary of Teva Pharmaceutical Industries Ltd. (“Teva Agreement”). We look to the underlying delivery of goods and/or services which give rise to the
payment of consideration under the Teva Agreement to determine the appropriate revenue recognition. Consideration received as a result of research and
development-related activities performed under the Teva Agreement is initially deferred and recorded as a liability captioned “Deferred revenue”. We recognize the
deferred revenue on a straight-line basis over our expected period of performance for such services. Consideration received as a result of the manufacture and delivery
of products under the Teva Agreement is recognized at the time title and risk of loss passes to the customer which is generally when the product is received by Teva.
We recognize profit share revenue in the period earned.
OTC Partner revenue is related to our alliance and collaboration agreement with Pfizer, Inc., formerly Wyeth LLC (“Pfizer”) and our supply agreement with L.
Perrigo Company (“Perrigo”) with respect to the supply of over-the-counter pharmaceutical products. The OTC Partner sales channel is no longer a core area of our
business, and the over-the-counter pharmaceutical products we sell through this sales channel are older products which are only sold to Pfizer and Perrigo. We are
currently only required to manufacture the over-the-counter pharmaceutical products under our agreements with Pfizer and Perrigo. We recognize profit share revenue
in the period earned.
Research Partner. We have entered into development agreements with unrelated third-party pharmaceutical companies under which we are collaborating in
the development of five dermatological products, including four generic products and one branded dermatological product, and one branded CNS product. Under each
of the development agreements, we received an upfront fee with the potential to receive additional milestone payments upon completion of contractually specified
clinical and regulatory milestones. Additionally, we may also receive royalty payments from the sale, if any, of a successfully developed and commercialized branded
product under one of the development agreements. We defer and recognize revenue received from the achievement of contingent research and development
milestones in the period such payment is earned. We will recognize royalty fee income, if any, as current period revenue when earned.
Promotional Partner. We entered into a promotional services agreement with an unrelated third-party pharmaceutical company under which we provided
physician detailing sales calls services to promote certain of the unrelated third-party company’s branded drug products. We received service fee revenue in exchange
for providing this service. We recognized revenue from the provision of physician detailing sales calls as such services were rendered. Our obligation to provide
physician detailing sales calls under the promotional services agreement ended on June 30, 2012.
58
Estimated Lives of Alliance and Collaboration Agreements. Because we may defer revenue we receive under our alliance agreements, and recognize it over
the estimated life of the related agreement, or our expected period of performance, we are required to estimate the recognition period under each such agreement in
order to determine the amount of revenue to be recognized in each period. Sometimes this estimate is based on the fixed term of the particular alliance agreement. In
other cases the estimate may be based on more subjective factors as noted in the following paragraphs. While changes to the estimated recognition periods have been
infrequent, such changes, should they occur, may have a significant impact on our consolidated financial statements.
As an illustration, the consideration received from the provision of research and development services under the Joint Development Agreement with Valeant
Pharmaceuticals International, Inc. (“Valeant Agreement”), including the upfront fee and milestone payments received before January 1, 2011, have been initially
deferred and are being recognized as revenue on a straight-line basis over our expected period of performance to provide research and development services under the
Valeant Agreement. The completion of the final deliverable under the Valeant Agreement represents the end of our estimated expected period of performance, as we will
have no further contractual obligation to perform research and development services under the Valeant Agreement, and therefore the earnings process will be
complete. The expected period of performance was initially estimated to be a 48 month period, starting in December 2008, upon receipt of the $40.0 million upfront
payment, and ending in November 2012. During the year ended December 31, 2012, we extended the end of the revenue recognition period for the Valeant Agreement
from November 2012 to November 2013 and during the three month period ended March 31, 2013, we further extended the end of the revenue recognition period for the
agreement from November 2013 to December 2014 due to changes in the estimated timing of completion of certain research and development activities under the
agreement. All deferred revenue under the Valeant Agreement was completely recognized as of December 31, 2014.
Third-Party Research Agreements. In addition to our own research and development resources, we may use unrelated third-party vendors, including
universities and independent research companies, to assist in our research and development activities. These vendors provide a range of research and development
services to us, including clinical and bio-equivalency studies. We generally sign agreements with these vendors which establish the terms of each study performed by
them, including, among other things, the technical specifications of the study, the payment schedule, and timing of work to be performed. Third-party researchers
generally earn payments either upon the achievement of a milestone, or on a pre-determined date, as specified in each study agreement. We account for third-party
research and development expenses as they are incurred according to the terms and conditions of the respective agreement for each study performed, with an accrued
expense at each balance sheet date for estimated fees and charges incurred by us, but not yet billed to us. We monitor aggregate actual payments and compare them to
the estimated provisions to assess the reasonableness of the accrued expense balance at each quarterly balance sheet date.
Share-Based Compensation. We recognize the grant date fair value of each option and restricted share over its vesting period. Options and restricted shares
granted under the 2002 Plan generally vest over a three or four year period and generally have a term of ten years. We estimate the fair value of each stock option
award on the grant date using the Black-Scholes-Merton option-pricing model, wherein expected volatility is based on historical volatility of our common stock. We
base the expected term calculation on the “simplified” method described in SAB No. 107, Share-Based Payment and SAB No. 110, Share-Based Payment, because it
provides a reasonable estimate in comparison to our actual experience. We base the risk-free interest rate on the U.S. Treasury yield in effect at the time of grant for an
instrument with a maturity that is commensurate with the expected term of the stock options. The dividend yield is zero as we have never paid cash dividends on our
common stock, and have no present intention to pay cash dividends. During the year ended December 31, 2014, we granted shares of restricted stock that will vest
upon the achievement of certain stock price performance criteria. We valued these awards using a Monte Carlo simulation.
Income Taxes. We are subject to U.S. federal, state and local income taxes, Netherlands income tax and Taiwan R.O.C. income taxes. We create a deferred tax
asset, or a deferred tax liability, when we have temporary differences between the financial statement carrying values (GAAP) and the tax bases of our assets and
liabilities.
59
Fair Value of Financial Instruments. Our cash and cash equivalents include a portfolio of high-quality credit securities, including U.S. Government
sponsored entity securities, treasury bills, corporate bonds, short-term commercial paper, and/or high rated money market funds. Our entire portfolio matures in less
than one year. The carrying value of the portfolio approximated the market value at December 31, 2014. We carry our deferred compensation liability at fair value, based
upon observable market values. We had no debt outstanding as of December 31, 2014. Our only remaining debt instrument at December 31, 2014 was our credit facility
with Wells Fargo Bank, N.A., which would be subject to variable interest rates and principal payments should we decide to borrow under it. The credit facility matured
in accordance with its terms on February 11, 2015.
Contingencies. In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business,
covering a wide range of matters, including, among others, patent litigation, stockholder lawsuits, and product and clinical trial liability. In accordance with FASB ASC
Topic 450 - Contingencies, we record accrued loss contingencies when it is probable a liability will be incurred and the amount of loss can be reasonably estimated and
we do not recognize gain contingencies until realized.
Goodwill. In accordance with FASB ASC Topic 350, "Goodwill and Other Intangibles", rather than recording periodic amortization of goodwill, goodwill is
subject to an annual assessment for impairment by applying a fair-value-based test. Under FASB ASC Topic 350, if the fair value of the reporting unit exceeds the
reporting unit’s carrying value, including goodwill, then goodwill is considered not impaired, making further analysis not required. We consider each of our Global
Division and Impax Division operating segments to be a reporting unit, as this is the lowest level for each of which discrete financial information is available. We
attribute the entire carrying amount of goodwill to the Global Division. We concluded the carrying value of goodwill was not impaired as of December 31, 2014 and
2013, as the fair value of the Global Division exceeded its carrying value at each date. We perform our annual goodwill impairment test in the fourth quarter of each
year. We estimate the fair value of the Global Division using a discounted cash flow model for both the reporting unit and the enterprise, as well as earnings and
revenue multiples per common share outstanding for enterprise fair value. In addition, on a quarterly basis, we perform a review of our business operations to
determine whether events or changes in circumstances have occurred that could have a material adverse effect on the estimated fair value of the reporting unit, and
thus indicate a potential impairment of the goodwill carrying value. If such events or changes in circumstances were deemed to have occurred, we would perform an
interim impairment analysis, which may include the preparation of a discounted cash flow model, or consultation with one or more valuation specialists, to analyze the
impact, if any, on our assessment of the reporting unit’s fair value. To date, we have not deemed there to be any significant adverse changes in the legal, regulatory or
business environment in which we conduct our operations.
60
Results of Operations
Year Ended December 31, 2014 Compared to Year Ended December 31, 2013
Overview:
The following table sets forth our summarized, consolidated results of operations for the years ended December 31, 2014 and 2013:
(in $000’s)
Total revenues
Gross profit
Income (loss) from operations
Income before income taxes
Provision for income taxes
Net income
nm - not meaningful
Year Ended
December 31,
2014
December 31,
2013
$
596,049 $
312,653
511,502 $
199,300
Increase/
(Decrease)
$
84,547
113,353
%
88,816
(6,387)
95,203
90,559
33,206
57,353 $
146,940
45,681
101,259 $
(56,381)
(12,475)
(43,906)
$
17%
57%
nm
(38)%
(27)%
(43)%
Consolidated total revenues for the year ended December 31, 2014 increased $84.5 million, or 17%, as compared to the year ended December 31, 2013. New
product launches increased revenues during the year ended December 31, 2014 by $84.4 million, or 17%, compared to the prior year period, primarily related to sales of
our authorized generic Renvela® tablets and generic Solaraze®. Decreased product volumes (excluding new product launches) decreased revenues during the year
ended December 31, 2014 by $20.3 million, or 4%, compared to the prior year period, while selling price and product mix increased revenues by $20.4 million, or 4%,
compared to the prior year period. Revenues from our Global Division increased $150.7 million during the year ended December 31, 2014, as compared to the prior year
period, driven primarily by sales of our authorized generic Renvela® tablets, in addition to higher sales of our Digoxin and generic Solaraze® products. Revenues from
our Impax Division decreased $66.2 million in 2014 as compared to 2013, as a result of a decline in sales of our Impax-labeled branded Zomig® products. In May 2013,
our exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and we launched authorized generic versions of those products in the
United States.
Net income for the year ended December 31, 2014 was $57.4 million, a decrease of $43.9 million as compared to $101.3 million for the year ended December 31,
2013. The decrease from the prior year period was primarily attributable to a $102.0 million gain in connection with the settlement of litigation with Endo which we
recorded as “Other Income” in the three month period ended March 31, 2013, as well as the receipt of a $48.0 million payment from Shire in the three month period
ended March 31, 2013, in connection with the settlement of litigation and for which there were no corresponding gains or payments during the year ended December
31, 2014 and which were both partially offset by the tax consequences of the settlements. Also contributing to the change in net income was an increase in Global
Product sales related to increased sales on several of our higher margin products, partially offset by a decline in sales of our Impax-labeled branded Zomig® products,
as discussed above.
61
Global Division
The following table sets forth results of operations for the Global Division for the years ended December 31, 2014 and 2013:
(in $000’s)
Revenues
Global Product sales, net
Rx Partner
Other Revenues
Total revenues
Cost of revenues
Gross profit
Operating expenses:
Research and development
Patent litigation
Selling, general and administrative
Total operating expenses
Income from operations
nm - not meaningful
Year Ended
December 31,
2014
December 31,
2013
Increase/
(Decrease)
$
%
$
$
528,512 $
14,114
6,456
549,082
260,459
288,623
40,927
5,333
17,144
63,404
225,219 $
383,652 $
11,639
3,049
398,340
253,836
144,504
41,384
16,545
17,684
75,613
68,891 $
144,860
2,475
3,407
150,742
6,623
144,119
(457)
(11,212)
(540)
(12,209)
156,328
38%
21%
nm
38%
3%
nm
(1)%
(68)%
(3)%
(16)%
nm
Revenues
Total revenues for the Global Division for the year ended December 31, 2014, were $549.1 million, an increase of 38% from the same period in 2013, resulting
from increases in Global Product sales, net, and Other Revenues, as discussed below.
Global Product sales, net, were $528.5 million for the year ended December 31, 2014, an increase of 38% from the same period in 2013, primarily as a result of
sales of our authorized generic Renvela® tablets launched during the three month period ended June 30, 2014 as well as higher sales of our Digoxin products, in
addition to the launch of our generic Solaraze® during the fourth quarter of 2013.
Rx Partner revenues were $14.1 million for 2014, an increase of 21% over the prior year period resulting primarily from $3.3 million profit share earned pursuant
to our agreement with Perrigo related to the launch of generic Astepro®.
Other Revenues were $6.5 million for the year ended December 31, 2014, with the increase from the prior year period primarily resulting from the receipt of a
milestone payment pursuant to our agreement with a third-party pharmaceutical company.
62
Cost of Revenues
Cost of revenues was $260.5 million for the year ended December 31, 2014 and $253.8 million for the prior year, an increase of $6.6 million compared to the prior
year period. Cost of revenues increased due to increased revenue as discussed above. Such increases were partially offset by $10.3 of higher intangible asset
impairment charges taken in the prior year, as discussed in “Note 8 – Goodwill and Intangible Assets” and $13.0 million more in inventory reserves related to
discontinued product and other reserves for pre-launch inventory taken during the year ended December 31, 2013.
Gross Profit
Gross profit for the year ended December 31, 2014 was $288.6 million, or approximately 53% of total revenues, as compared to $144.5 million, or approximately
36% of total revenues, in the prior year. Gross profit as a percent of total revenues increased in 2014 as compared to the prior year period largely due to favorable
product contribution from higher margin products, including Renvela®, as well as the other items noted above under Cost of Revenues.
Research and Development Expenses
Total research and development expenses for the year ended December 31, 2014 were $40.9 million, a decrease of 1%, as compared to the same period of the
prior year. Generic research and development expenses decreased in 2014 compared to the prior year period primarily due to lower external development spending of
$5.8 million and a decrease in professional fees of $0.5 million as well as an intangible impairment charge of $0.8 million in the period ended December 31, 2013, for
which there was no comparable charge in the current period. These decreases were partially offset by an overall increase of $4.6 million associated with internal
development spending and an increase in personnel costs of $2.0 million, which included $0.7 million of severance expense associated with the reduction in workforce
primarily related to our research and development organization during the fourth quarter ended December 31, 2014.
Patent Litigation
Patent litigation for the year ended December 31, 2014 was $5.3 million, a decrease of 68%, as compared to the same period of the prior year. The decrease in
patent litigation expenses in 2014 of $11.2 million compared to the prior year period was the result of legal activity related to several cases in the prior period for which
there was no corresponding activity in the present period.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the year ended December 31, 2014 were $17.1 million, a 3% decrease over the prior year period. The decrease
from the prior year period was primarily due to $2.9 million in lower customer claims relating to failure to supply products in accordance with their contractual terms.
This decrease was partially offset by an increase in personnel expense of $2.5 million primarily related to severance expenses associated with the reduction in
workforce during the fourth quarter ended December 31, 2014.
63
Impax Division
The following table sets forth results of operations for the Impax Division for the years ended December 31, 2014 and 2013:
(in $000’s)
Revenues
Impax Product sales, net
Other Revenues
Total revenue
Cost of revenues
Gross profit
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
nm - not meaningful
Year Ended
December 31,
2014
December 31,
2013
Increase/
(Decrease)
$
%
$
$
45,938 $
1,029
46,967
22,937
24,030
38,187
43,307
81,494
(57,464) $
111,900 $
1,262
113,162
58,366
54,796
27,470
44,915
72,385
(17,589) $
(65,962)
(233)
(66,195)
(35,429)
(30,766)
10,717
(1,608)
9,109
(39,875)
(59)%
(18)%
(58)%
(61)%
(56)%
39%
(4)%
13%
nm
Revenues
Total revenues were $47.0 million for the year ended December 31, 2014, a decrease of $66.2 million compared to the year ended December 31, 2013, due to
lower sales of our Impax-labeled branded Zomig® products which we began selling during the year ended December 31, 2012. In May 2013, our exclusivity period for
branded Zomig® tablets and orally disintegrating tablets expired and we launched authorized generic versions of those products in the United States. We continue to
sell the branded Zomig® nasal spray.
Other Revenues for the year ended December 31, 2014 were relatively consistent with Other Revenues for the prior year period, representing the recognition
of an initial $10.0 million upfront payment we received in June 2010 under a Development and Co-Promotion Agreement with Endo Pharmaceuticals, Inc. We are
currently recognizing this upfront payment as revenue on a straight-line basis over our expected period of performance during the development period, which we
currently estimate to be the 112 month period ending September 2019.
Cost of Revenues
Cost of revenues were $22.9 million for the year ended December 31, 2014, a decrease of $35.4 million over the prior year period, commensurate with a
reduction in revenues and lower amortization costs related to the loss of exclusivity on branded Zomig® tablets and orally disintegrating tablets in May 2013.
Gross Profit
Gross profit for the year ended December 31, 2014 was $24.0 million, a decrease of $30.8 million over the prior year period, commensurate with a reduction in
revenues and other costs noted above.
Research and Development Expenses
Total research and development expenses for the year ended December 31, 2014 were $38.2 million, an increase of 39%, as compared to $27.5 million in the
prior year period. The increase was primarily driven by an increase in research and development expenses related to our branded initiatives, a $2.0 million upfront fee
paid to DURECT Corporation (“Durect”) under an agreement to acquire the exclusive worldwide rights to develop and commercialize Durect’s investigational
transdermal bupivacaine patch for the treatment of pain associated with PHN, referred to as IPX239, and increased personnel costs of $2.0 million.
64
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $43.3 million in the year ended December 31, 2014, a decrease of $1.6 million as compared to $44.9 million in
the prior year period. The decrease was primarily driven by a $1.4 million reduction in advertising and promotion expenses for Zomig® due to loss of exclusivity of
branded Zomig® tablets and orally disintegrating tablets during 2013, a $1.0 million reduction in legal support of brand licensing initiatives and a $0.9 million reduction
in sales force expenses due to a reduction in workforce. These reductions were partially offset by a $1.1 million increase in advertising and promotion expenses for pre-
launch support for RYTARY™ and increased personnel costs of $0.5 million.
65
Corporate and other
The following table sets forth corporate general and administrative expenses, as well as other items of income and expense presented below income from
operations for the years ended December 31, 2014 and 2013:
(in $000’s)
General and administrative expenses
Total operating expenses
Loss from operations
Other income (expense), net
Interest income
Interest expense
Income (loss) before income taxes
Provision for income taxes
nm - not meaningful
Year Ended
December 31,
2014
December 31,
2013
Increase/
(Decrease)
$
%
$
$
78,939 $
78,939
(78,939)
313
1,473
43
(77,196)
33,206 $
57,689 $
57,689
(57,689)
152,447
1,299
419
95,638
45,681 $
21,250
21,250
(21,250)
(152,134)
174
(376)
(172,834)
(12,475)
37%
37%
(37)%
nm
13%
(90)%
nm
(27)%
General and Administrative Expenses
General and administrative expenses for the year ended December 31, 2014 were $78.9 million, a $21.3 million increase, as compared to $57.7 million in the prior
period. The increase was principally driven by increases in business development expenses of $10.2 million, information technology expenses of $3.8 million, legal
expenses of $3.6 million, and net other costs of $3.5 million.
Other Income (Expense), Net
Other income, net of $0.3 million in the year ended December 31, 2014, a decrease of $152.1 million from the prior year period, primarily due to a prior year
$102.0 million gain in connection with the settlement of litigation with Endo which we recorded as Other Income in the three month period ended March 31, 2013, as
well as a $48.0 million payment received from Shire in connection with the settlement of litigation in the three month period ended March 31, 2013, for which there were
no comparable charges during the current year period. In addition, we recorded a $3.0 million gain in connection with the settlement of litigation in Other Income during
the three month period ended June 30, 2013, for which there was no comparable charge during the current year period. Partially offsetting this income in the prior year
period was a $0.9 million loss on disposal of software in the three month period ended March 31, 2013.
Interest Income
Interest income in the year ended December 31, 2014 was $1.5 million, a slight increase from the same period in 2013.
Interest Expense
Interest expense in the year ended December 31, 2014 was less than $0.1 million, a decrease of $0.4 million from the same period in 2013, resulting from a
reduction in the interest related to our liability for uncertain tax positions.
Income Taxes
During the year ended December 31, 2014, we recorded an aggregate tax provision of $33.2 million for U.S. domestic income taxes and for foreign income taxes,
a decrease of $12.5 million compared to an aggregate tax provision of $45.7 million we recorded during the prior year period. The decrease in the tax provision during
2014 compared to the prior year period resulted from lower income before taxes in the year ended December 31, 2014 as compared to the prior year. The effective tax rate
increased to 36% for the year ended December 31, 2014 as compared to 31% for the year ended December 31, 2013. The 2013 effective tax rate was lower due to two
years of the federal tax benefit being recorded as a result of the legislation’s enactment date. In addition, the 2014 effective tax rate was affected by losses incurred in
certain zero rate jurisdictions, for which there were no corresponding costs in the prior year period.
66
Year Ended December 31, 2013 Compared to Year Ended December 31, 2012
Overview:
The following table sets forth our summarized, consolidated results of operations for the years ended December 31, 2013 and 2012:
(in $000’s)
Total revenues
Gross profit
(Loss) income from operations
Income before income taxes
Provision for income taxes
Net income
nm - not meaningful
Year Ended
December 31,
2013
December 31,
2012
Increase/
(Decrease)
$
%
$
511,502 $
199,300
581,692 $
282,554
(70,190)
(83,254)
(6,387)
82,992
(89,379)
146,940
45,681
101,259 $
83,311
27,438
55,873 $
63,629
18,243
45,386
$
(12)%
(29)%
nm
76%
66%
81%
Consolidated total revenues for 2013 decreased $70.2 million, or 12%, as compared to 2012. New product launches increased revenues during the year ended
December 31, 2013 by $97.1 million, or 17%, compared to the prior year period, primarily related to our January 2013 launch of Oxymorphone Hydrochloride Extended-
Release Tablets and our July 2013 launch of authorized generic Trilipix® delayed release capsules. Decreased product volumes (excluding new product launches)
decreased revenues during the year ended December 31, 2013 by $85.5 million, or 15%, compared to the prior year period, while selling price and product mix decreased
revenues by $81.8 million, or 14%, compared to the prior year period. Revenues from our Global Division decreased $50.3 million during the year ended December 31,
2013, as compared to the prior year period, driven primarily by lower sales of our authorized generic Adderall XR® and fenofibrate products, as discussed below.
Revenues from our Impax Division decreased $19.8 million in 2013 as compared to 2012, as a result of a decline in sales of our Impax-labeled branded Zomig® products.
In May 2013, our exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and we launched authorized generic versions of those
products in the United States.
Net income for the year ended December 31, 2013 was $101.3 million, an increase of $45.4 million as compared to $55.9 million for the year ended December 31,
2012. The increase from the prior year period was primarily attributable to a $102.0 million gain in connection with the settlement of litigation with Endo which we
recorded as Other Income in the three month period ended March 31, 2013, as well as the receipt of a $48.0 million payment from Shire in the three month period ended
March 31, 2013, in connection with the settlement of litigation.
67
Global Division
The following table sets forth results of operations for the Global Division for the years ended December 31, 2013 and 2012:
(in $000’s)
Revenues
Global Product sales, net
Rx Partner
Other Revenues
Total revenues
Cost of revenues
Gross profit
Operating expenses:
Research and development
Patent litigation
Selling, general and administrative
Total operating expenses
Income from operations
Year Ended
December 31,
December 31,
2013
2012
Increase/
(Decrease)
$
%
$
$
383,652 $
11,639
3,049
398,340
253,836
144,504
41,384
16,545
17,684
75,613
68,891 $
421,875 $
6,445
20,362
448,682
229,355
219,327
48,604
9,772
15,377
73,753
145,574 $
(38,223)
5,194
(17,313)
(50,342)
24,481
(74,823)
(7,220)
6,773
2,307
1,860
(76,683)
(9)%
81%
(85)%
(11)%
11%
(34)%
(15)%
69%
15%
3%
(53)%
Revenues
Total revenues for the Global Division for the year ended December 31, 2013, were $398.3 million, a decrease of 11% from 2012, resulting from decreases in
Global Product sales, net, and Other Revenues, as discussed below.
Global Product sales, net, were $383.7 million for the year ended December 31, 2013, a decrease of 9% from the same period in 2012, primarily as a result of
lower sales of our authorized generic Adderall XR® and our fenofibrate products. With respect to our authorized generic Adderall XR® products, we have experienced
significant declines in both market share and average net selling prices as a result of an unrelated pharmaceutical company receiving FDA approval in June 2012 for a
competitor product that was launched in the market. With respect to sales of our fenofibrate products, the entrance of a competitor in late 2012 to the fenofibrate
capsules market adversely impacted our 2013 results.
Rx Partner revenues were $11.6 million for 2013, an increase of 81% over the prior year period resulting primarily from higher profit share receipts earned under
the Teva Agreement. Rx Partner revenue also included a charge of $2.0 million in the year ended December 31, 2012 related to the voluntary market withdrawal of our
buproprion XL 300 mg products for which there was no similar charge in the current year.
Other Revenues were $3.0 million for the year ended December 31, 2013, with the decrease from the prior year period resulting from the recognition of $9.0
million of previously deferred revenue related to our product marketed under our OTC Partner alliance agreement with Pfizer during the year ended December 31, 2012,
for which there was no similar amount in the current year, as well as a $6.9 million decrease related to the extension of the revenue recognition period for the Valeant
Agreement which resulted from changes in the estimated timing of completion of certain research and development activities under the agreement.
68
Cost of Revenues
Cost of revenues was $253.8 million for the year ended December 31, 2013 and $229.4 million for the prior year, an increase of $24.5 million compared to the
prior year period. Cost of revenues increased primarily as a result of an intangible asset impairment charge of $13.2 million, as discussed in “Note 8 – Goodwill and
Intangible Assets,” in addition to an increase in remediation-related costs, manufacturing inefficiencies related to lower production activity, separation expenses and
inventory reserves for products discontinued by the Company and other reserves for pre-launch inventory due to delays caused by the warning letter related to our
Hayward, California manufacturing facility. These costs were partially offset by lower profit share expense related to sales of our authorized generic Adderall XR®
during the year ended December 31, 2013 compared to the prior year period.
Gross Profit
Gross profit for the year ended December 31, 2013 was $144.5 million, or approximately 36% of total revenues, as compared to $219.3 million, or approximately
49% of total revenues, in the prior year. Gross profit as a percent of total revenues decreased in 2013 as compared to the prior year period primarily as the result of the
intangible asset impairment charge noted above and an increase in expenses associated with new product launch delays caused by the warning letter related to our
Hayward, California manufacturing facility, including a $6.4 million charge related to pre-launch inventory for products which will no longer be marketed and $6.7
million of inventory reserves recorded in the three month period ended March 31, 2013 for products discontinued by us during the period. Partially offsetting these
reductions in gross profit margin was the benefit of lower profit share expenses related to sales of our authorized generic Adderall XR® during the year ended
December 31, 2013 compared to the prior year period.
Research and Development Expenses
Total research and development expenses for the year ended December 31, 2013 were $41.4 million, a decrease of 15%, as compared to the same period of the
prior year. Generic research and development expenses decreased in 2013 compared to the prior year period primarily due to the timing of completion of certain research
and development projects.
Patent Litigation
Patent litigation for the year ended December 31, 2013 was $16.5 million, an increase of 69%, as compared to the same period of the prior year. The increase in
patent litigation expenses in 2013 of $6.8 million compared to the prior year period was primarily the result of the receipt of $5.0 million in the prior year period for the
reimbursement of legal fees received pursuant to the settlement of patent litigation.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the year ended December 31, 2013 were $17.7 million, a 15% increase over the prior year period. The increase
resulted primarily from an increase in marketing expenses of $1.5 million, in addition to an increase in freight expenses of $0.8 million due to higher product unit volume
compared to the prior year period.
69
Impax Division
The following table sets forth results of operations for the Impax Division for the years ended December 31, 2013 and 2012:
(in $000’s)
Revenues
Impax Product sales, net
Other Revenues
Total revenue
Cost of revenues
Gross profit
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
nm - not meaningful
Year Ended
December 31,
2013
December 31,
2012
Increase/
(Decrease)
$
%
$
$
111,900 $
1,262
113,162
58,366
54,796
27,470
44,915
72,385
(17,589) $
118,115 $
14,895
133,010
69,783
63,227
32,716
37,896
70,612
(7,385) $
(6,215)
(13,633)
(19,848)
(11,417)
(8,41)
(5,246)
7,019
1,773
(10,204)
(5)%
(92)%
(15)%
(16)%
(13)%
(16)%
19%
3%
nm
Revenues
Total revenues were $113.2 million for the year ended December 31, 2013, a decrease of $19.8 million compared to 2012, due primarily to a decline in sales of our
Impax-labeled branded Zomig® products. Other Revenues for the year ended December 31, 2012 included $6.5 million in revenue for amortization of the $11.5 million
upfront payment received under our License, Development and Commercialization Agreement with GSK in December 2010, which we recognized as revenue on a
straight-line basis over the 24 month development period that ended in December 2012. In addition, our Co-Promotion Agreement with Pfizer ended on June 30, 2012,
resulting in the $7.1 million decrease in Promotional Partner revenue for the year ended December 31, 2013.
Cost of Revenues
Cost of revenues was $58.4 million for the year ended December 31, 2013, a decrease of $11.4 million over the prior year period primarily as a result of a
decrease of $10.6 million in costs during 2013 compared to the prior year period related to our Impax-labeled branded Zomig® products which we commenced selling
during 2012. In addition, cost of revenues for the year ended December 31, 2012 included $5.8 million in charges related to our branded products sales force, for which
there were no similar amounts included in cost of revenues in the current year period. Charges for our branded products sales force had been included as a component
of cost of revenues in the prior year period as the sales force was previously engaged in providing co-promotion services to Pfizer under an agreement which ended on
June 30, 2012. Partially offsetting these decreases was a $5.0 million reserve recorded in the three month period ended March 31, 2013 for pre-launch inventory related
to RYTARY™, as a result of the Complete Response Letter we received from the FDA during the year ended December 31, 2013.
Gross Profit
Gross profit for the year ended December 31, 2013 was $54.8 million, a decrease of $8.4 million over the prior year period primarily resulting from recognition of
other revenues and related charges in the year ended December 31, 2012 noted above.
Research and Development Expenses
Total research and development expenses for the year ended December 31, 2013 were $27.5 million, a decrease of 16%, as compared to $32.7 million in the prior
year period. The $5.2 million decrease for the year ended December 31, 2013 compared to the prior year period was principally driven by a reduction in research and
development expenses related to our branded product initiatives.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $44.9 million in the year ended December 31, 2013 as compared to $37.9 million in the prior year period.
Charges for our branded products sales force of $5.8 million had been included as a component of cost of revenues in the prior year period as the sales force was
previously engaged in providing co-promotion services to Pfizer under an agreement which ended on June 30, 2012. We also incurred $4.5 million in increased
compensation costs related to the expansion of the sales, marketing and administrative group and $1.8 million in increased expenses for administrative support. These
increases were partially offset by a $1.2 million and $3.1 million reduction, respectively, in advertising and promotion expenses for Zomig® (due to loss of our
exclusivity period for branded Zomig® tablets and orally disintegrating tablets during 2013) and pre-launch support for RYTARY™.
70
Corporate and other
The following table sets forth corporate general and administrative expenses, as well as other items of income and expense presented below Income from
operations for the years ended December 31, 2013 and 2012:
(in $000’s)
General and administrative expenses
Total operating expenses
Loss from operations
Other expense, net
Interest income
Interest expense
Income (loss) before income taxes
Provision for income taxes
nm - not meaningful
Year Ended
December 31,
2013
December 31,
2012
Increase/
(Decrease)
$
%
$
$
57,689 $
57,689
(57,689)
152,447
1,299
419
95,638
45,681 $
55,197 $
55,197
(55,197)
(138)
1,089
632
(54,878)
27,438 $
2,492
2,492
(2,492)
152,585
210
(213)
150,516
18,243
5%
5%
(5)%
nm
19%
(34)%
nm
66%
General and Administrative Expenses
General and administrative expenses for the year ended December 31, 2013 were $57.7 million, a $2.5 million increase over the prior period. The increase was
principally driven by higher executive severance of $3.1 million and an increase in personnel expenses of $2.5 million, in addition to an increase in information
technology resource expenses of $1.0 million compared to the prior year period, partially offset by a decrease in litigation expenses of $2.7 million and a decrease in
outside consulting expenses of $1.7 million compared to the prior year period.
Other Income (Expense), Net
Other income, net of $152.4 million in the year ended December 31, 2013, an increase of $152.6 million from the prior year period, primarily due to a $102.0
million gain in connection with the settlement of litigation with Endo which we recorded as Other Income in the three month period ended March 31, 2013, as well as a
$48.0 million payment received from Shire in connection with the settlement of litigation in the three month period ended March 31, 2013. In addition, we recorded a $3.0
million gain in connection with the settlement of litigation in Other Income during the three month period ended June 30, 2013. Partially offsetting this income was a
$0.9 million loss on disposal of software in the three month period ended March 31, 2013.
Interest Income
Interest income in the year ended December 31, 2013 was $1.3 million, a slight increase from the same period in 2012.
Interest Expense
Interest expense in the year ended December 31, 2013 was $0.4 million, a slight decrease from the same period in 2012.
Income Taxes
During the year ended December 31, 2013, we recorded an aggregate tax provision of $45.7 million for U.S. domestic income taxes and for foreign income taxes.
During the year ended December 31, 2012, we recorded an aggregate tax provision of $27.4 million for U.S. domestic income taxes and for foreign income taxes. The
increase in the tax provision during 2013 compared to the prior year period resulted from higher income before taxes in the year ended December 31, 2013 as compared
to the prior year. The effective tax rate decreased to 31% for the year ended December 31, 2013 as compared to 33% for the year ended December 31, 2012.
71
Liquidity and Capital Resources
We have historically funded our operations with the proceeds from the sale of debt and equity securities and with cash from operations. Currently, our
principal source of liquidity is cash from operations, consisting of the proceeds from the sales of our products and the provision of services, as well as payments
received in connection with legal settlements.
We expect to incur significant operating expenses, including research and development activities and patent litigation expenses, for the foreseeable future. In
addition, we are generally required to make cash expenditures to manufacture or acquire finished product inventory in advance of selling the finished product to our
customers and collecting payment, which may result in significant periodic uses of cash. We believe our existing cash and cash equivalents and short-term investment
balances, together with cash expected to be generated from operations will be sufficient to meet our financing requirements through the next 12 months. We may,
however, seek additional financing through alliance, collaboration, and/or licensing agreements, as well as from the debt and equity capital markets to fund capital
expenditures, research and development plans, potential acquisitions, and potential revenue shortfalls due to delays in new product introductions or otherwise. Please
refer to “Item 1. Financial Statements – Note 1. The Company” for details regarding our proposed acquisition of Tower Holdings, Inc. and Lineage Therapeutics, Inc.
Cash and Cash Equivalents
At December 31, 2014, we had $214.9 million in cash and cash equivalents, an increase of $30.3 million as compared to $184.6 million at December 31, 2013. As
more fully discussed below, the increase in cash and cash equivalents during the year ended December 31, 2014 was driven by $32.8 million of cash provided by
operating activities and $14.4 million of cash provided by financing activities, partially offset by net cash used in investing activities of $16.6 million.
Cash Flows
Year Ended December 31, 2014 Compared to Year Ended December 31, 2013.
Net cash provided by operating activities for the year ended December 31, 2014 was $32.8 million, a decrease of $117.1 million as compared to the prior year
$149.9 million net cash provided by operating activities. The period-over-period change in net cash provided by operating activities was driven by lower net income as
a result of the payments received in connection with various legal settlements in 2013 as well as an increased investment in working capital. The increased net
investment in working capital compared to the prior year was largely driven by accounts receivable and inventory. The 2014 increase in accounts receivable was
primarily due to increased sales in the fourth quarter of 2014 compared to the fourth quarter of 2013. The increase in accounts receivable in 2013 was due to timing of
cash collections as we experienced some delays in payments. The 2014 increase in inventory was incurred to support the 2015 launch of RYTARY™ as well as to
support commercial activities on certain backordered products.
Net cash used in investing activities for the year ended December 31, 2014 was $16.6 million as compared to $115.9 million for the prior year. The decrease in
cash used in investing activities was due primarily due to a year-over-year increase in cash provided by net maturities of short-term investments of $109.4 million. This
change was caused by the receipt of over $150 million in legal settlements in 2013 and our subsequent investment in short-term investments. Purchases of property,
plant and equipment for the year ended December 31, 2014 were $29.9 million as compared to $32.8 million for the prior year period, due to reduced spending on the
Taiwan manufacturing facility, which was partially offset by increased remediation related projects.
Net cash provided by financing activities for the year ended December 31, 2014 was $14.4 million, representing an increase of $5.4 million as compared to the
prior year $9.0 million of net cash provided by financing activities. The year-over-year increase in net cash provided by financing activities was due to a $2.9 million
increase in the cash proceeds received from the exercise of stock options and contributions to the employee stock purchase plan and a $2.6 million increase in tax
benefits related to the exercise of employee stock options.
72
Year Ended December 31, 2013 Compared to Year Ended December 31, 2012.
Net cash provided by operating activities for the year ended December 31, 2013 was $149.9 million, an increase of $44.1 million as compared to the prior year
$105.8 million net cash provided by operating activities. The period-over-period change in net cash provided by operating activities was driven by higher net income
as a result of the payments received in connection with various legal settlements in 2013 partially offset by lower business levels, higher remediation expenses and
charges for inventory reserves incurred in relation to the FDA warning letter regarding our Hayward facility. In addition, lower cash payments related to our profit
share arrangements were largely offset by an investment in working capital in 2013 versus a reduction of working capital in 2012. The net investment in working capital
compared to the prior year was largely driven by accounts receivable and inventory. The 2013 increase in accounts receivable was primarily due to lower cash
collections as we experienced some delays in payments. The 2012 decrease in accounts receivable was largely the result of lower sales in the last two months of the
year compared to 2011.
Net cash used in investing activities for the year ended December 31, 2013 was $115.9 million as compared to $85.8 million for the prior year. The increase in
cash used in investing activities was due to a year over year decrease in cash provided by net maturities of short-term investments of $157.0 million. This decrease was
partially offset by a decrease in licensing payments of $92.8 million, representing a decrease of $83.8 million of licensing payments to AstraZeneca under the AZ
Agreement, net of amounts received from AstraZeneca during the transition period, and a decrease of $9.0 million of licensing payments to Tolmar under the Tolmar
Agreement. Purchases of property, plant and equipment for the year ended December 31, 2013 were $32.8 million as compared to $66.9 million for the prior year period.
Net cash provided by financing activities for the year ended December 31, 2013 was $9.0 million, representing a decrease of $8.3 million as compared to the
prior year $17.3 million of net cash provided by financing activities. The year-over-year decrease in net cash provided by financing activities was due to a $4.4 million
decrease in the cash proceeds received from the exercise of stock options and contributions to the employee stock purchase plan and a $3.9 million decrease in tax
benefits related to the exercise of employee stock options.
73
Commitments and Contractual Obligations
Our contractual obligations as of December 31, 2014 were as follows:
($ in 000s)
Total
Less Than 1 Year
1-3 Years
3-5 Years
More Than 5
Years
Payments Due by Period
Contractual Obligations:
Open Purchase Order Commitments
Operating Leases(a)
Construction Contracts(b)
Total(c)
_____________________________
$
$
42,627 $
9,153
428
52,208 $
42,627 $
2,348
428
45,403 $
--- $
2,570
---
2,570 $
--- $
1,651
---
1,651 $
---
2,584
---
2,584
(a)
(b)
(c)
We lease office, warehouse, and laboratory facilities under non-cancelable operating leases through January 2020. We also lease certain equipment under
various non-cancelable operating leases with various expiration dates through August 2019.
Construction contracts are related to ongoing expansion activities at our manufacturing facility in Taiwan.
Liabilities for uncertain tax positions FASB ASC Topic 740, Sub-topic 10, were excluded as we are not able to make a reasonably reliable estimate of the
amount and period of related future payments. As of December 31, 2014, we had a $4.8 million provision for uncertain tax positions.
Off-Balance Sheet Arrangements
We did not have any off-balance sheet arrangements as of December 31, 2014.
74
Outstanding Debt Obligations
Senior Lenders; Wells Fargo Bank, N.A.
As of December 31, 2014, we had a Credit Agreement, as amended (the “Credit Agreement”) with Wells Fargo Bank, N.A., as a lender and as administrative
agent (the “Administrative Agent”). The Credit Agreement provided us with a revolving line of credit in the aggregate principal amount of up to $50,000,000 (the
“Revolving Credit Facility”). Under the Revolving Credit Facility, up to $10,000,000 is available for letters of credit, the outstanding face amounts of which reduced
availability under the Revolving Credit Facility on a dollar for dollar basis. Proceeds under the Credit Agreement could be used for working capital, general corporate
and other lawful purposes. The outstanding principal amount of all revolving credit loans, together with accrued and unpaid interest thereon, was due and payable on
the maturity date, which occurred on February 11, 2015. There were no balances outstanding under the Revolving Credit Facility as of December 31, 2014.
Our borrowings under the Credit Agreement were secured by substantially all of our personal property assets pursuant to a Security Agreement (the “Security
Agreement”) entered into by us and the Administrative Agent. As further security, we also pledged to the Administrative Agent, 65% of our equity interest in our
wholly owned subsidiary Impax Laboratories (Taiwan), Inc., all of our equity interests in our wholly owned domestic subsidiaries and must similarly pledge all or a
portion of our equity interest in future subsidiaries. During the years ended December 31, 2014, 2013 and 2012, unused line fees incurred under the Credit Agreement
were $124,000, $,139,000 and $95,000, respectively.
In connection with the Stock Purchase Agreement pursuant to which we will acquire Tower and Lineage, on January 2, 2015, we entered into a second
amended and restated commitment letter (the “Commitment Letter”), which amended and restated the commitment letter dated as of October 8, 2014, as first amended
and restated on October 22, 2014 with Barclays Bank plc (“Barclays”), Royal Bank of Canada (“Royal Bank”), Wells Fargo Bank, National Association (“Wells Fargo”)
and Wells Fargo Securities, LLC (“Wells Fargo Securities” and together with Barclays, Royal Bank and Wells Fargo, the “Lenders”) pursuant to which the Lenders
have severally but not jointly committed to provide a $50.0 million senior secured revolving credit facility and a $435.0 million senior secured term loan facility in an
aggregate principal amount of up to $485.0 million for purposes of financing the Transaction and the related fees and expenses. The obligations of the Lender to
provide debt financing under the Commitment Letter are subject to a number of customary conditions, including (i) absence of a Material Adverse Effect (as defined in
the Stock Purchase Agreement) that would result in a failure of a condition under the Stock Purchase Agreement; (ii) execution and delivery by the Company of
definitive documentation with respect to the debt financing consistent with the term sheet attached to the Commitment Letter; (iii) the accuracy of certain specified
representations and warranties in the debt documents; (iv) concurrent consummation of the Transaction in accordance with the Stock Purchase Agreement; (v)
delivery of certain customary closing documents (including, among others, a customary solvency certificate), specified items of collateral (where applicable) and
certain Tower and Lineage financial statements; and (vi) payment of applicable costs, fees and expenses. The final termination date of the Commitment Letter is March
30, 2015.
75
Recent Accounting Pronouncements
In March 2013, the FASB issued updated guidance on foreign currency matters. The update applies to the release of the cumulative translation adjustment
into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of
assets within a foreign entity. We adopted this guidance on January 1, 2014 and the adoption did not have a material effect on our consolidated financial statements.
In July 2013, the FASB issued updated guidance related to presentation of an unrecognized tax benefit. The guidance requires an entity to present an
unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) carryforward, or similar tax loss, or tax credit carryforward, rather than as a
liability under certain circumstances. We adopted this guidance on January 1, 2014 and the adoption did not have a material effect on our consolidated financial
statements.
In May 2014, the FASB issued updated guidance regarding the accounting for and disclosures of revenue recognition. The update provides a single
comprehensive model for accounting for revenue from contracts with customers. The model requires that revenue recognized reflect the actual consideration to which
the entity expects to be entitled in exchange for the goods or services defined in the contract, including in situations with multiple performance obligations. This
guidance will be the same for both U.S. GAAP and International Financial Reporting Standards (IFRS) and is effective for annual and interim periods beginning after
December 15, 2016. We are currently evaluating the effect that this guidance may have on our consolidated financial statements.
In July 2014, the IRS issued final regulations related to the branded pharmaceutical drug (“BPD”) annual fee under the Patient Protection and Affordable Care
Act and the Health Care and Education Affordability Reconciliation Act of 2010. The final regulations indicate that an entity’s obligation to pay its portion of the BPD
fee in any given calendar year is not triggered by the first qualifying sale in that calendar year but instead by the qualifying sales in the previous year. As a result,
during the three month period ended September 30, 2014, we recorded a charge of $0.7 million in connection with the implementation of this updated guidance.
76
Item 7A. Quantitative and Qualitative Disclosures about Market Risk
Our cash and cash equivalents, and short-term investments include a portfolio of high credit quality securities, including U.S. government securities, treasury
bills, short-term commercial paper, and highly-rated money market funds. Our entire portfolio matures in less than one year. The carrying value of the portfolio
approximates the market value at December 31, 2014.
Our portfolio is subject to interest rate risk. Based on the average duration of our investments as of December 31, 2014 and 2013, an increase of one
percentage point in interest rates would have resulted in increases in interest income of approximately $2.4 million and $2.0 million, respectively.
Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents, short-term investments and
accounts receivable. We limit our credit risk associated with cash and cash equivalents and short-term investments by placing investments with high credit quality
securities, including U.S. government securities, treasury bills, corporate debt, short-term commercial paper and highly-rated money market funds. We limit our credit
risk with respect to accounts receivable by performing credit evaluations when deemed necessary. We do not require collateral to secure amounts owed to us by our
customers.
We had no debt outstanding as of December 31, 2014. Our only remaining debt instrument at December 31, 2014 was the Wells Fargo revolving credit facility,
which would be subject to variable interest rates and principal payments should we decide to borrow against it. The credit facility matured in accordance with the terms
therein on February 11, 2015.
We do not use derivative financial instruments and have no material foreign currency exchange exposure, or commodity price risks. See “Item 15. Exhibits and
Financial Statement Schedules – Note 17. Segment Information” for more information regarding the value of our investment in Impax Laboratories (Taiwan), Inc.
77
Item 8.
Financial Statements and Supplementary Data
The consolidated financial statements and schedule listed in the Index to Financial Statements beginning on page F-1 are filed as part of this Annual Report
on Form 10-K and incorporated by reference herein.
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
78
Item 9A. Controls and Procedures
Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to ensure information required to be
disclosed by the Company in reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in
the SEC’s rules and forms, and such information is accumulated and communicated to the Company’s management, including its principal executive officer and
principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the
Company’s disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based upon this evaluation, the Company’s
Chief Executive Officer and Chief Financial Officer concluded the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act,
were effective at the reasonable assurance level as of December 31, 2014.
Management Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f), to
provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles used in the United States (GAAP). Internal control over financial reporting includes those policies and procedures which (i)
pertain to the maintenance of records, in reasonable detail, to accurately and fairly record the transactions and dispositions of our assets; (ii) provide reasonable
assurance transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and our receipts and expenditures are being
made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of our assets which could have a material effect on the financial statements. Internal control over financial reporting
includes the controls themselves, monitoring of those controls, internal audit practices, and actions taken to correct deficiencies as identified. Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of internal control over financial reporting
effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.
Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2014, the end of our fiscal year, and has reviewed
the results of this assessment with the Audit Committee of our Board of Directors. Management based its assessment on criteria established in Internal Control-
Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management’s assessment included evaluation of
such elements as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control
environment. Based on the assessment, management has concluded our internal control over financial reporting was effective as of the end of the fiscal year to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance
with GAAP. The effectiveness of our internal control over financial reporting as of December 31, 2014, has been audited by KPMG LLP, an independent registered
public accounting firm, as stated in their report which is included immediately below.
79
The Board of Directors and Stockholders
Impax Laboratories, Inc.:
Report of Independent Registered Public Accounting Firm
We have audited Impax Laboratories, Inc.’s internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control
—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Impax Laboratories, Inc.’s management
is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting,
included in the accompanying Management Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal
control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and
evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we
considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial
reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions
and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with
authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.
In our opinion, Impax Laboratories, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2014, based
on criteria established in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets
of Impax Laboratories, Inc. and subsidiaries as of December 31, 2014 and 2013, and the related consolidated statements of operations, comprehensive income, changes
in stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2014, and our report dated February 26, 2015, expressed an
unqualified opinion on those consolidated financial statements.
/s/ KPMG LLP
Philadelphia, Pennsylvania
February 26, 2015
80
Changes in Internal Control over Financial Reporting
During the quarter ended December 31, 2014, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) of
the Exchange Act) which materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Item 9B. Other Information
None.
81
Item 10.
Code of Ethics
Directors, Executive Officers and Corporate Governance
PART III
We have adopted a Code of Business Conduct and Ethics (“Code of Ethics”) that applies to all of our directors and employees, including our Chief Executive
Officer, Chief Financial Officer and any other accounting officer, controller or persons performing similar functions. The Code of Ethics is available on our website
(www.impaxlabs.com) and accessible via the “Investor Relations” page. Any amendments to, or waivers of, the Code of Ethics will be disclosed on our website within
four business days following the date of such amendment or waiver.
Additional information required by this item is incorporated by reference to our definitive proxy statement for the Annual Meeting of Stockholders to be held
on May 13, 2015 (“Proxy Statement”).
Item 11.
Executive Compensation
The information required by this item is incorporated by reference to the Proxy Statement.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this item is incorporated by reference to the Proxy Statement, except information concerning the equity compensation plans table
which is set forth in “Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities” and which is
incorporated herein by reference.
Item 13.
Certain Relationships and Related Transactions, and Director Independence
The information required by this item is incorporated by reference to the Proxy Statement.
Item 14.
Principal Accounting Fees and Services
The information required by this item is incorporated by reference to the Proxy Statement.
82
Item 15.
Exhibits and Financial Statement Schedules
PART IV
(a)(1) Consolidated Financial Statements
The consolidated financial statements listed in the Index to Financial Statements beginning on page F-1 are filed as part of this Annual Report on Form 10-K.
(a)(2) Financial Statement Schedules
The financial statement schedule listed in the Index to Financial Statements on page F-1 is filed as part of this Annual Report on Form 10-K.
(a)(3) Exhibits
Exhibit No.
2.1
3.1.1
3.1.2
3.2
4.1
4.2
Description of Document
Stock Purchase Agreement, dated as of October 8, 2014, by and among the Company, Tower Holdings, Inc. (“Tower”), Lineage Therapeutics Inc.
(“Lineage”), Roundtable Healthcare Partners II, L.P., Roundtable Healthcare Investors II, L.P., the other stockholders of Tower and Lineage, the
holders of options to purchase shares of Tower common stock and options to purchase shares of Lineage common stock, the holders of warrants to
acquire shares of Tower common stock and warrants to acquire shares of Lineage common stock and, solely with respect to Section 8.3, Roundtable
Healthcare Management II, LLC.(1)
Restated Certificate of Incorporation of the Company dated as of August 30, 2004.(2)
Certificate of Designation of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of Delaware on January 21, 2009.(3)
Amended and Restated Bylaws of the Company, effective as of May 14, 2014.(4)
Specimen of Common Stock Certificate.(5)
Preferred Stock Rights Agreement, dated as of January 20, 2009, by and between the Company and StockTrans, Inc., as Rights Agent.(3)
10.1
Credit Agreement, dated as of February 11, 2011, by and among the Company, the Guarantors named therein, the Lenders named therein and Wells
Fargo Bank, National Association, as Administrative Agent.**(6)
10.1.1
Amendment dated as of March 19, 2012 to the Credit Agreement, dated as of February 11, 2011, by and among the Company, the Guarantors named
therein, the Lenders named therein and Wells Fargo Bank, National Association as Administrative Agent.(7)
10.1.2
10.1.3
10.2
Second Amendment to Credit Agreement, dated as of January 10, 2013, to the Credit Agreement, dated as of February 11, 2011, as amended, by and
among the Company, the Guarantors named therein, the Lenders named therein and Wells Fargo Bank, National Association, as Administrative Agent.
(8)
Third Amendment to Credit Agreement, dated as of February 20, 2014, to the Credit Agreement, dated as of February 11, 2011, as amended, by and
among the Company, the Guarantors named therein, the Lenders named therein and Wells Fargo Bank, National Association, as Administrative Agent.
(9)
Security Agreement, dated as of February 11, 2011, by and among the Company, the Guarantors named therein, the Lenders named therein and Wells
Fargo Bank, National Association, as Administrative Agent.(6)
10.3.1
Impax Laboratories, Inc. 1999 Equity Incentive Plan.*(10)
83
10.3.2
10.4
10.5.1
10.5.2
10.5.3
Form of Stock Option Grant under the Impax Laboratories, Inc. 1999 Equity Incentive Plan.*(10)
Impax Laboratories, Inc. 2001 Non-Qualified Employee Stock Purchase Plan.*(5)
Impax Laboratories, Inc. Second Amended and Restated 2002 Equity Incentive Plan.*(11)
Form of Stock Option Agreement under the Impax Laboratories, Inc. Second Amended and Restated 2002 Equity Incentive Plan.*(12)
Form of Restricted Stock (Stock Bonus) Agreement under the Impax Laboratories, Inc. Second Amended and Restated 2002 Equity Incentive Plan.*
(12)
10.6.1
Impax Laboratories, Inc. Executive Non-Qualified Deferred Compensation Plan, amended and restated effective January 1, 2008.*(13)
10.6.2
Amendment to Impax Laboratories, Inc. Executive Non-Qualified Deferred Compensation Plan, effective as of January 1, 2009.* (13)
10.7.1
Employment Agreement, dated as of January 1, 2010, between the Company and Larry Hsu, Ph.D.*(14)
10.7.2
Separation Agreement, dated as of June 24, 2013, between the Company and Larry Hsu, Ph.D.*(15)
10.7.3
Amendment, dated as of February 26, 2014, to the Separation Agreement by and between the Company and Larry Hsu, Ph.D., dated as of June 24,
2013.*(16)
10.8.1
Employment Agreement, dated as of January 1, 2010, between the Company and Charles V. Hildenbrand.*(14)
10.8.2
Confidential Separation and Release Agreement, dated as of July 5, 2011, between the Company and Charles V. Hildenbrand.*(17)
10.9.1
Employment Agreement, dated as of January 1, 2010, between the Company and Arthur A. Koch, Jr.*(14)
10.9.2
General Release and Waiver, effective as of July 17, 2012, between the Company and Arthur A. Koch, Jr.* (18)
10.10.1
Employment Agreement, dated as of January 1, 2010, between the Company and Michael J. Nestor.*(14)
10.10.2
Amendment, dated as of April 1, 2014, to the Employment Agreement, dated as of January 1, 2014, between the Company and Michael Nestor* (19)
10.11.1
Offer of Employment Letter, dated as of March 17, 2011, between the Company and Mark A. Schlossberg.*(20)
10.11.2
Employment Agreement, dated as of May 2, 2011, between the Company and Mark A. Schlossberg.*(20)
10.11.3
Amendment, dated as of April 1, 2014, to the Employment Agreement, dated as of May 2, 2011, between the Company and Mark A. Schlossberg* (19)
10.12.1
Offer of Employment Letter, dated as of August 18, 2011, between the Company and Carole Ben-Maimon, M.D.*(21)
84
10.12.2
Employment Agreement, dated as of November 7, 2011, between the Company and Carole Ben-Maimon, M.D.*(22)
10.12.3
Amendment dated, as of April 1, 2014, to the Employment Agreement, dated as of November 7, 2011, between the Company and Carole Ben-Maimon,
M.D.* (19)
10.12.4
Separation Agreement, dated as of October 22, 2014, between the Company and Carole Ben-Maimon, M.D.*
10.13.1
Employment Agreement, dated as of December 12, 2012, between the Company and Bryan M. Reasons.*(23)
10.13.2
Amendment, dated as of April 1, 2014, to the Employment Agreement, dated as of December 12, 2012 between the Company and Bryan M. Reasons*
(19)
10.14
Employment Agreement, dated as of April 21, 2014, by and between the Company and G. Frederick Wilkinson.*(24)
10.15.1
Employment Agreement, dated as of November 28, 2011, by and between the Company and Jeffrey Nornhold.*(25)
10.15.2
Amendment, dated as of April 1, 2014, to the Employment Agreement, dated as of November 28, 2011, by and between the Company and Jeffrey
Nornhold.*(25)
10.15.3
Letter Agreement, dated as of April 1, 2014, between the Company and Jeffrey Nornhold.*(25)
10.16
Amended and Restated License and Distribution Agreement, dated as of February 7, 2013, between the Company and Shire LLC.(26)**
10.17.1
10.17.2
10.17.3
Joint Development Agreement, dated as of November 26, 2008, between the Company and Medicis Pharmaceutical Corporation.**(6)
Settlement Agreement, dated as of January 21, 2011, between the Company and Medicis Pharmaceutical Corporation.**(27)
First Amendment, dated as of January 26, 2011, to the Joint Development Agreement, dated as of November 26, 2008, between the Company and
Medicis Pharmaceutical Corporation.(20)
10.18
Distribution, License, Development and Supply Agreement, dated as of January 31, 2012, between the Company and AstraZeneca UK Limited.**(28)
11.1
21.1
23.1
31.1
31.2
32.1
32.2
Statement re computation of per share earnings (incorporated by reference to Note 16 to the Notes to Consolidated Financial Statements in this
Annual Report on Form 10-K).
Subsidiaries of the registrant.
Consent of Independent Registered Public Accounting Firm.
Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
85
101
The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, formatted in XBRL (eXtensible
Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2014 and 2013, (ii) Consolidated Statements of Operations for each
of the three years in the period ended December 31, 2014, (iii) Consolidated Statements of Comprehensive Income for each of the three years in the
period ended December 31, 2014, (iv) Consolidated Statements of Changes in Stockholders’ Equity for each of the three years in the period ended
December 31, 2014, (v) Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2014 and (vi) Notes to
Consolidated Financial Statements for each of the three years in the period ended December 31, 2014.
* Management contract, compensatory plan or arrangement.
** Confidential treatment granted for certain portions of this exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), which portions are omitted and filed separately with the SEC.
(1) Incorporated by reference to the Company’s Current Report on Form 8-K filed on October 10, 2014.
(2) Incorporated by reference to Amendment No. 5 to the Company’s Registration Statement on Form 10 filed on December 23, 2008.
(3) Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 22, 2009.
(4) Incorporated by reference to the Company’s Current Report on Form 8-K filed on May 16, 2014.
(5) Incorporated by reference to the Company’s Registration Statement on Form 10 filed on October 10, 2008.
(6) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.
(7) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.
(8) Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 10, 2013.
(9) Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 25, 2014.
(10) Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008.
(11) Incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A filed on April 15, 2013.
(12) Incorporated by reference to the Company’s Registration Statement on Form S-8 (file No. 333-189360) filed on June 14, 2013.
(13) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.
(14) Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 14, 2010.
(15) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013.
(16) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
(17) Incorporated by reference to the Company’s Current Report on Form 8-K filed on July 11, 2011.
(18) Incorporated by reference to the Company’s Current Report on Form 8-K filed on July 18, 2012.
(19) Incorporated by reference to the Company’s Current Report on Form 8-K filed on April 2, 2014.
(20) Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.
(21) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.
(22) Incorporated by reference to the Company’s Current Report on Form 8-K filed on November 9, 2011.
(23) Incorporated by reference to the Company’s Current Report on Form 8-K filed on December 13, 2012.
(24) Incorporated by reference to the Company’s Current Report on Form 8-K filed on April 24, 2014.
(25) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014.
(26) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.
(27) Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
(28) Incorporated by reference to the Company’s Current Report on Form 8-K/A filed on April 2, 2012.
86
Impax Laboratories, Inc.
INDEX TO FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2014 and 2013
Consolidated Statements of Operations for each of the years in the three-year period ended December 31, 2014
Consolidated Statements of Comprehensive Income for each of the years in the three-year period ended December 31, 2014
Consolidated Statements of Changes in Stockholders’ Equity for each of the years in the three-year period ended December 31, 2014
Consolidated Statements of Cash Flows for each of the years in the three-year period ended December 31, 2014
Notes to Consolidated Financial Statements for each of the years in the three-year period ended December 31, 2014
Schedule II, Valuation and Qualifying Accounts
F-2
F-3
F-4
F-5
F-6
F-7
F-9
S-1
F-1
The Board of Directors and Stockholders
Impax Laboratories, Inc.
Report of Independent Registered Public Accounting Firm
We have audited the accompanying consolidated balance sheets of Impax Laboratories, Inc. and subsidiaries as of December 31, 2014 and 2013, and the
related consolidated statements of operations, comprehensive income, changes in stockholders’ equity, and cash flows for each of the years in the three-year period
ended December 31, 2014. In connection with our audits of the consolidated financial statements, we have also audited the related financial statement schedule. These
consolidated financial statements and the related financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an
opinion on these consolidated financial statements and financial statement schedule based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on
a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for
our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Impax Laboratories, Inc.
and subsidiaries as of December 31, 2014 and 2013, and the results of their operations and their cash flows for each of the years in the three-year period ended
December 31, 2014, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the related financial statement schedule, when considered in
relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Impax Laboratories, Inc.’s
internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control – Integrated Framework (1992) issued by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 26, 2015 expressed an unqualified opinion on the
effectiveness of the Company’s internal control over financial reporting.
/s/ KPMG LLP
Philadelphia, Pennsylvania
February 26, 2015
F-2
IMPAX LABORATORIES, INC.
CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share and per share data)
December 31,
2014
December 31,
2013
ASSETS
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable, net
Inventory, net
Deferred income taxes
Prepaid expenses and other current assets
Total current assets
Property, plant and equipment, net
Other assets
Deferred income taxes
Intangible assets, net
Goodwill
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Accrued profit sharing and royalty expenses
Deferred revenue
Total current liabilities
Deferred revenue
Other liabilities
Total liabilities
Commitments and contingencies (Notes 18 and 19)
Stockholders’ equity:
$
$
$
Preferred Stock, $0.01 par value, 2,000,000 shares authorized, no shares outstanding at December 31, 2014 and 2013
Common stock, $0.01 par value, 90,000,000 shares authorized and 71,470,802 and 69,927,609 shares issued at
December 31, 2014 and 2013, respectively
Additional paid-in capital
Treasury stock - 243,729 shares
Accumulated other comprehensive (loss) income
Retained earnings
Total stockholders’ equity
Total liabilities and stockholders’ equity
$
The accompanying notes are an integral part of these consolidated financial statements.
F-3
214,873 $
199,983
146,490
80,570
54,825
33,710
730,451
188,169
64,455
41,837
26,711
27,574
1,079,197 $
31,976 $
110,470
15,346
907
158,699
3,403
29,218
191,320
--
714
364,103
(2,157)
(6,009)
531,226
887,877
1,079,197 $
184,612
228,521
112,993
70,107
50,788
12,721
659,742
188,191
57,820
33,926
29,670
27,574
996,923
26,824
111,523
11,560
3,983
153,890
4,267
28,563
186,720
--
699
336,648
(2,157)
1,140
473,873
810,203
996,923
IMPAX LABORATORIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
2014
Years Ended December 31,
2013
2012
$
$
$
$
549,082 $
46,967
596,049
283,396
312,653
79,114
5,333
139,390
223,837
88,816
313
1,473
(43)
90,559
33,206
57,353 $
0.84 $
0.81 $
398,340 $
113,162
511,502
312,202
199,300
68,854
16,545
120,288
205,687
(6,387)
152,447
1,299
(419)
146,940
45,681
101,259 $
1.51 $
1.47 $
448,682
133,010
581,692
299,138
282,554
81,320
9,772
108,470
199,562
82,992
(138)
1,089
(632)
83,311
27,438
55,873
0.85
0.82
Revenues:
Global Division revenues, net
Impax Division revenues, net
Total revenues
Cost of revenues
Gross profit
Operating expenses:
Research and development
Patent litigation
Selling, general and administrative
Total operating expenses
Income (loss) from operations
Other income (expense), net
Interest income
Interest expense
Income before income taxes
Provision for income taxes
Net income
Net Income per share:
Basic
Diluted
Weighted average common shares outstanding:
Basic
Diluted
68,185,552
70,530,349
66,921,181
68,655,038
65,660,271
68,404,551
The accompanying notes are an integral part of these consolidated financial statements.
F-4
IMPAX LABORATORIES, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(amounts in thousands)
Comprehensive Income
Net income
Currency translation adjustments
Comprehensive income
2014
Years Ended December 31,
2013
2012
$
$
57,353 $
(7,149)
50,204 $
101,259 $
(4,104)
97,155 $
55,873
3,520
59,393
The accompanying notes are an integral part of these consolidated financial statements.
F-5
IMPAX LABORATORIES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED DECEMBER 31, 2014
(amounts in thousands)
Stockholders’ Equity
Balance at December 31, 2011
2012
Exercise of stock options, issuance of restricted
stock and sale of common stock under ESPP
Share-based compensation expense
Tax benefit related to exercise of stock options
and restricted stock
Currency translation adjustments
Net income
Balance at December 31, 2012
2013
Exercise of stock options, issuance of restricted
stock and sale of common stock under ESPP
Share-based compensation expense
Tax benefit related to exercise of stock options
and restricted stock
Currency translation adjustments
Net income
Balance at December 31, 2013
2014
Exercise of stock options, issuance of restricted
stock and sale of common stock under ESPP
Share-based compensation expense
Tax benefit related to exercise of stock options
and restricted stock
Currency translation adjustments
Net income
Balance at December 31, 2014
Common Stock
Shares
Par Value
Additional
Paid-In
Capital
Treasury
Stock
Accumulated
Other
Comprehensive
Income
(Loss)
Retained
Earnings
Total
66,504 $
667 $
285,966 $
(2,157) $
1,724 $
316,741 $
602,941
1,768
18
7,746
16,303
4,702
68,272
685
314,717
(2,157)
5,244
3,520
1,412
14
3,538
17,644
749
69,684
699
336,648
(2,157)
1,140
(4,104)
55,873
372,614
101,259
473,873
1,544
15
3,255
20,883
3,317
71,228 $
714 $
364,103 $
(2,157) $
(6,009) $
57,353
531,226 $
(7,149)
7,764
16,303
4,702
3,520
55,873
691,103
3,552
17,644
749
(4,104)
101,259
810,203
3,270
20,883
3,317
(7,149)
57,353
887,877
The accompanying notes are an integral part of these consolidated financial statements.
F-6
IMPAX LABORATORIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
2014
Years Ended December 31,
2013
2012
Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
$
57,353 $
101,259 $
55,873
Depreciation and amortization
Intangible asset impairment
Provision for inventory reserves
In-process research and development charge
Accretion of interest income on short-term investments
Deferred income taxes – net and uncertain tax positions
Tax benefit related to the exercise of employee stock options
Deferred revenue
Deferred product manufacturing costs
Recognition of deferred revenue
Amortization of deferred product manufacturing costs
Accrued profit sharing and royalty expense
Payments of profit sharing and royalty expense
Share-based compensation expense
Changes in certain assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other assets
Accounts payable and accrued expenses
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Purchase of short-term investments
Maturities of short-term investments
Purchases of property, plant and equipment
Payments for product licensing rights, net
Investment in cash surrender value of insurance
Net cash used in investing activities
Cash flows from financing activities:
Cash flows from financing activities:
Proceeds from exercise of stock options and ESPP
Tax benefit related to the exercise of employee stock options and restricted stock
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
$
34,026
2,876
7,964
2,000
(774)
(11,810)
(3,317)
--
--
(3,939)
--
52,208
(48,422)
20,883
(33,497)
(24,302)
(9,952)
(8,980)
500
32,817
(366,092)
395,404
(29,913)
(13,000)
(3,000)
(16,601)
11,097
3,317
14,414
(369)
30,261
184,612
214,873 $
36,006
13,906
12,476
--
(659)
(21,132)
(749)
--
--
(4,390)
--
61,118
(54,494)
17,644
(20,744)
7,095
(7,646)
4,698
5,552
149,940
(357,092)
285,986
(32,785)
(12,000)
--
(115,891)
8,213
749
8,962
(561)
42,450
142,162
184,612 $
77,934
--
(372)
1,550
(639)
(23,561)
(4,702)
2,278
(2,823)
(29,099)
11,669
72,106
(107,935)
16,303
61,524
(33,692)
(22,301)
28,462
3,254
105,829
(210,688)
296,566
(66,900)
(104,760)
--
(85,782)
12,614
4,702
17,316
380
37,743
104,419
142,162
The accompanying notes are an integral part of these consolidated financial statements.
F-7
Supplemental disclosure of non-cash investing and financing activities:
(in $000s)
Cash paid for interest
Cash paid for income taxes, net
2014
Years Ended December 31,
2013
2012
$
$
17 $
72,174 $
89 $
34,272 $
546
55,356
Unpaid vendor invoices of approximately $1,932,000, $6,210,000 and $10,017,000 which were accrued as of December 31, 2014, 2013 and 2012, respectively, are
excluded from the purchase of property, plant, and equipment and the change in accounts payable and accrued expenses.
The accompanying notes are an integral part of these consolidated financial statements.
F-8
IMPAX LABORATORIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2014, 2013, 2012
1. THE COMPANY
Impax Laboratories, Inc. (“Impax” or “Company”) is a technology-based, specialty pharmaceutical company. The Company has two reportable segments,
referred to as the Global Pharmaceuticals Division (“Global Division”) and the Impax Pharmaceuticals Division (“Impax Division”).
The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products primarily through four sales channels: the “Global
products” sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the “Private
Label” sales channel, for generic pharmaceutical over-the-counter (“OTC”) and prescription products the Company sells to unrelated third-party customers who in-
turn sell the product under their own label; the “Rx Partner” sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities
under their own label pursuant to alliance and collaboration agreements; and the “OTC Partner” sales channel, for generic pharmaceutical OTC products sold through
unrelated third-party pharmaceutical entities under their own label pursuant to alliance, collaboration and supply agreements. Revenues from the “Global Products”
sales channel and the “Private Label” sales channel are reported under the caption “Global Product sales, net” in “Note 20 - Supplementary Financial Information.” The
Company also generates revenue from research and development services provided under a joint development agreement with an unrelated third party pharmaceutical
company, and reports such revenue under the caption “Other Revenues” in “Note 20 - Supplementary Financial Information.” The Company provides these services
through the research and development group in the Global Division.
The Impax Division is engaged in the development of proprietary brand pharmaceutical products through improvements to already-approved pharmaceutical
products to address central nervous system (“CNS”) disorders. The Impax Division currently has one internally developed branded pharmaceutical product,
RYTARY™ (IPX066), an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and
parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the FDA on January 7, 2015. The Company
currently plans to fully launch its sales and marketing efforts for the product in early April 2015. The Impax Division is also currently engaged, through its specialty
direct sales force, in the product sales and promotion of Zomig® (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations pursuant to the terms of
a Distribution, License, Development and Supply Agreement (the “AZ Agreement”) with AstraZeneca UK Limited (“AstraZeneca”). The Impax Division has a number
of product candidates that are in varying stages of development. Additionally, the Company generates revenue in the Impax Division from research and development
services provided under a development and license agreement with another unrelated third-party pharmaceutical company.
In California, the Company utilizes a combination of owned and leased facilities mainly located in Hayward. The Company’s primary properties in California
consist of a leased office building used as the Company’s corporate headquarters, in addition to five properties it owns, including a research and development center
facility and a manufacturing facility. Additionally, the Company leases three facilities in Hayward, utilized for additional research and development, administrative
services, equipment storage and quality assurance support. In Pennsylvania, the Company owns a packaging, warehousing, and distribution center located in
Philadelphia and leases a facility in New Britain used for sales and marketing, finance, and administrative personnel, as well as used for additional warehouse space.
Outside the United States, in Taiwan, R.O.C., the Company owns a manufacturing facility and leases an office in the Netherlands.
CEO transition
On June 25, 2013, the Company announced that Dr. Larry Hsu planned to retire as President and Chief Executive Officer of Impax and on April 21, 2014, Dr.
Hsu retired from those positions at Impax. Dr. Hsu currently remains as a member of the Board of Directors. In connection with his retirement, Dr. Hsu entered into a
Separation Agreement with the Company dated June 24, 2013 (the “Separation Agreement”). Pursuant to the Separation Agreement, the Company provided Dr. Hsu
with certain termination benefits and payments. The Company recorded $5.0 million in costs associated with Dr. Hsu’s retirement in the three month period ended June
30, 2013, comprised of $2.7 million of separation pay and benefits and $2.3 million of accelerated expense related to Dr. Hsu’s outstanding stock options and restricted
stock. Refer to “Note 14 – Share-based Compensation” for more information on the acceleration of Dr. Hsu’s equity awards.
On April 21, 2014, the board of directors of the Company announced that it had appointed Fred Wilkinson as the Company’s new President and Chief
Executive Officer effective as of April 29, 2014. Mr. Wilkinson succeeds Larry Hsu, Ph.D. who retired from his positions as President and Chief Executive Officer of the
Company. In connection with Mr. Wilkinson’s appointment, Mr. Wilkinson and the Company entered into an Employment Agreement dated April 21, 2014 (the
“Employment Agreement”). The Company will provide certain compensation and benefits as set forth in the Employment Agreement.
F-9
Management changes
During the three month period ended March 31, 2014, the Company announced a management change. The Company’s then Senior Vice President, Global
Operations announced plans to retire and a Senior Vice President, Technical Operations was appointed. The Company’s then Senior Vice President, Global Operations
subsequently retired from the Company in July 2014. In conjunction with the transition, the Company recorded $0.9 million in separation charges and accelerated
share-based compensation expense in the six month period ended June 30, 2014.
On October 22, 2014, the Company announced that Carole S. Ben-Maimon, M.D., President of the Company’s Global Pharmaceuticals Division, informed the
Company of her decision to retire from her position effective November 3, 2014. In connection with her retirement, Dr. Ben-Maimon entered into a Separation
Agreement with the Company dated October 22, 2014 which provided Dr. Ben-Maimon with $1.9 million of certain termination benefits and payments that were
recorded during the fourth quarter of 2014.
Workforce reductions
On June 4, 2013, the Company committed to a reduction in the Company’s workforce, eliminating approximately 110 positions, with the majority of these
positions at the Company’s Hayward, California manufacturing facility. The reduction in workforce is part of the Company’s efforts to streamline its operations in
response to the need to reduce expenses and adapt to changing market conditions. The Company recorded an accrual for severance and related termination costs of
$3.0 million in the three month period ended June 30, 2013 as a result of this workforce reduction. As of December 31, 2013, all accrued severance and related
termination costs had been paid.
On October 30, 2014, the Company committed to a reduction in the Company’s workforce, eliminating approximately 41 positions, including 35 positions in the
Company’s research and development (“R&D”) organization. The reduction in workforce is part of the Company’s reorganization of its R&D organizations by
consolidating the product development and analytical functions of the generic and brand R&D organizations. The workforce reduction resulted in charges of $2.1
million for severance and related termination costs, of which $1.8 million was paid during the quarter ended December 31, 2014. The Company expects the remaining
balance to be paid during the first quarter of 2015.
Acquisition of Tower Holdings, Inc. and Lineage Therapeutics Inc.
On October 8, 2014, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) pursuant to which the Company will acquire
all the outstanding shares of common stock of Tower Holdings, Inc. (“Tower”), including its operating subsidiaries CorePharma, LLC and Amedra Pharmaceuticals
LLC, and of Lineage Therapeutics Inc. (“Lineage”), (the “Transaction”) for a purchase price of $700.0 million in cash, subject to customary adjustments for working
capital, net debt and transaction expenses. The closing of the Transaction is subject to the satisfaction or waiver of certain customary closing conditions, including
approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the accuracy of the representations and warranties, and performance of covenants. The
privately-held companies to be acquired in the Transaction specialize in the development, manufacture and commercialization of complex generic and branded
pharmaceutical products. Following the closing of the Transaction, which is expected to occur during the first quarter of 2015, Tower and Lineage will become wholly
owned subsidiaries of the Company. The Company expects to finance the Transaction from cash on hand and borrowings under a new credit facility, as discussed in
“Note 11 – Revolving Line of Credit.”
F-10
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) and the rules and
regulations of the U.S. Securities & Exchange Commission (“SEC”) requires the use of estimates and assumptions, based on complex judgments considered
reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant judgments are employed in estimates used
in determining values of tangible and intangible assets, legal contingencies, tax assets and tax liabilities, fair value of share-based compensation related to equity
incentive awards issued to employees and directors, and estimates used in applying the Company’s revenue recognition policy including those related to accrued
chargebacks, rebates, product returns, Medicare, Medicaid, and other government rebate programs, shelf-stock adjustments, and the timing and amount of deferred
and recognized revenue and deferred and amortized product manufacturing costs related to alliance and collaboration agreements. Actual results may differ from
estimated results. Certain prior year amounts have been reclassified to conform to the presentation for the year ended December 31, 2014.
Principles of Consolidation
The consolidated financial statements of the Company include the accounts of the operating parent company, Impax Laboratories, Inc., its wholly owned
subsidiaries, including Impax Laboratories (Taiwan) Inc., and an equity investment in Prohealth Biotech, Inc. (“Prohealth”), in which the Company held a 57.54%
majority ownership interest at December 31, 2014. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents
The Company considers all short-term investments with maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash
equivalents are stated at cost, which, for cash equivalents, approximates fair value due to their short-term maturity. The Company is potentially subject to financial
instrument concentration of credit risk through its cash and cash equivalents. The Company maintains cash and cash equivalents with several major financial
institutions. Such amounts frequently exceed Federal Deposit Insurance Corporation (“FDIC”) limits.
Short-Term Investments
Short-term investments represent investments in fixed rate financial instruments with maturities of greater than three months but less than 12 months at the
time of purchase. The Company’s short-term investments are held in U.S. Treasury securities, corporate bonds, and high grade commercial paper, which are not insured
by the FDIC. They are stated at amortized cost, which approximates fair value due to their short-term maturity, generally based upon observable market values of
similar securities.
Fair Value of Financial Instruments
The Company’s deferred compensation liability is carried at the value of the amount owed to participants, and is derived from observable market data by
reference to hypothetical investments. The carrying values of other financial assets and liabilities such as accounts receivable, accounts payable and accrued
expenses approximate their fair values due to their short-term nature.
F-11
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Contingencies
In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, covering a
wide range of matters, including, among others, patent litigation, stockholder lawsuits, and product and clinical trial liability. In accordance with Financial Accounting
Standards Board (“FASB”) Accounting Standards Codification
(“ASC”) Topic 450, "Contingencies", the Company records accruals for such loss contingencies
when it is probable a liability will been incurred and the amount of loss can be reasonably estimated. The Company, in accordance with FASB ASC Topic 450, does not
recognize gain contingencies until realized. The Company records an accrual for legal costs in the period incurred. A discussion of contingencies is included in the
“Commitments and Contingencies,” and “Legal and Regulatory Matters” footnotes below.
T M
Allowance for Doubtful Accounts
The Company maintains allowances for doubtful accounts for estimated losses resulting from amounts deemed to be uncollectible from its customers; these
allowances are for specific amounts on certain accounts based on facts and circumstances determined on a case-by-case basis.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk are cash, cash equivalents, short-term investments, and accounts
receivable. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with high quality money
market funds, corporate debt, and short-term commercial paper and in securities backed by the U.S. Government. The Company limits its credit risk with respect to
accounts receivable by performing credit evaluations when deemed necessary. The Company does not require collateral to secure amounts owed to it by its customers.
The following tables present the percentage of total accounts receivable and gross revenues represented by the Company’s five largest customers as of and
for the years ended December 31, 2014, 2013 and 2012:
Percent of Total Accounts Receivable
2014
2013
2012
Customer #1
Customer #2
Customer #3
Customer #4
Customer #5
Customer #6
Customer #7
Customer #8
Total five largest customers
Percent of Gross Revenues
Customer #1
Customer #2
Customer #3
Customer #4
Customer #5
Customer #6
Customer #7
Total five largest customers
36.9%
28.2%
19.6%
1.8%
1.7%
--%
--%
--%
88.2%
28.8%
35.1%
18.5%
2.9%
--%
--%
--%
1.0%
86.3%
2014
2013
2012
36.0%
20.7%
19.3%
2.5%
1.9%
--%
--%
80.4%
30.6%
25.1%
20.3%
2.5%
--%
--%
2.4%
80.9%
23.3%
31.9%
18.4%
--%
--%
3.7%
3.1%
--%
80.4%
21.8%
25.2%
15.1%
--%
--%
9.2%
2.9%
74.2%
During the years ended December 31, 2014, 2013 and 2012, the Company’s top ten generic products accounted for 62%, 68% and 70%, respectively, of Global
Product sales, net. In the Impax Division, revenue from sales of branded Zomig® products pursuant to the AZ Agreement with AstraZeneca accounted for 100% of
the Company’s Impax Product sales, net. Refer to “Note 20 - Supplemental Financial Information” for more information.
F-12
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Inventory
Inventory is stated at the lower of cost or market. Cost is determined using a standard cost method, and the cost flow assumption is first in, first out (“FIFO”)
flow of goods. Standard costs are revised annually, and significant variances between actual costs and standard costs are apportioned to inventory and cost of goods
sold based upon inventory turnover. Costs include materials, labor, quality control, and production overhead. Inventory is adjusted for short-dated, unmarketable
inventory equal to the difference between the cost of inventory and the estimated value based upon assumptions about future demand and market conditions. If actual
market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Consistent with industry practice, the
Company may build pre-launch inventories of certain products which are pending required approval from the FDA and/or resolution of patent infringement litigation,
when, in the Company’s assessment, such action is appropriate to prepare for the anticipated commercial launch and FDA approval is expected in the near term and/or
the related litigation will be resolved in the Company’s favor. The Company accounts for all costs of idle facilities, excess freight and handling costs, and wasted
materials (spoilage) as a current period charge in accordance with GAAP.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are
capitalized. Costs incurred in connection with the construction or major renovation of facilities, including interest directly related to such projects, are capitalized as
construction in progress. Depreciation is recognized using the straight-line method based on the estimated useful lives of the related assets, which are generally 40
years for buildings, 10 to 15 years for building improvements, eight to 10 years for equipment, and four to 10 years for office furniture and equipment. Land and
construction-in-progress are not depreciated.
Goodwill
In accordance with FASB ASC Topic 350, "Goodwill and Other Intangibles", rather than recording periodic amortization, goodwill is subject to an annual
assessment for impairment by applying a fair value based test. Under FASB ASC Topic 350, if the fair value of the reporting unit exceeds the reporting unit’s carrying
value, including goodwill, then goodwill is considered not impaired, making further analysis not required. The Company considers the Global Division and the Impax
Division operating segments to each be a reporting unit. The Company attributes the entire carrying amount of goodwill to the Global Division.
The Company concluded the carrying value of goodwill was not impaired as of December 31, 2014 and 2013 as the fair value of the Global Division exceeded
its carrying value at each date. The Company performs its annual goodwill impairment test in the fourth quarter of each year. The Company estimated the fair value of
the Global Division using a discounted cash flow model for both the reporting unit and the enterprise. In addition, on a quarterly basis, the Company performs a review
of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair
value of the reporting unit, and thus indicate a potential impairment of the goodwill carrying value. If such events or changes in circumstances were deemed to have
occurred, the Company would perform an interim impairment analysis, which may include the preparation of a discounted cash flow model, or consultation with one or
more valuation specialists, to determine the impact, if any, on the Company’s assessment of the reporting unit’s fair value. The Company has not to date deemed there
to have been any significant adverse changes in the legal, regulatory, or general economic environment in which the Company conducts its business operations.
F-13
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Revenue Recognition
The Company recognizes revenue when the earnings process is complete, which under SEC Staff Accounting Bulletin No. 104, Topic No. 13, “Revenue
Recognition” (“SAB 104”), is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or
services has occurred, the sales price is fixed or determinable, and collectability is reasonably assured.
The Company accounts for material revenue arrangements which contain multiple deliverables in accordance with FASB ASC Topic 605-25, revenue
recognition for arrangements with multiple elements, which addresses the determination of whether an arrangement involving multiple deliverables contains more than
one unit of accounting. A delivered item within an arrangement is considered a separate unit of accounting only if both of the following criteria are met:
●
●
the delivered item has value to the customer on a stand-alone basis; and
if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable
and substantially in the control of the vendor.
Under FASB ASC Topic 605-25, if both of the criteria above are not met, then separate accounting for the individual deliverables is not appropriate. Revenue
recognition for arrangements with multiple deliverables constituting a single unit of accounting is recognized generally over the greater of the term of the arrangement
or the expected period of performance, either on a straight-line basis or on a modified proportional performance method.
The Company accounts for milestones related to research and development activities in accordance with FASB ASC Topic 605-28, milestone method of
revenue recognition. FASB ASC Topic 605-28 allows for the recognition of consideration, which is contingent on the achievement of a substantive milestone, in its
entirety in the period the milestone is achieved. A milestone is considered to be substantive if all of the following criteria are met: the milestone is commensurate with
either: (1) the performance required to achieve the milestone, or (2) the enhancement of the value of the delivered items resulting from the performance required to
achieve the milestone; the milestone relates solely to past performance; and, the milestone payment is reasonable relative to all of the deliverables and payment terms
within the agreement.
F-14
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Global Product sales, net, and Impax Product sales, net:
The Global Product sales, net and Impax Product sales, net include revenue recognized related to shipments of generic and branded pharmaceutical products
to the Company’s customers, primarily drug wholesalers and retail chains. Gross sales revenue is recognized at the time title and risk of loss passes to the customer,
which is generally when product is received by the customer. Global and Impax Product revenue, net may include deductions from the gross sales price related to
estimates for chargebacks, rebates, distribution service fees, returns, shelf-stock, and other pricing adjustments. The Company records an estimate for these
deductions in the same period when revenue is recognized. A summary of each of these deductions is as follows:
Chargebacks
The Company has agreements establishing contract prices for certain products with certain indirect customers, such as managed care organizations, hospitals
and government agencies who purchase products from drug wholesalers. The contract prices are lower than the prices the customer would otherwise pay to the
wholesaler, and the price difference is referred to as a chargeback, which generally takes the form of a credit memo issued by the Company to reduce the invoiced gross
selling price charged to the wholesaler. An estimated accrued provision for chargeback deductions is recognized at the time of product shipment. The primary factors
considered when estimating the provision for chargebacks are the average historical chargeback credits given, the mix of products shipped, and the amount of
inventory on hand at the major drug wholesalers with whom the Company does business. The Company also monitors actual chargebacks granted and compares them
to the estimated provision for chargebacks to assess the reasonableness of the chargeback reserve at each quarterly balance sheet date.
Rebates
The Company maintains various rebate programs with its customers in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. The rebates generally take the form of a credit memo to reduce the invoiced gross selling price charged to a customer for products shipped. An
estimated accrued provision for rebate deductions is recognized at the time of product shipment. The primary factors the Company considers when estimating the
provision for rebates are the average historical experience of aggregate credits issued, the mix of products shipped and the historical relationship of rebates as a
percentage of total gross product sales, the contract terms and conditions of the various rebate programs in effect at the time of shipment, and the amount of inventory
on hand at the major drug wholesalers with whom the Company does business. The Company also monitors actual rebates granted and compares them to the
estimated provision for rebates to assess the reasonableness of the rebate reserve at each quarterly balance sheet date.
Distribution Service Fees
The Company pays distribution service fees to several of its wholesaler customers related to sales of its Impax Products. The wholesalers are generally
obligated to provide the Company with periodic outbound sales information as well as inventory levels of the Company’s Impax Products held in their warehouses.
Additionally, the wholesalers have agreed to manage the variability of their purchases and inventory levels within specified days on hand limits. An accrued provision
for distribution service fees is recognized at the time products are shipped to wholesalers.
Returns
The Company allows its customers to return product if approved by authorized personnel in writing or by telephone with the lot number and expiration date
accompanying any request and if such products are returned within six months prior to or until twelve months following, the products’ expiration date. The Company
estimates and recognizes an accrued provision for product returns as a percentage of gross sales based upon historical experience. The product return reserve is
estimated using a historical lag period, which is the time between when the product is sold and when it is ultimately returned, and estimated return rates which may be
adjusted based on various assumptions including changes to internal policies and procedures, changes in business practices, and commercial terms with customers,
competitive position of each product, amount of inventory in the wholesaler supply chain, the introduction of new products, and changes in market sales information.
The Company also considers other factors, including significant market changes which may impact future expected returns, and actual product returns. The Company
monitors actual returns on a quarterly basis and may record specific provisions for returns it believes are not covered by historical percentages.
F-15
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Shelf-Stock Adjustments
Based upon competitive market conditions, the Company may reduce the selling price of certain Global Division products. The Company may issue a credit
against the sales amount to a customer based upon their remaining inventory of the product in question, provided the customer agrees to continue to make future
purchases of product from the Company. This type of customer credit is referred to as a shelf-stock adjustment, which is the difference between the sales price and the
revised lower sales price, multiplied by an estimate of the number of product units on hand at a given date. Decreases in selling prices are discretionary decisions made
by the Company in response to market conditions, including estimated launch dates of competing products and declines in market price. The Company records an
estimate for shelf-stock adjustments in the period it agrees to grant such a credit memo to a customer.
Medicaid and Other Government Pricing Programs
As required by law, the Company provides a rebate on drugs dispensed under the Medicaid program, Medicare Part D, TRICARE, and other U.S. government
pricing programs. The Company determines its estimated government rebate accrual primarily based on historical experience of claims submitted by the various states
and other jurisdictions and any new information regarding changes in the various programs which may impact the Company’s estimate of government rebates. In
determining the appropriate accrual amount, the Company considers historical payment rates and processing lag for outstanding claims and payments. The Company
records estimates for government rebates as a deduction from gross sales, with a corresponding adjustment to accrued liabilities.
Cash Discounts
The Company offers cash discounts to its customers, generally 2% of the gross selling price, as an incentive for paying within invoice terms, which generally
range from 30 to 90 days. An estimate of cash discounts is recorded in the same period when revenue is recognized.
F-16
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Rx Partner and OTC Partner:
The Rx Partner and OTC Partner contracts include revenue recognized under alliance and collaboration agreements between the Company and unrelated third-
party pharmaceutical companies. The Company has entered into these alliance agreements to develop marketing and/or distribution relationships with its partners to
fully leverage its technology platform.
The Rx Partners and OTC Partners alliance agreements obligate the Company to deliver multiple goods and/or services over extended periods. Such
deliverables include manufactured pharmaceutical products, exclusive and semi-exclusive marketing rights, distribution licenses, and research and development
services. In exchange for these deliverables the Company receives payments from its agreement partners for product shipments and research and development
services, and may also receive other payments including royalty, profit sharing, upfront, and periodic milestone payments. Revenue received from the alliance
agreement partners for product shipments under these agreements is not subject to deductions for chargebacks, rebates, product returns, and other pricing
adjustments. Royalty and profit sharing amounts the Company receives under these agreements are calculated by the respective agreement partner, with such royalty
and profit share amounts generally based upon estimates of net product sales or gross profit which include estimates of deductions for chargebacks, rebates, product
returns, and other adjustments the alliance agreement partners may negotiate with their respective customers. The Company records the agreement partner's
adjustments to such estimated amounts in the period the agreement partner reports the amounts to the Company.
The Company applies the updated guidance of ASC 605-25 “Multiple Element Arrangements” to the Strategic Alliance Agreement with Teva Pharmaceuticals
Curacao N.V., a subsidiary of Teva Pharmaceutical Industries Limited (“Teva Agreement”). The Company looks to the underlying delivery of goods and/or services
which give rise to the payment of consideration under the Teva Agreement to determine the appropriate revenue recognition. The Company initially defers
consideration received as a result of research and development-related activities performed under the Teva Agreement. The Company recognizes deferred revenue on
a straight-line basis over the expected period of performance for such services. Consideration received as a result of the manufacture and delivery of products under
the Teva Agreement is recognized at the time title and risk of loss passes to the customer which is generally when product is received by Teva. The Company
recognizes profit share revenue in the period earned.
OTC Partner revenue is related to agreements with Pfizer, Inc., formerly Wyeth LLC (“Pfizer”) and L. Perrigo Company (“Perrigo”) with respect to the supply of
over-the-counter pharmaceutical products. The OTC Partner sales channel is no longer a core area of the business, and the over-the-counter pharmaceutical products
the Company sells through this sales channel are older products which are only sold to Pfizer and Perrigo. The Company is currently only required to manufacture the
over-the-counter pharmaceutical products under its agreements with Pfizer and Perrigo. The Company recognizes profit share revenue in the period earned.
F-17
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Research Partner:
The Research Partner contract includes revenue recognized under development agreements with unrelated third-party pharmaceutical companies. The
development agreements generally obligate the Company to provide research and development services over multiple periods. In exchange for this service, the
Company received upfront payments upon signing of each development agreement and is eligible to receive contingent milestone payments, based upon the
achievement of contractually specified events. Additionally, the Company may also receive royalty payments from the sale, if any, of a successfully developed and
commercialized product under one of these development agreements. The Company recognizes revenue received from the achievement of contingent research and
development milestones in the period such payment is earned. Royalty fee income, if any, will be recognized as current period revenue when earned.
Promotional Partner:
The Promotional Partner contract includes revenue recognized under a promotional services agreement with an unrelated third-party pharmaceutical company.
The promotional services agreement obligated the Company to provide physician detailing sales calls services to promote certain of the unrelated third-party
company’s branded drug products. The Company received service fee revenue in exchange for providing this service. The Company recognized revenue from
providing physician detailing sales calls services as the services were provided. The Company’s obligation to provide physician detailing sales calls under the
promotional services agreement ended on June 30, 2012.
Shipping and Handling Fees and Costs
Shipping and handling fees related to sales transactions are recorded as selling expense. Shipping costs were $2,382,000, $1,890,000 and $1,425,000 for the
years ended December 31, 2014, 2013 and 2012, respectively.
Research and Development
Research and development activities are expensed as incurred and consist of self-funded research and development costs and costs associated with work
performed by other participants under collaborative research and development agreements.
Derivatives
The Company does not engage in hedging transactions for trading or speculative purposes or to hedge exposure to currency or interest rate fluctuations.
From time to time, the Company may engage in transactions that result in embedded derivatives (e.g., convertible debt securities). In accordance with FASB ASC Topic
815, “Derivatives and Hedging”, the Company records the embedded derivative at fair value on the balance sheet and records any related gains or losses in current
earnings in the statement of operations.
Share-Based Compensation
The Company accounts for stock-based employee compensation arrangements in accordance with provisions of FASB ASC Topic 718, ”Stock
Compensation”. Under FASB ASC Topic 718, the Company recognizes the grant date fair value of stock-based employee compensation as expense on a straight-line
basis over the vesting period of the grant. The Company uses the Black Scholes option pricing model to determine the grant date fair value of employee stock options;
the fair value of restricted stock awards is equal to the closing price of the Company’s stock on the date such award was granted.
F-18
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Income Taxes
The Company provides for income taxes using the asset and liability method as required by FASB ASC Topic 740, “Income Taxes”. This approach recognizes
the amount of federal, state, local taxes, and foreign taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax
consequences of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize
the effects of changes in tax laws or enacted tax rates in the period during which they are signed into law. Under FASB ASC Topic 740, a valuation allowance is
required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.
FASB ASC Topic 740, Sub-topic 10, ”Tax Positions”, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to
be recognized in financial statements prepared in conformity with generally accepted accounting principles. Under FASB ASC Topic 740, Sub-topic 10, the Company
may recognize the tax benefit from an uncertain tax position only if it is more likely than not the tax position will be sustained on examination by the taxing authorities,
based solely on the technical merits of the tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on
the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. Additionally, FASB ASC Topic 740, Sub-topic
10 provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. In accordance
with the disclosure requirements of FASB ASC Topic 740, Sub-topic 10, the Company’s policy on income statement classification of interest and penalties related to
income tax obligations is to include such items as part of total interest expense and other expense, respectively.
Earnings per Share
Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted
earnings per share is computed by dividing net income by the weighted average number of common shares adjusted for the dilutive effect of common stock
equivalents outstanding during the period.
Other Comprehensive Income
The Company follows the provisions of FASB ASC Topic 220, ”Comprehensive Income”, which establishes standards for the reporting and display of
comprehensive income and its components. Comprehensive income is defined to include all changes in equity during a period except those resulting from investments
by owners and distributions to owners. The Company recorded foreign currency translation gains and losses, which are reported as comprehensive income. Foreign
currency translation gains (losses) for the years ended December 31, 2014, 2013 and 2012 were $(7,149,000), $(4,104,000) and $3,520,000 respectively.
Deferred Financing Costs
The Company capitalizes direct costs incurred with obtaining debt financing, which are included in other assets on the consolidated balance sheet. Deferred
financing costs, including costs incurred in obtaining debt financing, are amortized to interest expense over the term of the underlying debt on a straight-line basis,
which approximates the effective interest method. The Company recognized amortization of $30,000, $30,000 and $30,000 in the years ended December 31, 2014, 2013
and 2012, respectively.
Foreign Currency Translation
The Company translates the assets and liabilities of the Taiwan dollar functional currency of its majority-owned affiliate Prohealth Biotech, Inc. and its wholly-
owned subsidiary Impax Laboratories (Taiwan), Inc. into the U.S. dollar reporting currency using exchange rates in effect at the end of each reporting period. The
revenue and expense of these entities are translated using an average of the rates in effect during the reporting period. Gains and losses from these translations are
recorded as currency translation adjustments included in the consolidated statements of comprehensive income and the consolidated statements of changes in
stockholders’ equity.
F-19
3. RECENT ACCOUNTING PRONOUNCEMENTS
In March 2013, the FASB issued updated guidance on foreign currency matters. The update applies to the release of the cumulative translation adjustment
into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of
assets within a foreign entity. The Company adopted this guidance on January 1, 2014 and the adoption did not have a material effect on its consolidated financial
statements.
In July 2013, the FASB issued updated guidance related to presentation of an unrecognized tax benefit. The guidance requires an entity to present an
unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) carryforward, or similar tax loss, or tax credit carryforward, rather than as a
liability under certain circumstances. The Company adopted this guidance on January 1, 2014 and the adoption did not have a material effect on its consolidated
financial statements.
In May 2014, the FASB issued updated guidance regarding the accounting for and disclosures of revenue recognition. The update provides a single
comprehensive model for accounting for revenue from contracts with customers. The model requires that revenue recognized reflect the actual consideration to which
the entity expects to be entitled in exchange for the goods or services defined in the contract, including in situations with multiple performance obligations. This
guidance will be the same for both U.S. GAAP and International Financial Reporting Standards (IFRS) and is effective for annual and interim periods beginning after
December 15, 2016. The Company is currently evaluating the effect that this guidance may have on its consolidated financial statements.
In July 2014, the IRS issued final regulations related to the branded pharmaceutical drug (BPD) annual fee under the Patient Protection and Affordable Care
Act and the Health Care and Education Affordability Reconciliation Act of 2010. The final regulations indicate that an entity’s obligation to pay its portion of the BPD
fee in any given calendar year is not triggered by the first qualifying sale in that calendar year but instead by the qualifying sales in the previous year. As a result,
during the three month period ended September 30, 2014, the Company recorded a charge of $0.7 million in connection with the implementation of this updated
guidance.
F-20
4. INVESTMENTS
Investments consist of commercial paper and corporate bonds. The Company’s policy is to invest in only high quality “AAA-rated” or investment-grade
securities. Investments in debt securities are accounted for as “held-to-maturity” and are recorded at amortized cost, which approximates fair value, generally based
upon observable market values of similar securities. The Company has historically held all investments in debt securities until maturity, and has the ability and intent to
continue to do so. All of the Company’s investments have remaining contractual maturities of less than 12 months and are classified as short-term. Upon maturity, the
Company uses a specific identification method.
A summary of short-term investments as of December 31, 2014 and December 31, 2013 follows:
(in $000’s)
December 31, 2014
Commercial paper
Corporate bonds
Total short-term investments
(in $000’s)
December 31, 2013
Commercial paper
Corporate bonds
Total short-term investments
Gross
Gross
Amortized
Cost
Unrecognized Unrecognized
Gains
Losses
Fair
Value
$
$
68,972 $
131,011
199,983 $
17 $
--
17 $
-- $
(101)
(101) $
68,989
130,910
199,899
Gross
Gross
Amortized
Cost
Unrecognized Unrecognized
Gains
Losses
Fair
Value
$
$
91,480 $
137,041
228,521 $
26 $
13
39 $
-- $
(21)
(21) $
91,506
137,033
228,539
F-21
5. ACCOUNTS RECEIVABLE
The composition of accounts receivable, net is as follows:
(in $000’s)
Gross accounts receivable
Less: Rebate reserve
Less: Chargeback reserve
Less: Other deductions
Accounts receivable, net
December 31,
2014
December 31,
2013
$
$
287,362 $
(88,812)
(43,125)
(8,935)
146,490 $
246,319
(88,449)
(37,066)
(7,811)
112,993
A roll forward of the chargeback and rebate reserves activity for the years ended December 31, 2014, 2013 and 2012 is as follows:
(in $000’s)
Rebate reserve
Beginning balance
Provision recorded during the period
Credits issued during the period
Ending balance
(in $000’s)
Chargeback reserve
Beginning balance
Provision recorded during the period
Credits issued during the period
Ending balance
December 31,
2014
December 31,
2013
December 31,
2012
88,449 $
260,747
(260,384)
88,812 $
46,011 $
193,288
(150,850)
88,449 $
29,164
111,099
(94,252)
46,011
December 31,
2014
December 31,
2013
December 31,
2012
37,066 $
487,377
(481,318)
43,125 $
18,410 $
389,707
(371,051)
37,066 $
22,161
209,452
(213,203)
18,410
$
$
$
$
Other deductions include allowance for cash discounts and uncollectible amounts. The Company maintains an allowance for doubtful accounts for estimated
losses resulting from amounts deemed to be uncollectible from its customers, with such allowances for specific amounts on certain accounts. The Company had an
allowance for uncollectible amounts of $515,000 and $539,000 at December 31, 2014 and 2013, respectively.
F-22
6. INVENTORY
Inventory, net of carrying value reserves at December 31, 2014 and 2013 consisted of the following:
(in $000’s)
Raw materials
Work in process
Finished goods
Total inventory
Less: Non-current inventory
Total inventory-current
December 31,
2014
December 31,
2013
$
$
34,681 $
2,447
55,102
92,230
11,660
80,570 $
27,981
1,434
47,416
76,831
6,724
70,107
Inventory carrying value reserves were $25,639,000 and $17,702,000 at December 31, 2014 and 2013, respectively. During the three month period ended March
31, 2013, the Company decided to discontinue the manufacture and distribution of certain unprofitable products after the Company conducted a strategic review of its
currently manufactured generic product portfolio. As a result of this decision, the Company recorded an inventory reserve of $6,700,000 related to the discontinued
products. In addition, upon receipt of the Complete Response Letter from the FDA for RYTARY™ in January 2013, the Company evaluated the impact of the expected
delay of FDA approval on its ability to sell the associated inventory. The Company determined that a reserve of $5,000,000 was appropriate and recorded this amount
in the three month period ended March 31, 2013. The Company subsequently received FDA approval for RYTARY™ on January 7, 2015. During the three month period
ended March 31, 2013, the Company also recorded a $6,400,000 reserve for pre-launch inventory of a product manufactured for another third-party pharmaceutical
company due to the anticipated delayed launch of such product as a result of the warning letter related to our Hayward, California manufacturing facility. The carrying
value of unapproved inventory less reserves was $7,312,000 and $6,462,000 at December 31, 2014 and 2013, respectively.
The Company recognizes pre-launch inventories at the lower of its cost or the expected net selling price. Cost is determined using a standard cost method,
which approximates actual cost, and assumes a FIFO flow of goods. Costs of unapproved products are the same as approved products and include materials, labor,
quality control, and production overhead. When the Company concludes FDA approval is expected within approximately six months, the Company will generally begin
to schedule manufacturing process validation studies as required by the FDA to demonstrate the production process can be scaled up to manufacture commercial
batches. Consistent with industry practice, the Company may build quantities of pre-launch inventories of certain products pending required final FDA approval
and/or resolution of patent infringement litigation, when, in the Company’s assessment, such action is appropriate to prepare for the anticipated commercial launch,
FDA approval is expected in the near term, and/or the related litigation will be resolved in the Company’s favor. The capitalization of unapproved pre-launch inventory
involves risks, including, among other items, FDA approval of product may not occur; approvals may require additional or different testing and/or specifications than
used for unapproved inventory; and, in cases where the unapproved inventory is for a product subject to litigation, the litigation may not be resolved or settled in
favor of the Company. If any of these risks were to materialize and the launch of the unapproved product delayed or prevented, then the net carrying value of
unapproved inventory may be partially or fully reserved. Generally, the selling price of a generic pharmaceutical product is at discount from the corresponding brand
product selling price. Typically, a generic drug is easily substituted for the corresponding brand product, and once a generic product is approved, the pre-launch
inventory is typically sold within the next three months. If the market prices become lower than the product inventory carrying costs, then the pre-launch inventory
value is reduced to such lower market value. If the inventory produced exceeds the estimated market acceptance of the generic product and becomes short-dated, a
carrying value reserve will be recorded. In all cases, the carrying value of the Company's pre-launch product inventory is lower than the respective estimated net
selling prices.
To the extent inventory is not scheduled to be utilized in the manufacturing process and/or sold within twelve months of the balance sheet date, it is included
as a component of other non-current assets. Amounts classified as non-current inventory consist of raw materials, net of valuation reserves. Raw materials generally
have a shelf life of approximately three to five years, while finished goods generally have a shelf life of approximately two years.
F-23
7. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment, net consisted of the following:
(in $000’s)
Land
Buildings and improvements
Equipment
Office furniture and equipment
Construction-in-progress
Property, plant and equipment, gross
Less: Accumulated depreciation
Property, plant and equipment, net
December 31,
2014
December 31,
2013
$
$
$
5,773 $
154,374
122,184
12,623
9,404
304,358 $
(116,189)
188,169 $
5,773
139,657
114,950
11,523
15,910
287,813
(99,622)
188,191
Depreciation expense was $20,353,000, $16,782,000 and $15,982,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
F-24
8. GOODWILL AND INTANGIBLE ASSETS
Goodwill was $27,574,000 at December 31, 2014 and 2013, and the Company attributes the entire carrying amount of goodwill to the Global Division. Goodwill
is tested at least annually for impairment or whenever events or changes in circumstances have occurred which could have a material adverse effect on the estimated
fair value of the reporting unit, and thus indicate a potential impairment of the goodwill carrying value. The Company concluded the carrying value of goodwill was not
impaired as of December 31, 2014 and 2013.
Intangible assets consisted of the following:
(in $000’s)
December 31, 2014
Intangible assets:
®
Zomig product rights
Tolmar product rights
Perrigo product rights
Ursodiol product rights
Other product rights
Total intangible assets
(in $000’s)
December 31, 2013
Intangible assets:
®
Zomig product rights
Tolmar product rights
Other product rights
Total intangible assets
Initial
Cost
Accumulated
Amortization
Impairment
Carrying
Value
$
$
$
$
41,783 $
33,450
1,000
3,000
7,250
86,483 $
(31,561) $
(10,801)
(297)
(331)
---
(42,990) $
--- $
(16,032)
---
---
(750)
(16,782) $
10,222
6,617
703
2,669
6,500
26,711
Initial
Cost
Accumulated
Amortization
Impairment
Carrying
Value
41,783 $
31,450
2,250
75,483 $
(28,641) $
(3,266)
---
(31,907) $
--- $
(13,156)
(750)
(13,906) $
13,142
15,028
1,500
29,670
The Zomig® product rights under the AZ Agreement with AstraZeneca were amortized on a straight-line basis over a period of 14 months starting in April
2012 and ending upon the expiration of the underlying patent for the tablet and over a period of 11 months starting in July 2012 and ending upon the expiration of the
underlying patent for the orally disintegrating tablet. The Zomig® product rights under the AZ Agreement are also being amortized over a period of 72 months starting
in July 2012 for the nasal spray.
In June 2012, the Company entered into a Development, Supply and Distribution Agreement (the “Tolmar Agreement”) with TOLMAR, Inc. (“Tolmar”). Under
the terms of the Tolmar Agreement, Tolmar granted to the Company an exclusive license to commercialize up to 11 generic topical prescription drug products, including
ten currently approved products and one product pending approval at the FDA, in the United States and its territories. Under the terms of the Tolmar Agreement,
Tolmar is responsible for developing and manufacturing the products, and the Company is responsible for the marketing and sale of the products. During the three
month period ended September 30, 2013, as a result of the most recent market share data obtained by the Company and the Company’s revised five year projections for
the Tolmar product lines, the Company performed an intangible asset impairment test on the Tolmar products. Based on the results of the impairment analysis, the
Company recorded a $13.2 million impairment charge to cost of revenues for the Global Division in the three month period ended September 30, 2013. During the three
month period ended March 31, 2014, as a result of a further decline in pricing, the Company revised its projections and performed an intangible asset impairment
analysis. Based on the results of this analysis, the Company recorded a $2.9 million charge to cost of revenues for the Global Pharmaceuticals Division, which was
100% of the remaining net book value of this asset. The remaining carrying value of the Tolmar product rights are being amortized over the remaining estimated useful
lives of the underlying products over a period ranging from five to 12 years, starting upon commencement of commercialization activities by the Company during the
year ended December 31, 2012. During the fourth quarter of 2014, the Company paid a $2.0 million milestone related to the Diclofenac Sodium Gel 3% product to Tolmar
pursuant to the Tolmar Agreement in accordance with the terms thereof. This milestone payment was capitalized as an intangible asset. Information concerning the AZ
Agreement and the Tolmar Agreement can be found in “Note 12 - Alliance and Collaboration Agreements.”
During the three month period ended June 30, 2014, the Company paid a $1.0 million milestone payment to Perrigo Company, plc (“Perrigo”) in conjunction
with its launch of a generic version of Astepro nasal spray pursuant to a development agreement between the Company and an affiliate of Perrigo. The milestone was
capitalized as an intangible asset acquisition and will be amortized over the expected cash flows of the product.
F-25
During the three month period ended September 30, 2014, the Company acquired from Actavis plc two generic products including one product marketed
under an existing ANDA, the Ursodiol tablet, and one approved product that was not yet then marketed, the Lamotrigine orally disintegrating tablet. The entire
purchase price of $8.0 million was allocated to identifiable intangible assets and the Ursodiol intangible will be amortized over an eight year period. As of the year
ended December 31, 2014, the Lamotrigine product was considered in-process research and development and will begin amortizing when commercialized. Other product
rights consist of ANDAs which have been filed with the FDA. During the three month period ended September 30, 2013, as a result of a decision by management to
withdraw one of these ANDAs and no longer seek FDA approval, the Company recorded an intangible asset impairment charge of $0.8 million in research and
development expense, representing the full carrying value of the ANDA. For the remaining ANDAs, the Company will either commence amortization upon FDA
approval and commercialization over the estimated useful life of the product rights, or will expense the related costs immediately upon failure to obtain FDA approval.
Amortization expense is included as a component of Cost of Revenues on the Company’s consolidated statements of operations and was $11,083,000,
$13,061,000 and $18,846,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
The following schedule shows the expected amortization of the Zomig , Tolmar, Perrigo and Ursodiol product rights for the next five years and thereafter:
®
(in $000’s)
2015
2016
2017
2018
2019
Thereafter
Total
Amortization
Expense
$
$
5,846
4,618
4,230
2,625
1,005
1,887
20,211
F-26
9. ACCRUED EXPENSES
The following table sets forth the Company’s accrued expenses:
(in $000’s)
Payroll-related expenses
Product returns
Government rebates
Legal and professional fees
Income taxes payable
Physician detailing sales force fees
Litigation accrual
Other
Total accrued expenses
Product Returns
December 31,
2014
December 31,
2013
$
$
33,812 $
27,174
18,272
9,497
40
2,336
12,750
6,589
110,470 $
27,985
28,089
23,351
3,162
21,186
1,512
--
6,238
111,523
The Company maintains a return policy to allow customers to return product within specified guidelines. The Company estimates a provision for product
returns as a percentage of gross sales based upon historical experience for sales made through its Global Products and Impax Products sales channels. Sales of
product under the Private Label, Rx Partner and OTC Partner alliance, collaboration and supply agreements are not subject to returns. A roll forward of the return
reserve activity for the years ended December 31, 2014, 2013 and 2012 is as follows:
(in $000's)
Returns Reserve
December 31,
2014
December 31,
2013
December 31,
2012
Beginning balance
Provision related to sales recorded in the period
Credits issued during the period
Ending balance
$
$
28,089 $
12,016
(12,931)
27,174 $
23,440 $
11,015
(6,366)
28,089 $
24,101
3,003
(3,664)
23,440
F-27
10. INCOME TAXES
The Company is subject to federal, state and local income taxes in the United States, and income taxes in Taiwan, R.O.C. and the Netherlands. The provision
for income taxes is comprised of the following:
(in $000’s)
Current:
Federal taxes
State taxes
Foreign taxes
Total current tax expense
Deferred:
Federal taxes
State taxes
Foreign taxes
Total deferred tax (benefit) expense
Provision for income taxes
2014
For the Years Ended December 31,
2013
2012
$
$
$
42,635 $
2,467
832
45,934
(9,039) $
(3,597)
(92)
(12,728)
33,206 $
67,407 $
2,569
742
70,718
(21,050) $
(1,965)
(2,022)
(25,037)
45,681 $
49,636
1,721
453
51,810
(21,650)
(2,537)
(185)
(24,372)
27,438
A reconciliation of the difference between the tax provision at the federal statutory rate and actual income taxes on income before income taxes, which
includes federal, state, and other income taxes, is as follows:
$
2014
90,559
For the Years Ended December 31,
2013
146,940
$
$
2012
83,311
31,696
35.0%
51,429
35.0%
29,159
35.0%
(in $000’s)
Income before income taxes
Tax provision at the federal
statutory rate
Increase (decrease) in tax rate
resulting from:
Tax rate differential and
permanent items on foreign
income
State income taxes, net of
federal benefit
State research and
development credits
Federal research and
development credits
Share-based compensation
Executive compensation
Domestic manufacturing
deduction
Other permanent book/tax
differences
Provision for uncertain tax
positions
Revision of prior years’
estimates
Prior year Federal research and
development credits
Other, net
Provision for income taxes
$
2,285
887
2.5%
1.0%
383
0.3%
(1,259)
1,616
1.1%
1,906
(2,133)
(2.4)%
(1,787)
(1.2)%
(1,560)
(2,401)
189
1,552
(2.6)%
0.2%
1.7%
(1,900)
92
336
(1.3)%
0.1%
0.2%
---
326
825
(679)
(0.7)%
(1,666)
(1.1)%
(2,010)
170
952
664
---
24
33,206
0.2%
1.1%
(967)
(0.7)%
1,718
1.1%
0.7%
(1,150)
(0.8)%
--%
0.0%
36.7% $
(1,950)
(473)
45,681
(1.3)%
(0.3)%
31.1% $
(185)
801
(392)
---
(173)
27,438
(1.5)%
2.3%
(1.9)%
--%
0.4%
1.0%
(2.4)%
(0.2)%
0.9%
(0.5)%
--%
(0.2)%
32.9%
On January 3, 2013, the research and development credit (the “R&D credit”) was reinstated retroactively as a part of The American Taxpayer Relief Act of
2012 for expenses paid or incurred from January 1, 2012 through December 31, 2012. Due to the fact that this legislation was not enacted prior to the Company’s 2012
year-end, no tax benefit related to potential R&D credits was reflected within the 2012 year-end tax provision. The 2012 R&D credit was reflected within the Company’s
first quarter tax provision for the year ended December 31, 2013.
F-28
10. INCOME TAXES (continued)
Deferred income taxes result from temporary differences between the financial statement carrying values and the tax bases of the Company’s assets and
liabilities. Deferred tax assets principally result from deferred revenue related to certain of the Company’s alliance and collaboration agreements (see “Note 12 –
Alliance and Collaboration Agreements” below for a discussion of the Company's alliance and collaboration agreements), certain accruals and reserves currently not
deductible for tax purposes, acquired product rights and intangibles, capitalized legal and share based compensation expense. Deferred tax liabilities principally result
from the use of accelerated depreciation methods for income tax purposes. The components of the Company’s deferred tax assets and liabilities are as follows:
(in $000’s)
Deferred tax assets:
Deferred revenues
Accrued expenses
Inventory reserves
Net operating loss carryforwards
Depreciation and amortization
Acquired product rights and intangibles
Capitalized legal fees
R&D credit carryforwards
Share based compensation expense
Other
Deferred tax assets
Deferred tax liabilities:
Tax depreciation and amortization in excess of book amounts
Deferred manufacturing costs
Other
Deferred tax liabilities
Deferred tax assets, net
December 31,
2014
2013
$
$
$
$
$
1,550 $
46,206
10,223
46
284
18,788
12,829
4,331
4,397
1,048
99,702 $
1,028 $
65
1,947
3,040 $
96,662 $
The breakdown between current and long-term deferred tax assets and tax liabilities is as follows:
(in $000’s)
Current deferred tax assets
Current deferred tax liabilities
Current deferred tax assets, net
Non-current deferred tax assets
Non-current deferred tax liabilities
Non-current deferred tax assets, net
Deferred tax assets, net
December 31,
2014
2013
56,772 $
(1,947)
54,825
42,930
(1,093)
41,837
96,662 $
$
$
F-29
2,961
44,404
6,681
61
275
15,147
11,245
3,238
4,786
745
89,543
2,592
65
2,172
4,829
84,714
52,959
(2,171)
50,788
36,583
(2,657)
33,926
84,714
10. INCOME TAXES (continued)
A rollforward of unrecognized tax benefits for the years ended December 31, 2014, 2013 and 2012 is as follows:
(in $000’s)
Unrecognized tax benefits beginning of year
Gross change for current year positions
Gross change for prior period positions
Decrease due to settlements and payments
Unrecognized tax benefits end of year
2014
For the Years Ended December 31,
2013
2012
$
$
5,292 $
1,089
310
(174)
6,517 $
2,920 $
797
1,575
--
5,292 $
1,791
249
1,231
(351)
2,920
The amount of unrecognized tax benefits at December 31, 2014, 2013 and 2012 was $6.5 million, $5.3 million and $2.9 million respectively, of which $5.0 million,
$4.1 million and $2.3 million would impact the Company’s effective tax rate, respectively, if recognized. The Company currently does not believe that the total amount of
unrecognized tax benefits will increase or decrease significantly over the next twelve months. Interest expense related to income taxes is included in “Interest expense”
on the consolidated statement of operations. Net interest expense related to unrecognized tax benefits for the year ended December 31, 2014 was $5,000 principally due
to the settlement of the 2007-2009 California audit, compared to $299,000 in 2013. Accrued interest expense as of December 31, 2014 and 2013 was $597,000 and
$602,000, respectively. Income tax penalties are included in “Other income (expense)” on the consolidated statements of operations. Accrued tax penalties are not
significant.
The Company is currently not under audit for its federal income tax, but is currently under audit by the State of California Franchise Tax Board for the tax
years ended December 31, 2010 and 2011. No provision has been made for U.S. federal deferred income taxes on accumulated earnings on foreign subsidiaries since it is
the current intention of management to indefinitely reinvest the undistributed earnings in the foreign subsidiary.
F-30
11. REVOLVING LINE OF CREDIT
As of December 31, 2014, the Company had a Credit Agreement, as amended (the “Credit Agreement”) with Wells Fargo Bank, N.A., as a lender and as
administrative agent (the “Administrative Agent”). The Credit Agreement provided the Company with a revolving line of credit in the aggregate principal amount of up
to $50,000,000 (the “Revolving Credit Facility”). Under the Revolving Credit Facility, up to $10,000,000 was available for letters of credit, the outstanding face amounts
of which reduced availability under the Revolving Credit Facility on a dollar for dollar basis. Proceeds under the Credit Agreement could be used for working capital,
general corporate and other lawful purposes. The Credit Agreement matured in accordance with the terms therein on February 11, 2015. The Company did not borrow
any amounts under the Revolving Credit Facility.
The Company’s borrowings under the Credit Agreement were secured by substantially all of the personal property assets of the Company pursuant to a
Security Agreement (the “Security Agreement”) entered into by the Company and the Administrative Agent. As further security, the Company also pledged to the
Administrative Agent, 65% of the Company’s equity interest in its wholly owned subsidiary Impax Laboratories (Taiwan), Inc., all of the Company’s equity interests in
its wholly owned domestic subsidiaries and must similarly pledge all or a portion of its equity interest in future subsidiaries. Under the Credit Agreement, among other
things:
● The outstanding principal amount of all revolving credit loans, together with accrued and unpaid interest thereon, was due and payable on the maturity date,
which occurred on February 11, 2015. There were no balances outstanding under the credit facility as of December 31, 2014.
● Borrowings under the Revolving Credit Facility bore interest, at the Company’s option, at either an Alternate Base Rate (as defined in the Credit Agreement)
plus the applicable margin in effect from time to time ranging from 0.5% to 1.5%, or a LIBOR Rate (as defined in the Credit Agreement) plus the applicable margin
in effect from time to time ranging from 1.5% to 2.5%. The Company was also required to pay an unused commitment fee ranging from 0.25% to 0.45% per annum
based on the daily average undrawn portion of the Revolving Credit Facility. The applicable margin described above and the unused commitment fee in effect at
any given time were determined based on the Company’s Total Net Leverage Ratio (as defined in the Credit Agreement), which was based upon the Company’s
consolidated total debt, net of unrestricted cash in excess of $100 million, compared to Consolidated EBITDA (as defined in the Credit Agreement) for the
immediately preceding four quarters.
● The Company could prepay any outstanding loan under the Revolving Credit Facility without premium or penalty.
● The Company was required under the Credit Agreement and the Security Agreement to comply with a number of affirmative, negative and financial covenants.
Among other things, these covenants (i) required the Company to provide periodic reports, notices of material events and information regarding collateral, (ii)
restricted the Company’s ability, subject to certain exceptions and baskets, to incur additional indebtedness, grant liens on assets, undergo fundamental
changes, change the nature of its business, make investments, undertake acquisitions, sell assets, make restricted payments (including the ability to pay
dividends and repurchase stock) or engage in affiliate transactions, and (iii) required the Company to maintain a Total Net Leverage Ratio (which was, generally,
total funded debt, net of unrestricted cash in excess of $100 million, over EBITDA for the preceding four quarters) of less than 3.75 to 1.00, a Senior Secured
Leverage Ratio (which was, generally, total senior secured debt over EBITDA for the preceding four quarters) of less than 2.50 to 1.00, Consolidated EBITDA of
at least $50.0 million and Minimum Liquidity (which was, generally unrestricted cash and cash equivalents) of at least $100.0 million. As of December 31, 2014,
the Company was in compliance with the various covenants contained in the Credit Agreement and the Security Agreement. Prior to the Company’s execution
of the definitive agreement under which the Company will acquire Tower Holdings, Inc. and Lineage Therapeutics, Inc., the Company received the
Administrative Agent’s consent that the execution of such agreement would not result in a breach of the covenants in the Credit Agreement.
● The Credit Agreement contained customary events of default (subject to customary grace periods, cure rights and materiality thresholds), including, among
others, failure to pay principal, interest or fees, violation of covenants, material inaccuracy of representations and warranties, cross-default and cross-
acceleration of material indebtedness and other obligations, certain bankruptcy and insolvency events, certain judgments, certain events related to the
Employee Retirement Income Security Act of 1974, as amended, and a change of control.
● Following an event of default under the Credit Agreement, the Administrative Agent would be entitled to take various actions, including the acceleration of
amounts due under the Credit Agreement and seek other remedies that may be taken by secured creditors.
F-31
During the years ended December 31, 2014, 2013 and 2012, unused line fees incurred under the Credit Agreement were $124,000, $139,000 and $95,000,
respectively.
In connection with the Stock Purchase Agreement pursuant to which the Company will acquire Tower and Lineage, on January 2, 2015, the Company entered
into a second amended and restated commitment letter (the “Commitment Letter”), which amended and restated the commitment letter dated as of October 8, 2014, as
first amended and restated on October 22, 2014 with Barclays Bank plc (“Barclays”), Royal Bank of Canada (“Royal Bank”), Wells Fargo Bank, National Association
(“Wells Fargo”) and Wells Fargo Securities, LLC (“Wells Fargo Securities” and together with Barclays, Royal Bank and Wells Fargo, the “Lenders”) pursuant to which
the Lenders have severally but not jointly committed to provide a $50.0 million senior secured revolving credit facility and a $435.0 million senior secured term loan
facility in an aggregate principal amount of up to $485.0 million for purposes of financing the Transaction and the related fees and expenses. The obligations of the
Lender to provide debt financing under the Commitment Letter are subject to a number of customary conditions, including (i) absence of a Material Adverse Effect (as
defined in the Stock Purchase Agreement) that would result in a failure of a condition under the Stock Purchase Agreement; (ii) execution and delivery by the
Company of definitive documentation with respect to the debt financing consistent with the term sheet attached to the Commitment Letter; (iii) the accuracy of certain
specified representations and warranties in the debt documents; (iv) concurrent consummation of the Transaction in accordance with the Stock Purchase Agreement;
(v) delivery of certain customary closing documents (including, among others, a customary solvency certificate), specified items of collateral (where applicable) and
certain Tower and Lineage financial statements; and (vi) payment of applicable costs, fees and expenses. The final termination date of the Commitment Letter is March
30, 2015.
F-32
12. ALLIANCE AND COLLABORATION AGREEMENTS
The Company has entered into several alliance, collaboration, license and distribution agreements, and similar agreements with respect to certain of its
products and services, with unrelated third-party pharmaceutical companies. The statement of operations includes revenue recognized under agreements the Company
has entered into to develop marketing and/or distribution relationships with its partners to fully leverage its technology platform, revenue recognized under
development agreements which generally obligate the Company to provide research and development services over multiple periods, and revenue recognized under a
promotional services agreement which obligates the Company to provide physician detailing sales calls services to promote its promotional partner’s branded drug
products over multiple periods.
The Company’s alliance and collaboration agreements often include milestones and provide for milestone payments upon achievement of these milestones.
Generally, the milestone events contained in the Company’s alliance and collaboration agreements coincide with the progression of the Company’s products and
technologies from pre-commercialization to commercialization.
The Company groups pre-commercialization milestones in its alliance and collaboration agreements into clinical and regulatory categories, each of which may
include the following types of events:
Clinical Milestone Events:
● Designation of a development candidate. Following the designation of a development candidate, generally, IND-enabling animal studies
for a new development candidate take 12 to 18 months to complete.
●
●
●
Initiation of a Phase I clinical trial. Generally, Phase I clinical trials take one to two years to complete.
Initiation or completion of a Phase II clinical trial. Generally, Phase II clinical trials take one to three years to complete.
Initiation or completion of a Phase III clinical trial. Generally, Phase III clinical trials take two to four years to complete.
● Completion of a bioequivalence study. Generally, bioequivalence studies take three months to one year to complete.
Regulatory Milestone Events:
●
Filing or acceptance of regulatory applications for marketing approval such as a New Drug Application in the United States or
Marketing Authorization Application in Europe. Generally, it takes six to 12 months to prepare and submit regulatory filings and
approximately two months for a regulatory filing to be accepted for substantive review.
● Marketing approval in a major market, such as the United States or Europe. Generally it takes one to three years after an application is
submitted to obtain approval from the applicable regulatory agency.
● Marketing approval in a major market, such as the United States or Europe for a new indication of an already-approved product.
Generally it takes one to three years after an application for a new indication is submitted to obtain approval from the applicable regulatory
agency.
F-33
12. ALLIANCE AND COLLABORATION AGREEMENTS (continued)
Commercialization milestones in the Company’s alliance and collaboration agreements may include the following types of events:
●
●
First commercial sale in a particular market, such as in the United States or Europe.
Product sales in excess of a pre-specified threshold, such as annual sales exceeding $100 million. The amount of time to achieve this type of
milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace
at which customers begin using the product.
License and Distribution Agreement with Shire
In January 2006, the Company entered into a License and Distribution Agreement with an affiliate of Shire Laboratories, Inc., which was subsequently
amended (“Prior Shire Agreement”), under which the Company received a non-exclusive license to market and sell an authorized generic of Shire’s Adderall XR®
product (“AG Product”) subject to certain conditions, but in any event by no later than January 1, 2010. The Company commenced sales of the AG Product in October
2009. On February 7, 2013, the Company entered into an Amended and Restated License and Distribution Agreement with Shire (the “Amended and Restated Shire
Agreement”), which amended and restated the Prior Shire Agreement. The Amended and Restated Shire Agreement was entered into by the parties in connection with
the settlement of the Company’s litigation with Shire relating to Shire’s supply of the AG Product to the Company under the Prior Shire Agreement. During 2013, the
Company received a payment of $48,000,000 from Shire in connection with such litigation settlement, which was recorded in the first quarter of 2013 under the line item
“Other Income” on the consolidated statement of operations. Under the Amended and Restated Shire Agreement Shire was required to supply the AG Product and
Company was responsible for marketing and selling the AG Product subject to the terms and conditions thereof until the earlier of (i) the first commercial sale of the
Company’s generic equivalent product to Adderall XR® and (ii) September 30, 2014 (the “Supply Term”), subject to certain continuing obligations of the parties upon
expiration or early termination of the Supply Term, including Shire’s obligation to deliver AG Products still owed to the Company as of the end of the Supply Term. The
Company is required to pay a profit share to Shire on sales of the AG Product, of which the Company owed a profit share payable to Shire of $21,089,000, $20,406,000
and $70,948,000 on sales of the AG Product during the years ended December 31, 2014, 2013 and 2012, respectively, with a corresponding charge included in the cost of
revenues line in the consolidated statement of operations. Although the Supply Term expired on September 30, 2014, the Company is permitted to sell any AG Products
in its inventory or owed to the Company by Shire under the Amended and Restated Shire Agreement until all such products are sold. The Company will continue to
pay a profit share to Shire on sales of such products.
Development, Supply and Distribution Agreement with TOLMAR, Inc.
In June 2012, the Company entered into the Tolmar Agreement with Tolmar. Under the terms of the Tolmar Agreement, Tolmar granted to the Company an
exclusive license to commercialize up to 11 generic topical prescription drug products, including ten currently approved products and one product pending approval at
the FDA, in the United States and its territories. Under the terms of the Tolmar Agreement, Tolmar is responsible for developing and manufacturing the products, and
the Company is responsible for marketing and sale of the products. The Company is required to pay a profit share to Tolmar on sales of each product commercialized
pursuant to the terms of the Tolmar Agreement. The Company paid Tolmar a $21,000,000 upfront payment upon signing of the agreement and a $1,000,000 milestone
payment in the year ended December 31, 2012. During the fourth quarter ended December 31, 2013, the Company made a $12,000,000 payment to Tolmar upon Tolmar’s
achievement of a regulatory milestone event in accordance with the terms of the agreement. The upfront payment for the Tolmar product rights has been allocated to
the underlying topical products based upon the relative fair value of each product and will be amortized over the remaining estimated useful life of each underlying
product, ranging from five to 12 years, starting upon commencement of commercialization activities by the Company during the second half of 2012. The amortization
of the Tolmar product rights has been included as a component of cost of revenues on the consolidated statement of operations. The Company initially allocated
$1,550,000 of the upfront payment to two products which are still in development and has recorded such amount as in-process research and development expense in
its results of operations for the year ended December 31, 2012. The Company similarly recorded the $1,000,000 milestone paid in the year ended December 31, 2012 as a
research and development expense. The Company is required to pay a profit share to Tolmar on sales of the topical products, of which the Company owed a profit
share payable to Tolmar of $15,995,000, $3,905,000 and $551,000 during the years ended December 31, 2014, 2013 and 2012, respectively, with a corresponding charge
included in the cost of revenues line in the Company’s consolidated statement of operations. Under the Tolmar Agreement, the Company has the potential to pay up to
an aggregate of $10,000,000 in additional contingent milestone payments if certain commercialization events occur.
F-34
Contingent milestone payments will be initially recognized in the period the triggering event occurs. Milestone payments which are contingent upon
commercialization events will be accounted for as an additional cost of acquiring the product license rights. Milestone payments which are contingent upon regulatory
approval events will be capitalized and amortized over the remaining estimated useful life of the approved product. As discussed in “Note 8 – Goodwill and Intangible
Assets,” the Company recorded a $13.2 million intangible asset impairment charge to cost of revenues in the three month period ended September 30, 2013 related to
the Tolmar product rights acquired under the Tolmar Agreement. During the fourth quarter of 2013, the Company made a $12.0 million payment to Tolmar upon Tolmar’s
achievement of a regulatory milestone event in accordance with the terms of the Tolmar Agreement. During the fourth quarter of 2014, the Company paid a $2.0 million
milestone related to the Diclofenac Sodium Gel 3% or Solaraze product to Tolmar pursuant to the Tolmar Agreement.
The Company entered into a Loan and Security Agreement with Tolmar in March 2012 (the “Tolmar Loan Agreement”), under which the Company agreed to
lend to Tolmar one or more loans through December 31, 2014, in an aggregate amount not to exceed $15,000,000. As of December 31, 2014, Tolmar borrowed $15,000,000
under the Tolmar Loan Agreement, which is included in “Other Assets” on the consolidated balance sheet. The outstanding principal amount of, including any
accrued and unpaid interest on, the loans under the Tolmar Loan Agreement are payable by Tolmar beginning from March 31, 2017 through March 31, 2020 or the
maturity date, in accordance with the terms therein. Tolmar may prepay all or any portion of the outstanding balance of the loans prior to the maturity date without
penalty or premium.
Strategic Alliance Agreement with Teva
The Company entered into a Strategic Alliance Agreement with Teva Pharmaceuticals Curacao N.V., a subsidiary of Teva Pharmaceutical Industries Limited, in
June 2001 (“Teva Agreement”). The Teva Agreement commits the Company to develop and manufacture, and Teva to distribute, a specified number controlled release
generic pharmaceutical products (“generic products”), each for a 10-year period. The Company is required to develop the products, obtain FDA approval to market the
products, and manufacture the products for Teva. The revenue the Company earns from the sale of product under the Teva Agreement consists of Teva’s
reimbursement of the Company’s manufacturing costs plus a profit share on Teva’s sales of the product to its customers. The Company invoices Teva for the
manufacturing costs or products it ships to Teva and payment is due within 30 days. Teva has the right to determine all terms and conditions of the product sales to its
customers. Within 30 days of the end of each calendar quarter, Teva is required to provide the Company with a report of its net sales and profits during the quarter and
to pay the Company its share of the profits resulting from those sales. Net sales are Teva’s gross sales less discounts, rebates, chargebacks, returns, and other
adjustments, all of which are based upon fixed percentages, except chargebacks, which are estimated by Teva and subject to a true-up reconciliation.
As of February 6, 2015, the Company was supplying Teva with Ditropan XL® 5,10 and 15 mg extended release tablets as the other products under the Teva
Agreement have either been returned to the Company, are being manufactured by Teva at its election, were voluntarily withdrawn from the market, have not yet been
approved by the FDA or the Company’s obligations to supply such product had expired or were terminated in accordance with the agreement.
The following tables show the additions to and deductions from the deferred revenue under the Teva Agreement:
(in $000’s)
Deferred revenue
Beginning balance
Less amounts recognized
Ending deferred revenue
For the Years Ended December 31,
2014
2013
2012
$
$
1,087 $
(1,087)
--- $
F-35
2,396 $
(1,309)
1,087 $
3,705
(1,309)
2,396
12. ALLIANCE AND COLLABORATION AGREEMENTS (continued)
OTC Partner Alliance Agreement
In June 2002, the Company entered into a Development, License and Supply Agreement with Pfizer, Inc., formerly Wyeth LLC (“Pfizer”), for a term of
approximately 15 years, relating to the Company’s Loratadine and Pseudoephedrine Sulfate 5 mg/120 mg 12-hour Extended Release Tablets and Loratadine and
Pseudoephedrine Sulfate 10 mg/240 mg 24-hour Extended Release Tablets for the OTC market. The Company previously developed the products, and is currently only
responsible for manufacturing the products, and Pfizer is responsible for marketing and sale. The agreement included payments to the Company upon achievement of
development milestones, as well as royalties paid to the Company by Pfizer on its sales of the product. Pfizer launched this product in May 2003 as Alavert® D-12
Hour. In February 2005, the agreement was partially cancelled with respect to the 24-hour Extended Release Product due to lower than planned sales volume. In
December 2011, Pfizer and the Company entered into an agreement with L. Perrigo Company (“Perrigo”) whereby the parties agreed that the Company would supply
the Company’s generic Claritin-D® 5 mg/120 mg 12-hour extended release product tablets to Perrigo in the United States and its territories. The agreements with Pfizer
and Perrigo are no longer a core area of the Company’s business, and the over-the-counter pharmaceutical products the Company sells to Pfizer and Perrigo under the
agreements are older products which are only sold to Pfizer and Perrigo. As noted above, the Company is currently only required to manufacture the products under
its agreements with Pfizer and Perrigo. The Company recognizes profit share revenue in the period earned.
Agreements with Valeant Pharmaceuticals International, Inc.
In November 2008, the Company and Valeant Pharmaceuticals International, Inc., formerly Medicis Pharmaceutical Corporation (“Valeant”), entered into a Joint
Development Agreement and a License and Settlement Agreement (“Joint Development Agreement”).
Joint Development Agreement
The Joint Development Agreement provides for the Company and Valeant to collaborate in the development of a total of five dermatology products, including
four of the Company’s generic products and one branded advanced form of Valeant’s SOLODYN® product. Under the provisions of the Joint Development Agreement
the Company received a $40,000,000 upfront payment, paid by Valeant in December 2008. The Company has also received an aggregate of $15,000,000 in milestone
payments composed of two $5,000,000 milestone payments, paid by Valeant in March 2009 and September 2009, a $2,000,000 milestone payment paid by Valeant in
December 2009, and a $3,000,000 milestone payment paid by Valeant in March 2011. The Company has the potential to receive up to an additional $8,000,000 of
contingent regulatory milestone payments each of which the Company believes to be substantive, as well as the potential to receive royalty payments from sales, if
any, by Valeant of its advanced form SOLODYN® brand product. Finally, to the extent the Company commercializes any of its four generic dermatology products
covered by the Joint Development Agreement, the Company will pay to Valeant a gross profit share on sales of such products. The Company began selling one of the
four generic dermatology products during the year ended December 31, 2011.
The Joint Development Agreement results in three items of revenue for the Company, as follows:
1. Research & Development Services
Revenue received from the provision of research and development services including the $40,000,000 upfront payment and the $12,000,000 of milestone
payments received prior to January 1, 2011, have been deferred and are being recognized on a straight-line basis over the expected period of performance of the
research and development services. During the three month period ended March 31, 2013, the Company extended the revenue recognition period for the Joint
Development Agreement from the previous recognition period ending in November 2013 to December 2014, due to changes in the estimated timing of completion of
certain research and development activities. This change was made on a prospective basis, and resulted in a reduced periodic amount of revenue recognized in current
and future periods. Revenue from the remaining $8,000,000 of contingent milestone payments, including the $3,000,000 received from Valeant in March 2011, will be
recognized using the Milestone Method of accounting. Deferred revenue is recorded as a liability captioned “Deferred revenue.” Revenue recognized under the Joint
Development Agreement is included in “Note 20 - Supplementary Financial Information”, in the line item captioned “Other Revenues”. The Company determined the
straight-line method better aligns revenue recognition with performance as the level of research and development services delivered under the Joint Development
Agreement are expected to be provided on a relatively constant basis over the period of performance.
F-36
12. ALLIANCE AND COLLABORATION AGREEMENTS (continued)
2. Royalty Fees Earned — Valeant’s Sale of Advanced Form SOLODYN® (Brand) Product
Under the Joint Development Agreement, the Company granted Valeant a license for the advanced form of the SOLODYN® product, with the Company
receiving royalty fee income under such license for a period ending eight years after the first commercial sale of the advanced form SOLODYN® product. Commercial
sales of the new SOLODYN® product, if any, are expected to commence upon FDA approval of Valeant’s NDA. The royalty fee income, if any, from the new
SOLODYN® product, will be recognized by the Company as current period revenue when earned.
3. Accounting for Sales of the Company’s Four Generic Dermatology Products
Upon FDA approval of the Company’s ANDA for each of the four generic products covered by the Joint Development Agreement, the Company will have the
right (but not the obligation) to begin manufacture and sale of its four generic dermatology products. The Company sells its manufactured generic products to all
Global Division customers in the ordinary course of business through its Global Product sales channel. The Company accounts for the sale, if any, of the generic
products covered by the Joint Development Agreement as current period revenue according to the Company’s revenue recognition policy applicable to its Global
products. To the extent the Company sells any of the four generic dermatology products covered by the Joint Development Agreement, the Company pays Valeant a
gross profit share, with such profit share payments accounted for as a current period cost of goods sold.
The following table shows the additions to and deductions from deferred revenue under the Joint Development Agreement with Valeant:
(in $000’s)
Deferred revenue
Beginning balance
Less amount recognized
Ending deferred revenue
2014
Years Ended December 31,
2013
2012
$
$
1,825 $
(1,825)
--- $
F-37
3,650 $
(1,825)
1,825 $
12,410
(8,760)
3,650
12. ALLIANCE AND COLLABORATION AGREEMENTS (continued)
Development and Co-Promotion Agreement with Endo Pharmaceuticals Inc.
In June 2010, the Company and Endo Pharmaceuticals, Inc. ("Endo") entered into a Development and Co-Promotion Agreement (“Endo Agreement”) under
which the Company and Endo have agreed to collaborate in the development and commercialization of a next-generation advanced form of the Company’s lead
branded product candidate ("Endo Agreement Product"). Under the provisions of the Endo Agreement, in June 2010, Endo paid to the Company a $10,000,000 upfront
payment. The Company has the potential to receive up to an additional $30,000,000 of contingent milestone payments which includes $15,000,000 contingent upon the
achievement of clinical events, $5,000,000 contingent upon the achievement of regulatory events, and $10,000,000 upon the achievement of commercialization events.
The Company believes all milestones under the Endo Agreement are substantive. Upon commercialization of the Endo Agreement Product in the United States, Endo
will have the right to co-promote such product to non-neurologists, which will require the Company to pay Endo a co-promotion service fee of up to 100% of the gross
profits attributable to prescriptions for the Endo Agreement Product which are written by the non-neurologists.
The Company is recognizing the $10,000,000 upfront payment as revenue on a straight-line basis over a period of 112 months, which is the estimated expected
period of performance of research and development activities under the Endo Agreement, commencing with the June 2010 effective date of the Endo Agreement and
ending in September 2019, the estimated date of FDA approval of the Company's NDA. The FDA approval of the Endo Agreement Product NDA represents the end of
the Company’s expected period of performance, as the Company will have no further contractual obligation to perform research and development activities under the
Endo Agreement, and therefore the earnings process will be completed. Deferred revenue is recorded as a liability captioned “Deferred revenue” on the consolidated
balance sheet and deferred revenue under the Endo Agreement was $4,310,000 as of December 31, 2014. Revenue recognized under the Endo Agreement is reported on
the consolidated statement of operations, in the line item captioned Research Partner. The Company determined the straight-line method aligns revenue recognition
with performance as the level of research and development activities performed under the Endo Agreement are expected to be performed on a ratable basis over the
Company’s estimated expected period of performance. Upon FDA approval of the Company’s Endo Agreement Product NDA, the Company will have the right (but not
the obligation) to begin manufacture and sale of such product. The Company will sell its manufactured branded product to customers in the ordinary course of
business through its Impax Pharmaceuticals Division. The Company will account for any sale of the product covered by the Endo Agreement as current period
revenue. The co-promotion service fee paid to Endo, as described above, if any, will be accounted for as a current period selling expense as incurred.
The Company and Endo also entered into a Settlement and License Agreement in June 2010 (the “Endo Settlement Agreement”) pursuant to which Endo
agreed to make a payment to the Company should prescription sales of Opana® ER (as defined in the Endo Settlement Agreement) fall below a predetermined
contractual threshold in the quarter immediately prior to the Company launching a generic version of Opana® ER. As a result of the Company’s launch of its generic
version of Opana ER in January 2013 and Endo’s prescription sales of Opana ER during the fourth quarter of 2012, the Company recorded a $102,049,000 settlement
gain during the three month period ended March 31, 2013, which is included in “Other Income” in the consolidated statement of operations. Payment of the
$102,049,000 settlement was received from Endo in April 2013.
F-38
12. ALLIANCE AND COLLABORATION AGREEMENTS (continued)
License, Development and Commercialization Agreement with Glaxo Group Limited
In December 2010, the Company entered into a License, Development and Commercialization Agreement with Glaxo Group Limited (“GSK”). Under the terms
of the agreement with GSK, GSK received an exclusive license to develop and commercialize IPX066 (brand name RYTARY™ in the United States) throughout the
world, except in the United States and Taiwan, and certain follow-on products at the option of GSK. Under the terms of the agreement, GSK paid an $11,500,000 upfront
payment in December 2010, and the Company had the potential to receive up to $169,000,000 of contingent milestone payments. The upfront payment was recognized
as revenue on a straight-line basis over the Company’s expected period of performance to provide research and development services which ended on December 31,
2012. In April 2013, the Company and GSK announced that they were terminating their collaboration for the development and commercialization of IPX066 outside the
United States and Taiwan as a result of delays in the anticipated regulatory approval and launch dates in countries in which GSK had rights to commercialize the
product and terminated the License, Development and Commercialization Agreement. At the end of July 2013, GSK’s rights to develop and commercialize IPX066
outside the United States and Taiwan were transferred back to the Company.
Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited
In January 2012, the Company entered into the AZ Agreement with AstraZeneca. Under the terms of the AZ Agreement, AstraZeneca granted to the
Company an exclusive license to commercialize the tablet, orally disintegrating tablet and nasal spray formulations of Zomig® (zolmitriptan) products for the treatment
of migraine headaches in the United States and in certain U.S. territories, except during an initial transition period when AstraZeneca fulfilled all orders of Zomig®
products on the Company’s behalf and AstraZeneca paid to the Company the gross profit on such Zomig® products. The Company is obligated to fulfill certain
minimum requirements with respect to the promotion of currently approved Zomig® products as well as other dosage strengths of such products approved by the
FDA in the future. The Company may, but has no obligation to, develop and commercialize additional products containing zolmitriptan and additional indications for
Zomig®, subject to certain restrictions as set forth in the AZ Agreement. The Company will be responsible for conducting clinical studies and preparing regulatory
filings related to the development of any such additional products and would bear all related costs. During the term of the AZ Agreement, AstraZeneca will continue
to be the holder of the NDA for existing Zomig® products, as well as any future dosage strengths thereof approved by the FDA, and will be responsible for certain
regulatory and quality-related activities for such Zomig® products. AstraZeneca will manufacture and supply Zomig® products to the Company and the Company will
purchase its requirements of Zomig® products from AstraZeneca until a date determined in the AZ Agreement. Thereafter, AstraZeneca may terminate its supply
obligations upon certain advance notice to the Company, in which case the Company would have the right to manufacture or have manufactured its own requirements
for the applicable Zomig® product.
Under the terms of the AZ Agreement, AstraZeneca was required to make payments to the Company representing 100% of the gross profit on sales of
AstraZeneca-labeled Zomig® products during the specified transition period. The Company received transition payments from AstraZeneca aggregating $43,564,000
during 2012. The Company accounted for these payments as a reduction of the related receivable that was recorded in the initial purchase price allocation. The
Company allocated $45,096,000 to an intangible asset, and the remaining $41,340,000 to prepaid royalty expense related to sales of Impax-labeled Zomig® products
during 2012, with such royalty expense included in cost of revenues on the consolidated statement of operations. Beginning in January 2013, the Company was
obligated to pay AstraZeneca tiered royalties on net sales of branded Zomig® products, depending on brand exclusivity and subject to customary reductions and
other terms and conditions set forth in the AZ Agreement. The Company is also obligated to pay AstraZeneca royalties after a certain specified date based on gross
profit from sales of authorized generic versions of the Zomig® products subject to certain terms and conditions set forth in the AZ Agreement. In May 2013, the
Company’s exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and the Company launched authorized generic versions of those
products in the United States.
F-39
12. ALLIANCE AND COLLABORATION AGREEMENTS (continued)
Co-Promotion Agreement with Pfizer
In March 2010, the Company and Pfizer, Inc. (“Pfizer”) entered into the First Amendment to the Co-Promotion Agreement (originally entered into with Wyeth
LLC, now a wholly owned subsidiary of Pfizer) ("Pfizer Co-Promotion Agreement"). The Company’s obligation to provide physician detailing sales calls under the
Pfizer Co-Promotion Agreement ended on June 30, 2012. Prior to such time, the Company had received a fixed fee, effective January 1, 2010, for providing such
physician detailing sales calls within a contractually defined range of an aggregate number of physician detailing sales calls rendered, determined on a quarterly basis.
The Company recognized the physician detailing sales force fee revenue as the related services were performed and the performance obligations were met. The
Company recognized $7,070,000 in the year ended December 31, 2012, which is included in the line item “Other Revenues” in “Note 20 - Supplementary Financial
Information.”
Agreement with DURECT Corporation
During the three month period ended March 31, 2014, the Company entered into an agreement with DURECT Corporation (“Durect”) granting the Company
the exclusive worldwide rights to develop and commercialize DURECT’s investigational transdermal bupivacaine patch for the treatment of pain associated with post-
herpetic neuralgia, referred to by the Company as IPX239. The Company paid Durect a $2,000,000 up-front payment upon signing of the agreement which was
recognized immediately as research and development expense. The Company has the potential to pay up to $61,000,000 in additional contingent milestone payments
upon the achievement of predefined development and commercialization milestones. If IPX239 is commercialized, Durect would also receive a tiered royalty on product
sales.
F-40
13. EMPLOYEE BENEFIT PLANS
401(k) Defined Contribution Plan
The Company sponsors a 401(k) defined contribution plan covering all employees. Participants are permitted to contribute up to 25% of their eligible annual
pre-tax compensation up to established federal limits on aggregate participant contributions. The Company matches 50% of the employee contributions up to a
maximum of 6% of employee compensation. Effective January 1, 2015, the Company updated its 401(k) policy and will match 100% of the employee contributions up to
a maximum of 5% of employee compensation. Discretionary profit-sharing contributions made by the Company, if any, are determined annually by the Board of
Directors. Participants are 100% vested in discretionary profit-sharing and matching contributions made by the Company after three years of service, and are 25% and
50% vested after one and two years of service, respectively. There were $1,615,000, $1,501,000 and $1,428,000 in matching contributions and no discretionary profit-
sharing contributions made under this plan for the years ended December 31, 2014, 2013 and 2012, respectively.
Employee Stock Purchase Plan
In February 2001, the Board of Directors of the Company approved the 2001 Non-Qualified Employee Stock Purchase Plan (“ESPP”), with a 500,000 share
reservation. The purpose of the ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common
stock of the Company. The ESPP provides the opportunity to purchase the Company’s common stock at a 15% discount to the market price through payroll deductions
or lump sum cash investments. Under the ESPP plan, for the years ended December 31, 2014, 2013 and 2012, the Company sold shares of its common stock to its
employees in the amount of 35,350, 39,748 and 44,731, respectively, for net proceeds of $788,000, $660,000 and $829,000, respectively.
Deferred Compensation Plan
In February 2002, the Board of Directors of the Company approved the Executive Non-Qualified Deferred Compensation Plan (“ENQDCP”) effective August
15, 2002 covering executive level employees of the Company as designated by the Board of Directors. Participants can defer up to 75% of their base salary and
quarterly sales bonus and up to 100% of their annual performance based bonus. The Company matches 50% of employee deferrals up to 10% of base salary and bonus
compensation. The maximum total match by the company cannot exceed 5% of total base and bonus compensation. Participants are vested in the employer match
contribution at 20% each year, with 100% vesting after five years of employment. Participants can earn a return on their deferred compensation based on hypothetical
investments in investment funds. Changes in the market value of the participant deferrals and earnings thereon are reflected as an adjustment to the liability for
deferred compensation with an offset to compensation expense. There were $850,000, $764,000 and $717,000 in matching contributions under the ENQDCP for the years
ended December 31, 2014, 2013 and 2012, respectively.
The deferred compensation liability is a non-current liability recorded at the value of the amount owed to the ENQDCP participants, with changes in the value
of such amounts recognized as a compensation expense in the consolidated statement of operations. The calculation of the deferred compensation obligation is
derived from observable market data by reference to hypothetical investments selected by the participants and is included in the line item captioned “Other liabilities”
on the consolidated balance sheet. The Company invests in corporate owned life insurance (“COLI”) policies, of which the cash surrender value is included in the line
item captioned “Other assets” on the consolidated balance sheet. As of December 31, 2014 and 2013, the Company had a cash surrender value asset of $29,241,000 and
$25,025,000, respectively, and a deferred compensation liability of $25,837,000 and $23,940,000, respectively, which approximated fair value. The asset representing the
cash surrender value of the corporate owned life insurance and the deferred compensation liability are both Level 2 fair value measurements.
F-41
14. SHARE-BASED COMPENSATION
The Company recognizes the grant date fair value of each option and restricted share over its vesting period. Options and restricted shares granted under the
Company’s Second Amended and Restated 2002 Equity Incentive Plan (“2002 Plan”) generally vest over a three or four year period and options have a term of ten
years.
Impax Laboratories, Inc. 1999 Equity Incentive Plan
In October 2000, the Company’s stockholders approved an increase in the aggregate number of shares of common stock to be issued pursuant to the
Company’s 1999 Equity Incentive Plan from 2,400,000 to 5,000,000 shares. Under the 1999 Equity Incentive Plan, 35,813, 50,312 and 115,785 stock options were
outstanding at December 31, 2014, 2013 and 2012, respectively.
Impax Laboratories, Inc. Amended and Restated 2002 Equity Incentive Plan
Under the Company’s 2002 Plan, the aggregate number of shares of common stock for issuance pursuant to stock option grants and restricted stock awards
was increased by the Company’s Board of Directors from 11,800,000 to 14,950,000 shares during 2013 and was approved by the Company’s stockholders. Under the
2002 Plan, stock options outstanding were 3,006,367, 3,720,593 and 4,061,436 at December 31, 2014, 2013 and 2012, respectively, and unvested restricted stock awards
outstanding were 2,327,176, 2,123,835 and 1,954,570 at December 31, 2014, 2013 and 2012, respectively.
The stock option activity for all of the Company’s equity compensation plans noted above is summarized as follows:
Stock Options
Outstanding at December 31, 2011
Options granted
Options exercised
Options forfeited
Outstanding at December 31, 2012
Options granted
Options exercised
Options forfeited
Outstanding at December 31, 2013
Options granted
Options exercised
Options forfeited
Outstanding at December 31, 2014
Options exercisable at December 31, 2014
Number of Shares
Under Option
Weighted-
Average
Exercise
Price
per Share
5,073,097
278,500
(1,060,746)
(113,630)
4,177,221
506,000
(814,177)
(98,139)
3,770,905
386,600
(778,112)
(337,213)
3,042,180
2,458,207 $
11.76
20.90
11.16
16.69
12.72
18.06
9.28
19.51
14.01
25.27
13.76
20.48
14.78
12.89
F-42
14. SHARE-BASED COMPENSATION (continued)
As of December 31, 2014, stock options outstanding and exercisable had average remaining contractual lives of 6.41 years and 5.45 years, respectively. Also,
as of December 31, 2014, stock options outstanding and exercisable each had aggregate intrinsic values of $52,022,000 and $46,194,000, respectively and restricted
stock awards outstanding had an aggregate intrinsic value of $73,724,936. As of December 31, 2014, the Company estimated 2,693,221 stock options and 2,060,233
restricted shares granted to employees which were vested or expected to vest.
The Company grants restricted stock to certain eligible employees as a component of its long-term incentive compensation program. The restricted stock
award grants are made in accordance with the Company’s 2002 Plan. A summary of the non-vested restricted stock awards is as follows:
Restricted Stock Awards
Non-vested at December 31, 2011
Granted
Vested
Forfeited
Non-vested at December 31, 2012
Granted
Vested
Forfeited
Non-vested at December 31, 2013
Granted
Vested
Forfeited
Non-vested at December 31, 2014
Non-Vested
Restricted
Stock
Awards
Weighted-
Average
Grant Date
Fair Value
1,663,911
1,015,937
(585,392)
(139,886)
1,954,570
1,032,924
(617,302)
(246,357)
2,123,835
1,449,585
(796,966)
(449,278)
2,327,176 $
17.20
23.41
14.72
19.08
20.97
19.92
18.80
20.69
21.13
25.35
21.36
21.47
23.61
Included in the 796,966 shares of restricted stock vested during the year ended December 31, 2014 are 284,842 shares with a weighted average fair value of
$27.47 per share that were withheld for minimum withholding tax purposes upon vesting of such awards from stockholders who elected to net share settle such tax
withholding obligation.
As of December 31, 2014, the Company had 2,711,649 shares available for issuance of either stock options or restricted stock awards, including 2,298,203
shares from the 2002 Plan, 296,921 shares from the 1999 Plan, and 116,525 shares from the ESPP Plan.
As of December 31, 2014, the Company had total unrecognized share-based compensation expense, net of estimated forfeitures, of $49,628,000 related to all of
its share-based awards, which will be recognized over a weighted average period of 2.11 years. The intrinsic value of options exercised during the years ended
December 31, 2014, 2013 and 2012 was $10,423,000, $8,780,000 and $12,380,000, respectively. The total fair value of restricted shares which vested during the years
ended December 31, 2014, 2013 and 2012 was $16,959,000, $11,604,000 and $8,614,000, respectively.
The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model with the following
assumptions:
Volatility (range)
Volatility (weighted average)
Risk-free interest rate (range)
Risk-free interest rate (weighted average)
Dividend yield
Expected life (years)
Weighted average grant date fair value
2014
For the Years Ended December 31,
2013
2012
40.1%-41.7%
40.2%
0.6%-1.9%
1.8%
0%
6.07
10.45
$
41.7%
41.7%
1.1%-1.9%
1.2%
0%
6.19
7.54
$
48.5%-49.3%
49.1%
0.9%-1.0%
1.0%
0%
6.19
9.93
$
F-43
14. SHARE-BASED COMPENSATION (continued)
The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model, wherein expected volatility
is based on historical volatility of the Company’s common stock. The expected term calculation is based on the “simplified” method described in SAB No. 107, Share-
Based Payment and SAB No. 110, Share-Based Payment, as the result of the simplified method provides a reasonable estimate in comparison to actual experience. The
risk-free interest rate is based on the U.S. Treasury yield at the date of grant for an instrument with a maturity that is commensurate with the expected term of the stock
options. The dividend yield of zero is based on the fact that the Company has never paid cash dividends on its common stock, and has no present intention to pay
cash dividends. Options granted under each of the above plans generally vest from three to four years and have a term of ten years.
The amount of share-based compensation expense recognized by the Company is as follows:
(in $000’s)
Cost of revenues
Research and development
Selling, general and administrative
Total
2014
For the Years Ended December 31,
2013
2012
$
$
2,494 $
5,072
13,317
20,883 $
2,035 $
4,885
10,724
17,644 $
2,405
4,658
9,240
16,303
In June 2013, the Company announced that Dr. Larry Hsu planned to retire as President and Chief Executive Officer of Impax and in April 2014, Dr. Hsu retired
from those positions at Impax. Pursuant to his Separation Agreement, all option grants and restricted stock grants expected to vest in the 12 month period following
his retirement date were accelerated and vested as of the retirement date. As a result, during the three month period ended June 30, 2013, the Company recorded $2.3
million of accelerated expense related to Dr. Hsu’s outstanding stock options and restricted stock.
On April 21, 2014, the board of directors of the Company announced that it had appointed Fred Wilkinson as the Company’s new President and Chief
Executive Officer effective as of April 29, 2014. In accordance with Mr. Wilkinson’s employment agreement, the Company granted 150,000 shares of the Company’s
restricted stock with a grant date fair value of $3.9 million, which will vest as to one-third of the underlying shares on each of the first three six-month anniversaries of
April 29, 2014, subject to Mr. Wilkinson’s continued employment with the Company on such vesting date. Further, Mr. Wilkinson also received an award of 375,000
shares of restricted stock that will vest in three tranches based upon continued service by Mr. Wilkinson to the Company and the achievement of certain performance
criteria as set forth in his employment agreement. The Company valued these restricted stock awards using a Monte Carlo simulation and is recognizing the $7.6 million
value of these awards over the longer of the derived or explicit service period, which is two years.
On October 22, 2014, the Company announced that Carole S. Ben-Maimon, M.D., President of the Company’s Global Pharmaceuticals Division, informed the
Company of her decision to retire from her position effective November 3, 2014. Pursuant to her Separation Agreement, all option grants and restricted stock grants
expected to vest in the 12 month period following her retirement date were accelerated and vested as of the retirement date. As a result, during the three month period
ended December 31, 2014, the Company recorded $0.5 million of accelerated expense related to Dr. Ben-Maimon’s outstanding stock options and restricted stock.
The after tax impact of recognizing the share-based compensation expense related to FASB ASC Topic 718 on basic earnings per common share was $0.20,
$0.19 and $0.18 for the years ended December 31, 2014, 2013 and 2012, respectively, and diluted earnings per common share was $0.20, $0.19 and $0.17 for the years
ended December 31, 2014, 2013 and 2012, respectively. The Company recognized a deferred tax benefit of $6,880,000, $4,829,000 and $4,335,000 in 2014, 2013 and 2012,
respectively, related to share-based compensation expense recorded for non-qualified employee stock options and restricted stock awards.
The Company’s policy is to issue new shares to satisfy stock option exercises and to grant restricted share awards. There were no modifications, other than
discussed above, to any stock options during the years ended December 31, 2014, 2013 or 2012.
F-44
15. STOCKHOLDERS’ EQUITY
Preferred Stock
Pursuant to its certificate of incorporation, the Company is authorized to issue 2,000,000 shares, $0.01 par value per share, “blank check” preferred stock,
which enables the Board of Directors of the Company, from time to time, to create one or more new series of preferred stock. Each series of preferred stock issued can
have the rights, preferences, privileges and restrictions designated by the Company’s Board of Directors. The issuance of any new series of preferred stock could
affect, among other things, the dividend, voting, and liquidation rights of the Company’s common stock. During the years ended December 31, 2014, 2013 and 2012, the
Company did not issue any preferred stock.
Common Stock
The Company’s Certificate of Incorporation, as amended, authorizes the Company to issue 90,000,000 shares of common stock with $0.01 par value.
F-45
16. EARNINGS PER SHARE
Basic earnings per common share is computed by dividing net earnings by the weighted average common shares outstanding for the period. Diluted earnings
per common share is computed by dividing net income by the weighted average common shares outstanding adjusted for the dilutive effect of stock options, restricted
stock awards, stock purchase warrants and convertible debt, excluding anti-dilutive shares.
A reconciliation of basic and diluted earnings per share is as follows:
(in $000’s, except share and per share amounts)
Numerator:
Net income
Denominator:
Weighted average common shares outstanding
Effect of dilutive stock options and and restricted stock
Diluted weighted average common shares outstanding
Basic net income per share
Diluted net income per share
2014
For the Years Ended December 31,
2013
2012
$
57,353 $
101,259 $
55,873
68,185,552
2,344,797
70,530,349
0.84 $
0.81 $
66,921,181
1,733,857
68,655,038
1.51 $
1.47 $
65,660,271
2,744,280
68,404,551
0.85
0.82
$
$
For the years ended December 31, 2014, 2013 and 2012, the Company excluded 946,288, 1,741,110 and 905,899, respectively, of stock options from the
computation of diluted net income per common share as the effect of these options would have been anti-dilutive.
F-46
17. SEGMENT INFORMATION
The Company has two reportable segments, the Global Division and the Impax Division. The Global Division develops, manufactures, sells, and distributes
generic pharmaceutical products, primarily through the following sales channels: the Global Products sales channel for sales of generic prescription products directly
to wholesalers, large retail drug chains, and others; the Private Label Product sales channel for generic over-the-counter and prescription products sold to unrelated
third-party customers who, in turn, sell the products under their own label; the Rx Partner sales channel for generic prescription products sold through unrelated third-
party pharmaceutical entities under their own label pursuant to alliance agreements; and the OTC Partner sales channel for over-the-counter products sold through
unrelated third-party pharmaceutical entities under their own labels pursuant to alliance and supply agreements. Revenues from the “Global Products” sales channel
and the “Private Label” sales channel are reported under the caption “Global Product sales, net” in “Note 20 – Supplementary Financial Information.” The Company
also generates revenue in its Global Division from research and development services provided under a joint development agreement with another unrelated third-
party pharmaceutical company, and reports such revenue under the caption “Other Revenues” in “Note 20 – Supplementary Financial Information.” Revenues from the
“OTC Partner” sales channel are also reported under the caption “Other Revenues” in “Note 20 – Supplementary Financial Information.”
The Impax Division is engaged in the development of proprietary brand pharmaceutical products that the Company believes represent improvements to
already-approved pharmaceutical products addressing CNS disorders. The Impax Division currently has one internally developed branded pharmaceutical product,
RYTARY™, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and
parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the FDA on January 7, 2015. The Company has
also filed the required documents for a Market Authorization Application to the European Medicines Agency (EMA) for IPX066 on November 5, 2014 and the filing
was accepted by the EMA on November 26, 2014. The Company is also seeking to identify a licensing partner for the development and commercialization of IPX066 in
countries outside of the U.S. The Impax Division is also engaged in the sale and distribution of branded Zomig® (zolmitriptan) products, indicated for the treatment of
migraine headaches, under the terms of the AZ Agreement with AstraZeneca in the United States and in certain U.S. territories. Revenues from Impax-labeled branded
Zomig® products are reported under the caption “Impax Product sales, net” in “Note 20 – Supplementary Financial Information.” The Impax Division also has a
number of product candidates that are in varying stages of development. Finally, the Company generates revenue in the Impax Division from research and
development services provided under a development and license agreement with another unrelated third-party pharmaceutical company, and reports such revenue
under the caption “Other Revenues” in “Note 20 – Supplementary Financial Information.”
The Company’s chief operating decision maker evaluates the financial performance of the Company’s segments based upon segment income (loss) before
income taxes. Items below income (loss) from operations are not reported by segment, since they are excluded from the measure of segment profitability reviewed by
the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-
operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment since it is not reviewed by
the Company’s chief operating decision maker. The accounting policies for the Company’s segments are the same as those described above in "Note 2 - Summary of
Significant Accounting Policies – Revenue Recognition.” The Company has no inter-segment revenue.
F-47
17. SEGMENT INFORMATION (continued)
The tables below present segment information reconciled to total Company financial results, with segment operating income or loss including gross profit less
direct research and development expenses, and direct selling expenses as well as any litigation settlements, to the extent specifically identified by segment:
(in $000’s)
Year Ended December 31, 2014
Revenues, net
Cost of revenues
Research and development
Patent litigation
Selling, general and administrative
Income (loss) before income taxes
Year Ended December 31, 2013
Revenues, net
Cost of revenues
Research and development
Patent litigation
Selling, general and administrative
Income (loss) before income taxes
Year Ended December 31, 2012
Revenues, net
Cost of revenues
Research and development
Patent litigation
Selling, general and administrative
Income (loss) before income taxes
Global
Division
Impax
Division
Corporate
and Other
Total
Company
549,082 $
260,459
40,927
5,333
17,144
225,219 $
46,967 $
22,937
38,187
--
43,307
(57,464) $
-- $
--
--
--
78,939
(77,196) $
596,049
283,396
79,114
5,333
139,390
90,559
Global
Division
Impax
Division
Corporate
and Other
Total
Company
398,340 $
253,836
41,384
16,545
17,684
68,891 $
113,162 $
58,366
27,470
--
44,915
(17,589) $
-- $
--
--
--
57,689
95,638 $
511,502
312,202
68,854
16,545
120,288
146,940
Global
Division
Impax
Division
Corporate
and Other
Total
Company
448,682 $
229,355
48,604
9,772
15,377
145,574 $
133,010 $
69,783
32,716
--
37,896
(7,385) $
-- $
--
--
--
55,197
(54,878) $
581,692
299,138
81,320
9,772
108,470
83,311
$
$
$
$
$
$
Foreign Operations
The Company’s wholly-owned subsidiary, Impax Laboratories (Taiwan) Inc., has constructed a facility in Taiwan which is utilized for manufacturing, research
and development, warehouse, and administrative functions, with approximately $126,381,000 and $137,137,000 of net carrying value of assets, composed principally of
a building and equipment, included in the Company's consolidated balance sheet at December 31, 2014 and 2013, respectively.
F-48
18. COMMITMENTS AND CONTINGENCIES
Leases
The Company leases land, office, warehouse and laboratory facilities under non-cancelable operating leases expiring between June 2015 and January 2020.
Rent expense for the years ended December 31, 2014, 2013 and 2012 was $2,162,000, $1,932,000 and $1,719,000, respectively. The Company recognizes rent expense on a
straight-line basis over the lease period. The Company also leases certain equipment under various non-cancelable operating leases with various expiration dates
between June 2015 and August 2019. Future minimum lease payments under the non-cancelable operating leases are as follows:
(in $000s)
2015
2016
2017
2018
2019
Thereafter
Total minimum lease payments
Purchase Order Commitments
Years Ended
December 31,
2,348
1,580
990
848
803
2,584
9,153
$
As of December 31, 2014, the Company had approximately $42,627,000 of open purchase order commitments, primarily for raw materials. The terms of these
purchase order commitments are generally less than one year in duration.
Taiwan Facility
The Company has entered into several contracts related to ongoing expansion activities at its Taiwan manufacturing facility. As of December 31, 2014, the
Company had remaining obligations under these contracts of approximately $428,048.
F-49
19. LEGAL AND REGULATORY MATTERS
Patent Infringement Litigation
There is substantial litigation in the pharmaceutical, biological, and biotechnology industries with respect to the manufacture, use, and sale of new products
which are the subject of conflicting patent and intellectual property claims. One or more patents typically cover most of the brand name controlled release products for
which the Company is developing generic versions.
Under federal law, when a drug developer files an ANDA for a generic drug seeking approval before expiration of a patent, which has been listed with the FDA
as covering the brand name product, the developer must certify its product will not infringe the listed patent(s) and/or the listed patent is invalid or unenforceable
(commonly referred to as a “Paragraph IV” certification). Notices of such certification must be provided to the patent holder, who may file a suit for patent infringement
within 45 days of the patent holder’s receipt of such notice. If the patent holder files suit within the 45 day period, the FDA can review and approve the ANDA, but is
prevented from granting final marketing approval of the product until a final judgment in the action has been rendered in favor of the generic drug developer, or 30
months from the date the notice was received, whichever is sooner. Lawsuits have been filed against the Company in connection with the Company’s Paragraph IV
certifications seeking an order delaying the approval of the Company’s ANDA until expiration of the patent(s) at issue in the litigation.
Should a patent holder commence a lawsuit with respect to an alleged patent infringement by the Company, the uncertainties inherent in patent litigation make
the outcome of such litigation difficult to predict. The delay in obtaining FDA approval to market the Company’s product candidates as a result of litigation, as well as
the expense of such litigation, whether or not the Company is ultimately successful, could have a material adverse effect on the Company’s results of operations and
financial position. In addition, there can be no assurance that any patent litigation will be resolved prior to the end of the 30-month period. As a result, even if the FDA
were to approve a product upon expiration of the 30-month period, the Company may elect to not commence marketing the product if patent litigation is still pending.
The Company is generally responsible for all of the patent litigation fees and costs associated with current and future products not covered by its alliance
and collaboration agreements. The Company has agreed to share legal expenses with respect to third-party and Company products under the terms of certain of the
alliance and collaboration agreements. The Company records the costs of patent litigation as expense in the period when incurred for products it has developed, as
well as for products which are the subject of an alliance or collaboration agreement with a third-party.
Although the outcome and costs of the asserted and unasserted claims is difficult to predict, the Company does not expect the ultimate liability, if any, for
such matters to have a material adverse effect on its financial condition, results of operations, or cash flows.
Takeda Pharmaceutical Co., Ltd, et al. v. Impax Laboratories, Inc. (Dexlansoprazole)
In April 2011, Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals LLC, and Takeda Pharmaceuticals
America, Inc. (collectively, “Takeda”) filed suit against the Company in the U.S. District Court for the Northern District of California (the “District Court”) alleging
patent infringement based on the filing of the Company’s ANDA relating to Dexlansoprazole Delayed Release Capsules, 30 and 60 mg, generic to Dexilant
. The
Company filed an answer and counterclaims. The trial court issued a claim construction ruling on April 11, 2012. In November 2012, the Company and Takeda filed
cross motions for summary judgment regarding infringement and validity of the patents at issue. On April 8, 2013, the District Court ruled on the summary judgment
motions as follows: (i) granted the Company’s motion for non-infringement of U.S. Patent No. 7,790,755, (ii) granted Takeda’s motion of infringement of U.S. Patent
Nos. 6,664,276, 6,462,058 and 6,939,971 and (iii) denied the Company’s motion of invalidity for U.S. Patent No. 6,939,971. A bench trial was conducted beginning on
June 5, 2013, and a decision was rendered on October 17, 2013, finding the asserted claims of U.S. Patent Nos. 6,462,058, 6,664,276, and 6,939,971 infringed and not
invalid. The Company filed a notice of appeal of the District Court’s decision on the 6,462,058, 6,664,276, and 6,939,971 patents to the United States Court of Appeals
for the Federal Circuit, and Takeda filed a notice of appeal of the District Court decision on the 7,790,755 patent to the Federal Circuit.
®
F-50
In May 2013, Takeda filed another complaint against the Company in the District Court, alleging infringement of U.S. Patent No. 8,173,158 based on the filing of
the Company’s ANDA relating to Dexlansoprazole Delayed Release Capsules, 30 and 60 mg, generic to Dexilant®. Takeda filed an amended complaint in July 2013,
alleging infringement of another patent, U.S. Patent No. 8,461,187. The Company filed an answer and counterclaims. Following a hearing on claim construction on June
12, 2014, the Court issued a claim construction order on June 6, 2014. The parties agreed to settle the matters on October 14, 2014 and the District Court and Federal
Circuit cases have been dismissed.
Endo Pharmaceuticals Inc. and Grunenthal GmbH v. Impax Laboratories, Inc. and ThoRx Laboratories, Inc. (Oxymorphone hydrochloride); Endo
Pharmaceuticals Inc. and Grunenthal GmbH v. Impax Laboratories, Inc. (Oxymorphone hydrochloride)
In November 2012, Endo Pharmaceuticals, Inc. and Grunenthal GmbH (collectively, “Endo”) filed suit against ThoRx Laboratories, Inc., a wholly owned
subsidiary of the Company (“ThoRx”), and the Company in the U.S. District Court for the Southern District of New York alleging patent infringement based on the
filing of ThoRx’s ANDA relating to Oxymorphone hydrochloride, Extended Release tablets, 5, 7.5, 10, 15, 20, 30 and 40 mg, generic to Opana ER®. In January 2013,
Endo filed a separate suit against the Company in the U.S. District Court for the Southern District of New York alleging patent infringement based on the filing of the
Company’s ANDA relating to the same products. ThoRx and the Company filed an answer and counterclaims to the November 2012 suit and the Company filed an
answer and counterclaims with respect to the January 2013 suit. Discovery is proceeding. Trial is currently scheduled to begin in March 2015.
In November 2014, Endo Pharmaceuticals Inc. and Mallinckrodt LLC filed suit against the Company in the U.S. District Court for the District of Delaware making
additional allegations of patent infringement based on the filing of the Company’s Oxymorphone hydrochloride ANDA described above. Also in November 2014, Endo
and Mallinckrodt filed a separate suit in the U.S. District Court for the District of Delaware making additional allegations of patent infringement based on the filing of
the ThoRx Oxymorphone hydrochloride ANDA described above. ThoRx and the Company filed an answer and counterclaim to those suits in which they are named as
a defendant. The cases are currently pending.
Pfizer Inc. and UCB Pharma GMBH v. Impax Laboratories, Inc. (Fesoterodine)
In June 2013, Pfizer Inc. and UCB Pharma GMBH filed suit against the Company in the U.S. District Court for the District of Delaware alleging patent
infringement based on the filing of the Company’s ANDA relating to Fesoterodine Fumarate Extended-Release Tablets, 4 and 8 mg, generic to Toviaz®. The Company
filed its answer and counterclaims. On September 2, 2014, the District Court entered a stipulation of dismissal without prejudice as to both the complaint and the
counterclaims.
F-51
19. LEGAL AND REGULATORY MATTERS (continued)
Impax Laboratories Inc., et al. v. Lannett Holdings, Inc. and Lannett Company
In July 2014, the Company filed suit against Lannett Holdings, Inc. and Lannett Company (collectively, “Lannett”) in the United States District Court for the
District of Delaware, alleging patent infringement based on the filing of the Lannett’s ANDA relating to Zolmitriptan Nasal Spray, 5mg, generic to Zomig® Nasal Spray.
Lannett filed an answer and counterclaims alleging non-infringement and invalidity in September 2014, and the Company filed an answer to the counterclaims in
October 2014. Discovery is proceeding, and trial is set for September 6, 2016.
Other Litigation Related to the Company’s Business
Civil Investigative Demand from the FTC (Minocycline Hydrochloride)
®
On May 2, 2012, the Company received a Civil Investigative Demand (“CID”) from the United States Federal Trade Commission (“FTC”) concerning its
investigation into the drug SOLODYN and its generic equivalents. According to the FTC, the investigation relates to whether Medicis Pharmaceutical Corporation,
now a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (“Medicis”), the Company, and six other companies have engaged or are engaged in
unfair methods of competition in or affecting commerce by (i) entering into agreements regarding SOLODYN or its generic equivalents and/or (ii) engaging in other
conduct regarding the sale or marketing of SOLODYN or its generic equivalents. The Company is cooperating with the FTC in producing documents, information and
witnesses in response to the investigation. To the knowledge of the Company, no FTC proceedings have been initiated against the Company to date, however no
assurance can be given as to the timing or outcome of this investigation.
®
®
Solodyn® Antitrust Class Actions
From July 2013 to March 2014, 15 class action complaints were filed against manufacturers of the brand drug Solodyn® and its generic equivalents, including
the Company.
On July 22, 2013, Plaintiff United Food and Commercial Workers Local 1776 & Participating Employers Health and Welfare Fund, an indirect purchaser, filed a
class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
On July 23, 2013, Plaintiff Rochester Drug Co-Operative, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Eastern
District of Pennsylvania on behalf of itself and others similarly situated.
On August 1, 2013, Plaintiff International Union of Operating Engineers Local 132 Health and Welfare Fund, an indirect purchaser, filed a class action complaint
in the United States District Court for the Northern District of California on behalf of itself and others similarly situated. On August 29, 2013, this Plaintiff withdrew its
complaint from the United States District Court for the Northern District of California, and on August 30, 2013, re-filed the same complaint in the United States Court for
the Eastern District of Pennsylvania, on behalf of itself and others similarly situated.
On August 9, 2013, Plaintiff Local 274 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the
Eastern District of Pennsylvania on behalf of itself and others similarly situated.
F-52
19. LEGAL AND REGULATORY MATTERS (continued)
On August 12, 2013, Plaintiff Sheet Metal Workers Local No. 25 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States
District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
On August 27, 2013, Plaintiff Fraternal Order of Police, Fort Lauderdale Lodge 31, Insurance Trust Fund, an indirect purchaser, filed a class action complaint in
the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
On August 29, 2013, Plaintiff Heather Morgan, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of
Pennsylvania on behalf of itself and others similarly situated.
On August 30, 2013, Plaintiff Plumbers & Pipefitters Local 178 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States
District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
On September 9, 2013, Plaintiff Ahold USA, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the District of
Massachusetts on behalf of itself and others similarly situated.
On September 24, 2013, Plaintiff City of Providence, Rhode Island, an indirect purchaser, filed a class action complaint in the United States District Court for the
District of Arizona on behalf of itself and others similarly situated.
On October 2, 2013, Plaintiff International Union of Operating Engineers Stationary Engineers Local 39 Health & Welfare Trust Fund, an indirect purchaser, filed
a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
On October 7, 2013, Painters District Council No. 30 Health and Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District
Court for the District of Massachusetts on behalf of itself and others similarly situated.
On October 25, 2013, Plaintiff Man-U Service Contract Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the
Eastern District of Pennsylvania on behalf of itself and others similarly situated.
On March 13, 2014, Plaintiff Allied Services Division Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the
District of Massachusetts on behalf of itself and others similarly situated.
On March 19, 2014, Plaintiff NECA-IBEW Welfare Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the
District of Massachusetts on behalf of itself and others similarly situated.
On February 25, 2014, the United States Judicial Panel on Multidistrict Litigation ordered the pending actions transferred to the District of Massachusetts for
coordinated pretrial proceedings, as In Re Solodyn (Minocycline Hydrochloride) Antitrust Litigation.
The consolidated amended complaints allege that Medicis engaged in anticompetitive schemes by, among other things, filing frivolous patent litigation
lawsuits, submitting frivolous Citizen Petitions, and entering into anticompetitive settlement agreements with several generic manufacturers, including the Company, to
delay generic competition of Solodyn® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things, unspecified monetary damages and
equitable relief, including disgorgement and restitution.
Civil Investigative Demand from the FTC (Oxymorphone Hydrochloride)
On February 25, 2014, the Company received a CID from the FTC concerning its investigation into the drug Opana® ER and its generic equivalents. According
to the FTC, the investigation relates to whether Endo Pharmaceuticals, Inc. (“Endo”) and the Company have engaged or are engaged in unfair methods of competition
in or affecting commerce by (i) entering into agreements regarding Opana® ER or its generic equivalents and/or (ii) engaging in other conduct regarding the regulatory
filings, sale or marketing of Opana® ER or its generic equivalents. The Company is cooperating with the FTC in producing documents, information and witnesses in
response to the CID. To the knowledge of the Company, no proceedings by the FTC have been initiated against the Company at this time, however no assurance can
be given as to the timing or outcome of this investigation.
F-53
Opana ER® Antitrust Class Actions
From June 2014 to January 2015, eleven class action complaints were filed against the manufacturer of the brand drug Opana ER® and the Company.
On June 4, 2014, Plaintiff Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund, an indirect purchaser, filed a class action complaint in the United
States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
On June 4, 2014, Plaintiff Rochester Drug Co-Operative, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Eastern
District of Pennsylvania on behalf of itself and others similarly situated.
On June 6, 2014, Plaintiff Value Drug Company, a direct purchaser, filed a class action complaint in the United States District Court for the Northern District of
California on behalf of itself and others similarly situated. On June 26, 2014, this Plaintiff withdrew its complaint from the United States District Court for the Northern
District of California, and on July 16, 2014, re-filed the same complaint in the United States District Court for the Northern District of Illinois, on behalf of itself and
others similarly situated.
On June 19, 2014, Plaintiff Wisconsin Masons’ Health Care Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the
Northern District of Illinois on behalf of itself and others similarly situated.
On July 17, 2014, Plaintiff Massachusetts Bricklayers, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern
District of Pennsylvania on behalf of itself and others similarly situated.
On August 11, 2014, Plaintiff Pennsylvania Employees Benefit Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court
for the Northern District of Illinois on behalf of itself and others similarly situated.
On September 19, 2014, Plaintiff Meijer Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Northern District of
Illinois on behalf of itself and others similarly situated.
On October 3, 2014, Plaintiff International Union of Operating Engineers, Local 138 Welfare Fund, an indirect purchaser, filed a class action complaint in the
United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
On December 19, 2014, Plaintiff Kim Mahaffay, an indirect purchaser, filed a class action complaint in the Superior Court of the State of California, Alameda
County, on behalf of herself and others similarly situated. On January 27, 2015, the Defendants removed the action to the United States District Court for the Northern
District of California.
On January 12, 2015, Plaintiff Plumbers & Pipefitters Local 178 Health & Welfare Trust Fund, an indirect purchaser, filed a class action complaint in the United
States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
On December 12, 2014, the United States Judicial Panel on Multidistrict Litigation ordered the pending actions transferred to the Northern District of Illinois for
coordinated pretrial proceedings, as In Re Opana ER Antitrust Litigation.
In each case, the complaints allege that Endo engaged in an anticompetitive scheme by, among other things, entering into an anticompetitive settlement
agreement with the Company to delay generic competition of Opana ER® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things,
unspecified monetary damages and equitable relief, including disgorgement and restitution. Consolidated amended complaints have not yet been filed in the
consolidated proceeding.
F-54
19. LEGAL AND REGULATORY MATTERS (continued)
Civil Investigation Demand from the Attorney General of the State of Alaska
On February 10, 2015, the “Company received three CIDs from the Office of the Attorney General of the State of Alaska (“Alaska AG”) concerning its
investigations into the drugs Adderall XR , Effexor XR and Opana ER (each a “Product” and collectively, the “Products”) and their generic equivalents. According
to the Alaska AG, the investigation is to determine whether the Company may have violated Alaskan state law by entering into settlement agreements with the
respective brand name manufacturer for each of the foregoing Products that delayed generic entry of such Product into the marketplace. The Company intends to
cooperate with the Alaska AG in producing documents and information in response to the CIDs. To the knowledge of the Company, no proceedings have been
initiated against the Company at this time, however no assurance can be given as to the timing or outcome of this investigation.
®
®
®
Justice Department Subpoena to Company Sales Representative
On November 3, 2014, a sales representative of the Company received a subpoena from the Justice Department’s Antitrust Division requesting the production
of documents to and testimony before the grand jury of the Eastern District of Pennsylvania. The request relates to any communication or correspondence with any
competitor (or an employee of any competitor) in the sale of generic prescription medications.
Securities and Derivative Class Actions
On March 7, 2013 and April 8, 2013, two class action complaints were filed against the Company and certain current and former officers and directors of the
Company in the United States District Court for the Northern District of California by Denis Mulligan, individually and on behalf of others similarly situated, and
Haverhill Retirement System, individually and on behalf of others similarly situated, respectively (“Securities Class Actions”), alleging that the Company and those
named officers and directors violated the federal securities law by making materially false and misleading statements and/or failed to disclose material adverse facts to
the public in connection with manufacturing deficiencies at the Hayward, California manufacturing facility, including but not limited to the impact the deficiencies
would have on the Company’s ability to gain approval from the FDA for the Company’s branded product candidate, RYTARY™ and its generic version of Concerta®.
These two Securities Class Actions were subsequently consolidated, assigned to the same judge, and lead plaintiff has been chosen. The plaintiff’s consolidated
amended complaint was filed on September 13, 2013. The Company filed a motion to dismiss the consolidated amended complaint on November 14, 2013. On April 18,
2014, the Court denied the Company’s motion to dismiss. On September 22, 2014, the Company, together with certain current and former officers and directors of the
Company, agreed to settle this consolidated securities class action, without any admission or concession of wrongdoing or liability by the Company or the other
defendants. Pursuant to the settlement, the Company will pay $8.0 million for a full and complete release of all claims that were or could have been asserted against the
Company or other defendants in this action. On January 16, 2015, the Court granted preliminary approval of the settlement. The Company will not be taking any
charges for the settlement as the settlement amount will be paid for and covered by the Company's insurance policies. The settlement remains subject to final court
approval and certain other conditions and does not resolve the related shareholder derivative litigations discussed below.
On March 19, 2013, Virender Singh, derivatively on behalf of the Company, filed a state court action against certain current and former officers and directors for
breach of fiduciary duty and unjust enrichment in the Superior Court of the State of California County of Santa Clara, asserting similar allegations as those in the
Securities Class Actions. That action has been stayed pending resolution of the Securities Class Actions. On September 24, 2014, Nicholas Karant, derivatively on
behalf of the Company, filed an action against certain current and former officers and directors in the United District Court for the Northern District of California,
asserting similar allegations as those by Virender Singh. In addition, the Company is aware of two letters from stockholders demanding action by the Company’s board
of directors, including to: (i) undertake an independent internal investigation into management’s alleged violations of Delaware and/or federal law; (ii) commence a civil
action against members of management to recover damages sustained as a result of alleged breaches of fiduciary duties; and/or (iii) spearhead meaningful corporate
reform to address alleged internal control inadequacies. Each letter further states that if such action is not commenced within a reasonable period of time, the
stockholder will commence a stockholder’s derivative action on behalf of the Company.
F-55
On August 13, 2014, a class action complaint was filed against the Company and certain current and former officers and directors of the Company in the
United States District Court for the Northern District of California by Linus Aruliah, individually and on behalf of all others similarly situated. The complaint alleged
that the Company and those named officers and directors violated the federal securities laws by making materially false and misleading statements and/or failed to
disclose material adverse facts to the public in connection with manufacturing deficiencies at the Company’s Taiwan manufacturing facility, including but not limited to
the impact the deficiencies would have on the Company’s ability to gain approval from the FDA for the Company’s then branded product candidate, RYTARY™ (which
was subsequently approved by the FDA on January 7, 2015). On January 13, 2015, the Company, together with certain current and former officers and directors of the
Company, agreed to settle this securities class action, without any admission or concession of wrongdoing or liability by the Company or the other defendants.
Pursuant to the settlement, the Company will pay $4.75 million for a full and complete release of all claims that were or could have been asserted against the Company
or other defendants in this action. The Company will not be taking any charges for the settlement as the settlement amount will be paid for and covered by the
Company’s insurance policies. The settlement remains subject to preliminary and final court approval and certain other conditions and does not resolve the related
shareholder derivative litigations.
On September 22, 2014, Randall Wickey, derivatively on behalf of the Company, filed an action against certain current and former officers and directors of the
Company in the United States District for the Northern District of California, alleging breaches of fiduciary duty in connection with the Company’s response to various
FDA notices and warnings regarding problems in the manufacturing and quality control processes at the Company’s Hayward, California and Taiwan manufacturing
facilities.
On November 10, 2014, International Union of Operating Engineers Local 478, derivatively on behalf of the Company, filed an action against certain current
and former officers and directors of the Company in the United States District for the Northern District of California, asserting similar allegations as those by Randall
Wickey.
Attorney General of the State of Connecticut Interrogatories and Subpoena Duces Tecum
On July 14, 2014, the Company received a subpoena and interrogatories (the “Subpoena”) from the State of Connecticut Attorney General (“Connecticut
AG”) concerning its investigation into sales of the Company’s generic product, digoxin. According to the Connecticut AG, the investigation is to determine whether
anyone engaged in a contract, combination or conspiracy in restraint of trade or commerce which has the effect of (i) fixing, controlling or maintaining prices or (ii)
allocating or dividing customers or territories relating to the sale of digoxin in violation of Connecticut state antitrust law. The Company intends to cooperate with the
Connecticut AG in producing documents and information in response to the Subpoena. To the knowledge of the Company, no proceedings by the Connecticut AG
have been initiated against the Company at this time, however no assurance can be given as to the timing or outcome of this investigation.
F-56
20. SUPPLEMENTARY FINANCIAL INFORMATION (unaudited)
Selected financial information for the quarterly periods noted is as follows:
(in $000’s except shares and per share amounts)
Revenue:
Global Product sales, gross
Less:
Chargebacks
Rebates
Product returns
Other credits
Global Product sales, net
Rx Partner
Other Revenues
Global Division revenues, net
Impax Product sales, gross
Less:
Chargebacks
Rebates
Product returns
Other credits
Impax Product sales, net
Other Revenues
Impax Division revenues, net
Total net revenues
Gross profit
Net income
Net income per share (basic)
Net income per share (diluted)
Weighted average:
common shares outstanding:
Basic
Diluted
March 31
June 30
September 30 December 31
2014 Quarters Ended:
$
265,850 $
375,269 $
340,379 $
322,707
95,714
52,054
1,294
10,671
106,117
2,435
589
109,141
110,518
74,079
5,140
21,571
163,961
9,204
3,229
176,394
115,419
64,442
3,494
13,449
143,575
1,447
611
145,633
131,882
66,685
993
8,288
114,859
1,028
2,028
117,915
20,643
24,375
23,840
23,348
8,230
1,070
181
1,853
9,309
268
9,577
10,107
938
216
1,654
11,460
267
11,727
8,787
469
223
2,261
12,100
266
12,366
6,720
1,010
475
2,074
13,069
227
13,296
118,718
188,121
157,999
131,211
57,622
109,772
84,438
60,821
$
$
$
6,425 $
35,071 $
15,737 $
0.09 $
0.09 $
0.52 $
0.50 $
0.23 $
0.22 $
120
0.00
0.00
67,702,296
69,938,872
68,095,159
70,313,491
68,254,327
70,715,226
68,678,779
70,988,328
Quarterly computations of net income per share amounts are made independently for each quarterly reporting period, and the sum of the per share amounts
for the quarterly reporting periods may not equal the per share amounts for the year-to-date reporting period.
F-57
20. SUPPLEMENTARY FINANCIAL INFORMATION (unaudited) (continued)
Selected financial information for the quarterly periods noted is as follows:
(in $000’s except shares and per share amounts)
Revenue:
Global Product sales, gross
Less:
Chargebacks
Rebates
Product Returns
Other credits
Global Product sales, net
Rx Partner
Other Revenues
Global Division revenues, net
Impax Product sales, gross
Less:
Chargebacks
Rebates
Product Returns
Other credits
Impax Product sales, net
Other Revenues
Impax Division revenues, net
Total net revenues
Gross profit
Net income (loss)
Net income (loss) per share (basic)
Net income (loss) per share (diluted)
Weighted average:
common shares outstanding:
Basic
Diluted
March 31
June 30
September 30 December 31
2013 Quarters Ended:
$
197,956 $
217,721 $
279,441 $
288,315
64,345
30,572
94
5,160
97,785
3,114
737
101,636
82,013
35,649
1,989
8,312
89,758
3,668
539
93,965
98,449
54,530
2,857
11,919
111,686
3,016
1,046
115,748
111,903
68,363
1,989
21,639
84,423
1,841
727
86,991
69,292
48,300
22,849
21,244
7,790
6,236
1,490
7,255
46,521
332
46,853
10,095
(1,735)
2,197
2,409
35,334
332
35,666
8,422
(812)
175
(1,498)
16,562
331
16,893
6,690
485
224
361
13,484
266
13,750
148,489
129,631
132,641
100,741
57,871
58,887
48,342
34,200
105,442 $
5,619 $
(180) $
(9,622)
1.59 $
1.55 $
0.08 $
0.08 $
0.00 $
0.00 $
(0.14)
(0.14)
$
$
$
66,487,470
68,178,355
66,748,864
68,287,948
67,051,121
67,051,121
67,385,969
67,385,969
Quarterly computations of net income (loss) per share amounts are made independently for each quarterly reporting period, and the sum of the per share
amounts for the quarterly reporting periods may not equal the per share amounts for the year-to-date reporting period.
F-58
SCHEDULE II, VALUATION AND QUALIFYING ACCOUNTS
For the Year Ended December 31, 2012
(in $000’s)
Column A
Description
Column B
Balance at
Beginning of
Period
Column C
Column D
Charge to
Costs and
Expenses
Charge to
Other
Accounts
Deductions
Column E
Balance at
End of
Period
Reserve for bad debts
$
612
---
---
(59) $
553
For the Year Ended December 31, 2013
(in $000’s)
Column A
Description
Column B
Balance at
Beginning of
Period
Column C
Column D
Charge to
Costs and
Expenses
Charge to
Other
Accounts
Deductions
Column E
Balance at
End of
Period
Reserve for bad debts
$
553
---
---
(14) $
539
For the Year Ended December 31, 2014
(in $000’s)
Column A
Description
Column B
Balance at
Beginning of
Period
Column C
Column D
Charge to
Costs and
Expenses
Charge to
Other
Accounts
Deductions
Column E
Balance at
End of
Period
Reserve for bad debts
$
539
---
---
(24) $
515
S-1
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
SIGNATURES
IMPAX LABORATORIES, INC.
/s/ Fred Wilkinson
By:
Name:Fred Wilkinson
Title: President and Chief Executive Officer
Date: February 26, 2015
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.
Signature
/s/ Fred Wilkinson
Fred Wilkinson
/s/ Bryan M. Reasons
Bryan M. Reasons
/s/ Robert L. Burr
Robert L. Burr
/s/ Leslie Z. Benet, Ph.D.
Leslie Z. Benet, Ph.D.
/s/ Allen Chao, Ph.D.
Allen Chao, Ph.D.
/s/ Nigel Ten Fleming, Ph.D.
Nigel Ten Fleming, Ph.D.
/s/ Larry Hsu, Ph.D.
Larry Hsu, Ph.D.
/s/ Michael Markbreiter
Michael Markbreiter
/s/ Peter R. Terreri
Peter R. Terreri
/s/ Mary K. Pendergast
Mary K. Pendergast
Title
President, Chief Executive Officer
(Principal Executive Officer) and Director
Senior Vice President, Finance, and
Chief Financial Officer (Principal Financial and Accounting Officer)
Date
February 26, 2015
February 26, 2015
Chairman of the Board
February 26, 2015
Director
Director
Director
Director
Director
Director
Director
February 26, 2015
February 26, 2015
February 26, 2015
February 26, 2015
February 26, 2015
February 26, 2015
February 26, 2015
Corporate Information
BOARD OF DIRECTORS
EXECUTIVE LEADERSHIP
ROBERT L. BURR
Chairman of the Board,
Impax Laboratories, Inc.
FRED WILKINSON
President and CEO,
Impax Laboratories, Inc.
LESLIE Z. BENET, Ph.D.
Professor, Biopharmaceutical
Sciences, University of California,
San Francisco
ALLEN CHAO, Ph.D.
Chairman, Newport Healthcare
Advisors, LLC
LARRY HSU, Ph.D.
Former President and CEO
Impax Laboratories, Inc.
MICHAEL MARKBREITER
Private Investor
MARY K. PENDERGAST, J.D.
President, Pendergast Consulting
NIGEL TEN FLEMING, Ph.D.
Chairman and CEO, G2B Pharma
Chairman, Minoryx Therapeutics SL
CEO, ADVentura Capital SL
PETER R. TERRERI
President and CEO,
CGM, Inc.
FRED WILKINSON
President and CEO,
Impax Laboratories, Inc.
MICHAEL NESTOR
President, Impax Specialty Pharma
JEFFREY D. NORNHOLD
Senior Vice President,
Technical Operations
BRYAN M. REASONS
Senior Vice President and
Chief Financial Officer
MARK A. SCHLOSSBERG
Senior Vice President, General Counsel
and Corporate Secretary
SENIOR LEADERSHIP
GODFREY A. BAKER
Senior Vice President,
Global Quality
SUNEEL GUPTA, Ph.D.
Chief Scientific Officer
Specialty Pharma
VISHAL GUPTA, Ph.D.
Senior Vice President,
Generic Product Development
ANDREW N. SCHASCHI
Senior Vice President,
Global Operations
BRANDON SMITH
Senior Vice President, Corporate
Development and Strategy
RICHARD TING
Senior Vice President,
Generic Product Development
STOCKHOLDER AND CORPORATE
INFORMATION
CORPORATE HEADQUARTERS
30831 Huntwood Avenue
Hayward, CA 94544
(510) 240-6000
www.impaxlabs.com
Listed: NASDAQ Global Market
Common Stock Symbol: IPXL
INDEPENDENT AUDITORS
KPMG LLP
1601 Market Street
Philadelphia, Pa 19103
CORPORATE COUNSEL
Latham & Watkins LLP
140 Scott Drive
Menlo Park, CA 94025
TRANSFER AGENT AND
REGISTRAR
American Stock Transfer and
Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
INVESTOR RELATIONS
CONTACT
Mark Donohue
Vice President, Investor Relations and
Corporate Communications
Impax Laboratories
121 New Britain Blvd
Chalfont, PA 18914
(215) 558-4526
ANNUAL MEETING OF
STOCKHOLDERS
Tuesday, May 12, 2015 at 9:00 am
(P.D.T.) at:
San Francisco Marriot Waterfront
1800 Old Bayshore Highway
Burlingame, CA
94010
CORPORATE HEADQUARTERS
30831 Huntwood Avenue Hawyard, CA 94544 (510) 240-6000
www.impaxlabs.com
Listed : NASDAQ Global Market Common Stock Symbol: IPXL